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SYNOSPIS
Obesity and type 2 diabetes (T2DM) are both inflammatory disorders with
parallel escalating epidemics. Novel insights provided by the new biology suggest
common pathways by which several pathogenic components of obesity affect glucose
metabolism and cellular responsiveness to insulin leading eventually to the development
of T2DM; inflammation is considered critical for the development of the above metabolic
disorders and is directly influenced by weight gain. Adipose tissue (AT), particularly the
abdominal fat depot is currently considered source of inflammatory agents that fuel
whole body’s low grade inflammatory state. The HLA-B Associated Transcript 1 (BAT1)
is a cellular member of the DExD/H-box RNA-helicases with essential role for cellular
mRNA export, that also attains anti-inflammatory properties, as it was shown by studies
investigating monocytes and T-cell lines. Furthermore, BAT1 polymorphisms were
linked to predisposition to immunopathologic disorders including type 1 diabetes. These
findings suggest a potential protective role of BAT1 against the obesity-associated low-
grade inflammatory state that contributes to T2DM development. The role of BAT1 in
the adipocytes has not been investigated so far.
Therefore, this thesis examined BAT1 expression and regulation within specific
human AT depots and the adipocyte itself. Initial studies indicated BAT1 expression in
ex vivo human AT but also the repressing effect of increasing adiposity and T2DM on
BAT 1 expression. Remarkably, there was no difference in BAT1 expression between
obese subjects and patients with T2DM indicating that BAT1 becomes suppressed with
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increasing adiposity and remains suppressed through to the development of T2DM and
thereafter; this could in turn reduce the capacity to response to the inflammatory insults.
As human AT contains many different types of cells besides adipocytes, including
fibroblasts, macrophages, lymphocytes, pre-adipocytes and endothelial cells, some of
which actually increase with increasing adiposity (e.g. macrophages and lymphocytes)
subsequent studies determined the expression of BAT1 particularly in isolated human
primary pre-adipocytes and mature adipocytes; the human pre-adipocyte cell line Chub-
S7 was used for this purpose. It was shown that BAT1 (mRNA and protein) was
expressed in both cell types with maximum expression in mature (lipid accumulating)
adipocytes. At the stage of complete maturation, the effects of nutrients and inflammatory
factors on BAT1 expression were examined. Both glucose and non-esterified fatty acids
(NEFA) were shown to repress BAT 1; these findings were in keeping with the ex vivo
data determined in terms of AT from obese and T2DM subjects. Furthermore, these
studies indicated a synergistic action of both JNK and NFB when used in combination
to reduce BAT1 expression, indicating interconnectivity between JNK and NFB
pathways, as noted in other human AT studies examining other molecules. Regarding
NEFA however, the JNK pathway seemed to mediate its repressing effect on BAT1.
These studies also showed that the potent inflammatory agent lipopolysacharide (LPS)
also significantly reduced BAT1 expression which was again in keeping with the
previous ex vivo AT data since LPS is raised in conditions of metabolic disease. Finally,
the investigation of the paracrine influences of leptin and resistin on differentiated
primary adipocytes highlighted BAT 1 repression whilst adiponectin appeared to have no
significant effect alone to alter BAT 1 expression or inhibit LPS-induced BAT1
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repression. Taken together, BAT1 was more susceptible to the repressing effects of
nutritional factors (glucose and NEFA) in excess than paracrine inflammatory or anti-
inflammatory adipokines. The fact that several factors modulate BAT1 expression may
suggest that BAT1 represents a first line, non-selective, cellular protective agent, which is
therefore influenced by several different factors through common inflammatory
pathways. Thus, BAT1 suppression may be an early key event in the pathogenesis of a
low chronic inflammatory state. As such BAT1 could represent an important target to
manipulate to combat the low chronic inflammatory state observed in both obese and
T2DM patients.
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Chapter 1
Introduction
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1.1 Obesity
1.1.2 Definition - Classification - Risk Status Assessment
Obesity is a serious growing global health problem affecting more than 400
million people worldwide. It is associated with more than 45 comorbidities and a cluster
of atherogenic disorders that compose the metabolic syndrome; the latter is recognized by
the International Diabetes Federation guidelines as a progressive condition that
contributes to the development of diabetes increases the risk of adverse cardiovascular
events and mortality from all causes. WHO, has defined obesity, as a ‘disorder of body
composition in that there is an abnormal, absolute or relative proportion of body fat in
relation to lean body mass, to the extent that health is impaired’ (WHO 2011).
According to the National Health and Nutrition Examination Survey III
(NHANES III), the morbidity and mortality rates are closely related to the degree of
obesity making the classification of the weight status imperative, as this enables health
practitioners to stratify individual’s health-risk and thus to modify the level of
intervention accordingly. Body Mass Index (BMI) and waist circumference correlate well
with total adiposity (Marc-Andre Cornier et al. 2002; Lemieux et al. 1996) and are used
in clinical practice for the estimation of weight status. Increasing BMI and increasing
waist circumference have been both associated with increasing risk of death from
cardiovascular disease and mortality from all causes (Despreset al. 1990), while the
presence of any obesity-related disorders increases further the overall mortality risk
(Yusufet al. 2002; Webster et al. 1984).
BMI is derived by dividing the body weight (kg), by the square of the height (m).
It is considered a relatively accurate marker of total body fat mass. Individuals with BMI
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between 18.5 and 24.9 kg/m2 are classified as normal weight, while those with BMI 25-
29.9 kg/m2 as overweight. Patients with BMI 30-34.9 kg/m2 are classified as obese-Class
I, those with BMI 35 -39.9 kg/m2 are classified as obese-Class II and finally those with
BMI of 40 kg/m2 or over are classified as extremely obese Class III. BMI values greater
than 25 kg/m2 increase the risk of morbidity and mortality for many diseases [6],
including type 2 diabetes mellitus (T2DM), hypertension, heart disease, stroke and
arthritis (Table 1.1.2).
Table 1.1.2 Increased Risk of Obesity Related Diseases with Higher BMI
Disease
BMI
≤25 kg/m2
BMI between
25 and 30 kg/m2
BMI between
30 and 35 kg/m2
BMI of
≥35 kg/m2
Arthritis 1.00 1.56 1.87 2.39
Heart Disease 1.00 1.39 1.86 1.67
Type 2 Diabetes 1.00 2.42 3.35 6.16
Gallstones 1.00 1.97 3.30 5.48
Hypertension 1.00 1.92 2.82 3.77
Stroke 1.00 1.53 1.59 1.75
Source: American Obesity Association; Centers for Disease Control. Third National
Health and Nutrition Examination Survey. Analysis by The Lewin Group, 1999
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1.1.3 Body Fat Distribution
Obesity is a heterogeneous condition with respect to regional distribution and
biological properties of fat tissue (Bouchard et al. 1993; Vague 1947). In the 1950s,
Vague (Vague 1947) first proposed that excess fat stored on the trunk could be
metabolically more damaging than fat stored on the limbs. This theory was later proved
to be true by Kissebah & Krakower in 1994 and Kahn and Flier in 2000, so that central
adiposity to be considered nowadays an independent risk factor for the development of
insulin resistance and T2DM later in life. Visceral adipose tissue refers to fat
accumulation within omental and mesenteric fat depots and constitutes about 6-20% of
total body fat tissue. It is less receptive to the anabolic effects of insulin and
metabolically-lipolytically more active than the peripheral fat tissue which refers to
subcutaneous fat accumulation and comprises 80% of total adipose tissue.
1.1.4 Obesity-associated morbidities
Many studies have shown increased morbidity and mortality among obese
individuals (Bell et al 2001; Kopelman PG 2000; Berrios et al 1997) which actually
begins to rise at BMI ≥25kg/m2 and even more sharply when BMI exceeds 30kg/ m2.
Hypertension, hyperlipidaemia, obstructive sleep apnoea insulin resistance and T2DM
are only some of the obesity-related diseases, while some types of cancer, such as breast,
colon, prostate and endometrial cancer, are also more common in obese individuals (Fig
1.1.4). As a result, obesity is not considered only as a cosmetic problem but as a very
serious disease which if left untreated increases T2DM, cardiovascular disease and
mortality from all causes.
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Medical Complications of Obesity:
Almost every organ system is affected
.
Phlebitis
venous stasis
Coronary heart disease
Pulmonary disease
abnormal function
obstructive sleep apnea
hypoventilation syndrome
Gall bladder disease
Gynecologic abnormalities
abnormal menses
infertility
polycystic ovarian syndrome
Gout
Stroke
Diabetes
Osteoarthritis
Cancer
breast, uterus, cervix
colon, esophagus, pancreas
kidney, prostate
Nonalcoholic fatty liver
disease
steatosis
steatohepatitis
cirrhosis Hypertension
Dyslipidemia
Cataracts
Skin
Idiopathic intracranial hypertension
Severe pancreatitis
Fig 1.1.4 Obesity-associated morbidities
1.1.5 Obesity and T2DM relation - Diabesity
The prevalence of diabetes took a sharp and unexpected upward turn in the last
couple of decades. Data from large epidemiologic studies reveal the parallel escalation of
obesity and diabetes epidemics and suggest increased risk of T2DM with increasing
obesity; it is estimated that 51-59% of patients with T2DM are obese (Fig 1.2) (Ogden et
al. 2002; Barsh GS et al. 2000). Obesity and diabetes are both characterized by defects of
insulin action; the term ‘diabesity’ express their close relationship to each other. Further
to the degree of adiposity, the duration of obesity, the genetic susceptibility (Comuzzie
2002; Maes et al. 1997) and the central adiposity estimated in clinical practice with the
use of waist circumference and waist to hip ratio seem to be better predictors of diabetes
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development (Stunkard et al. 1990). Results of recent studies in obese subjects and
patients with T2DM made the winds of change to blow in the treatment of diabetes.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial which investigated
the effect of intensive glycaemic control in patients with T2DM was stopped because of
increased mortality in the tight controlled group, which had gained at the same time the
more weight (Silventoinen et al. 2000). In The Swedish Obese Subjects (SOS) study
where morbidly obese patients were followed for an average of 11 years after bariatric
surgery it was demonstrated that weight loss reduced by >80% the diabetes mortality
(Carmichael and McGue 1995). Furthermore, the Diabetes Prevention Program (DPP)
showed 58% reduction in the incidence of diabetes following sustained moderate weight
loss of just 5-10% of the initial body weight (Knowler et al. 2002). Similar were the
findings of several other studies (Look AHEAD, Finnish Diabetes Prevention, Da Qing)
while modern non-insulin injectable forms of diabetes treatment with incretin analogues
and mimetics that reduce body weight appear to reduce the cardiovascular risk further,
supporting a current belief of a shift from glucocentric to weight-centric management of
diabetes. Up to date, several theories linking different pathogenic mechanisms that make
obese individuals prone to develop diabetes have been suggested. Although a unifying
hypothesis still remains elusive, most of them suggest insulin resistance and progressive
pancreatic ß-cells failure as the underlying pathogenic mechanism.
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Fig 1.1.5 Prevalence of Diabetes (%) by BMI level as it is revealed by the
epidemiologic studies SHIELD and NHAHES (Bays et al. 2007)
1.2 Obesity and impaired glucose metabolism
1.2.1 Physiologic Actions of Insulin and the Insulin-Signaling
Insulin is an important metabolic hormone released by the pancreatic β-cells in 
response to elevated levels of glucose and other nutrients in the blood, which also attains
anabolic properties. It facilitates the uptake of glucose, fatty acids and amino acids by
several tissues including liver, adipose tissue and muscle and promotes the storage of
these nutrients in the form of glycogen, lipids and protein, respectively. Insulin plays
principal role in the regulation of glucose homeostasis in fasting state and prostprandially
(Woerle et al. 2004; Woerle et al. 2003; Mitrakou et al. 1992). T2DM ensues by the
combination of peripheral resistance to insulin’s effects because of defects in the insulin
- 35 -
signaling pathway plus the pancreatic β-cell failure to properly secrete adequate amounts 
of insulin to meet the metabolic needs.
In respect to glucose metabolism, insulin exerts its effects by binding to its
receptor. The latter is composed of two extracellular a-subunits and two transmembrane
b-subunits linked together by disulphide bonds (Figure 3) (Bevan 2001). Binding of
insulin to the extracellular a-subunit results in receptor activation and
autophosphorylation of a number of tyrosine residues present in the b-subunit (Van
Obberghen et al. 2001) which are in turn recognized by specific phosphotyrosine-binding
domains of adaptor proteins including the insulin receptor substrates (IRS-1, IRS-2 and
IRS-3) (Saltiel and Kahn 2001; Lizcano and Alessi 2002). The phosphorylation of
tyrosine residues on IRS proteins by the activated insulin receptor, allows them to
associate with the regulatory subunit of phosphoinositide 3-kinase (PI3K). Once
activated, the catalytic subunit of PI3K phosphorylates phosphoinositides at the 3′ 
position of the inositol ring or proteins at serine residues. Among substrates that are
phosphorylated by PI3K is the phosphatidylinositol (4,5) bisphosphate (PtdIns(4,5)P2)
leading to Ptd(3,4,5)P3 formation. This signal pathway results in the activation of the 3-
Phosphoinositide-dependent kinase 1 (PDK1) which phosphorylates the activation loop
of a number of protein serine/threonine kinases of the AGC kinase super family,
including protein kinase B (PKB; also called Akt). The latter deactivates glycogen
synthase kinase 3 (GSK-3), thus promoting glycogen synthase and glucose storage as
glycogen while it also activates the translocation of GLUT-4 vesicles from their
intracellular pool to the plasma membrane (Asnaghi et al. 2004), thus cellular glucose
uptake. Saltiel and Kahn (2001) also described another PI3K-independent pathway by
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which GLUT4 is recruited to the plasma membrane. This pathway starts with insulin
binding to its receptor, followed by phosphorylation of Cbl (which is associated to its
adaptor protein CAP). The Cbl-CAP complex then translocates to the plasma membrane
where via Crk, C3G, TC10 and other adaptor molecules, it promotes GLUT4
translocation to the plasma membrane.
Further to glucose metabolism, insulin is also involved in protein metabolism as it
promotes cellular amino acid uptake and protein synthesis (Saltiel and Kahn 2001) while
at the same time it inhibits protein degradation. The suggested pathway is that of PI3K-
PDK1- Akt which deactivates GSK-3 thus facilitating protein synthesis and the storage of
amino acids (Lizcano and Alessi 2002). In addition, Akt activates the mammalian target
of rapamycin (mTOR), which enhances protein synthesis (Asnaghi et al. 2004).
Lipid homeostasis provides another metabolic pathway in which insulin is
implicated. Exerting anabolic effects, insulin promotes the cellular uptake of fatty acids
and the synthesis of lipids (via the steroid regulatory element-binding protein; SREBP)-
1c) (Shimomura et al. 1999), whilst inhibiting lipolysis (Kitamura et al. 1999). In
addition, insulin also attains mitogenic properties; MAPK cascade is the leading pathway
to its mitogenic responses (Ogawa et al. 1998) which may be activated via two different
pathways. The first cascade starts with IRS phosphorylation followed by activation of
GRB2 and SOS and the second one (IRS- independent pathway) starts with the
phosphorylation of SHC followed by GRB2 activation; both end up with MAPK cascade
stimulation.
Remarkably, negative feedback mechanisms characterize the insulin activated
pathways thus modulating insulin transduction molecules activity and insulin
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effectiveness. For example, the insulin/insulin receptor complexes are internalized into
endosomes within which they are subsequently dissociated and degraded, providing a
mechanism by which insulin receptors are downregulated in hyperinsulinaemic states as
in obesity thus aggravating IR. In addition, insulin promotes the production of SOCS
(suppressor of cytokine signaling) proteins that block the insulin signaling circuitry
(Emanuelli et al. 2000; Krebs et al. 2000; Endo et al. 1997; Matsumoto et al. 1997).
Similarly, the GSK-3β activation by Akt/PKB exerts negative feedback on insulin 
signaling by phosphorylating IRS-1 at serine 332 which blocks the insulin response by
inhibiting insulin receptor-mediated tyrosine phosphorylation of IRS-1 (Hotamisligil
2006); as GSK-3β also modulates some of the anti-inflammatory effects of insulin, it 
suggests a molecule that mediates both insulin resistance (IR) and inflammatory
responses (Dugo et al. 2006 and 2007)
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Fig 1.2.1 Insulin signaling pathway. Activation of the insulin receptor evokes increased
transcription of SREBP and the phosphorylation of members of the IRS family, SHC and
Cbl. Upon tyrosine phosphorylation, these proteins interact with signaling molecules
through their SH2 domains, which results in the activation of a variety of signaling
pathways, including PI 3-kinase signaling, MAPK activation and the activation of the
Cbl/CAP complex. These pathways act in a coordinated manner to regulate glucose, lipid
and protein metabolism (adopted by Bevan P 2001).
1.2.2 Modulation of insulin signaling in Obesity; Etiologic Factors and Molecular
Mechanisms
A principal mechanism for the maintenance of glucose homeostasis is the
appropriate secretion of insulin in response to increased glucose levels plus the effective
action of insulin in stimulating glucose uptake and metabolism in peripheral tissues.
T2DM ensues by the combination of peripheral insulin resistance and pancreatic beta
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cells failure to secrete sharply adequate amounts of insulin to meet the metabolic
needs. Regarding reduced response to insulin effect, a number of defects in insulin signal
transduction pathway have been described in human subjects with insulin resistance and
T2DM (Krook et al. 1998; Kerouz et al. 1997; Goodyear et al. 1995; Caro et al. 1987)
however, the detailed molecular basis for insulin resistance is not well understood in
every case.
In obesity-associated impaired glucose metabolism, the increased glucose levels
in the blood result from elevated glucose production in the liver (gluconeogenesis and
glycogenolysis) and decreased glucose uptake by muscle (Wellen and Hotamisligil 2005;
Saltiel and Kahn 2001). The traditional views on metabolic derangements of diabetes
have been largely "glucocentric", considering hyperglycemia the main underlying cause.
However, the recognition that obese individuals who usually suffer from hyper- or dys-
lipidaemia develop insulin resistance and diabetes much more frequently than lean people
and also that people with T2DM almost invariably manifest serious breakdown in lipid
dynamics, reflected by elevated levels of circulating non-esterified fatty acids (NEFAs)
and triglycerides (TG) (Zimmet et al. 2001; Baumann et al.2000; Maddux et al. 1993),
led researchers to investigate the potential role of altered lipid metabolism in the
pathogenesis of T2DM. Two theories mainly explain the close relationship between fat
excess and impaired glucose metabolism, the “Randle cycle“ that provides the reciprocal
relationship between fatty acid oxidation and glucose oxidation and the “Ectopic Fat
Storage Hypothesis” according to which the impaired insulin effect is due to deposition
of lipids within insulin-target tissues. Recently, two more hypotheses were added to the
suggested theories by which obesity may lead to T2DM; first, the identification of
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adipose tissue as an endocrine organ that produces and metabolizes multiple bioactive
factors, which may potentially impair glucose metabolism and second, change of adipose
tissue phenotype due to a low-grade inflammatory state that impairs insulin effectiveness.
Although these theories provide metabolic mechanisms that seem to be different in origin
and nature, the underlying trigger factor may be related to the effect of substrate excess
relative to what adipose tissue has the genetically determined capacity to store. As a
result, obese individuals develop insulin resistance, which is initially compensated for by
hyperinsulinemia, through which normal glucose tolerance is preserved. However, over
time further deterioration of glucose metabolism, either by increased insulin resistance or
by decreased compensatory insulin secretory responses or by both, accelerates the
progression to impaired glucose tolerance and eventually to overt T2DM. Chronic
hyperinsulinemia per-se has been also demonstrated by White et al (2003) to exacerbate
insulin resistance and contribute directly to beta-cell failure and diabetes.
1.2.3 ‘Randle’s Glucose-Fatty Acid’ Hypothesis - Oxidative stress
In 1963 Philip Randle (1963) first proposed one set of metabolic pathways by
which carbohydrate and fat metabolism interact. He called it a “cycle” because it
describes a series of events that interlink glucose and fat utilization within the cells. Its
basic outline is simple; carbohydrates, when available (postprandially), are preferred as
fuels than lipids, which are stored in adipose tissue for future use. Insulin plays a primary
role in this regulation, facilitating glucose peripheral uptake and utilization, while at the
same time it inhibits NEFAs mobilization from the adipose tissue, inactivating hormone-
sensitive lipase and thus it removes the competition for substrate utilization in peripheral
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tissues. In contrast, when carbohydrates are decreased (fasting state), the serum insulin
levels fall permitting lipolysis and NEFA mobilization, which then become the major fuel
for peripheral tissues. Randle went a step further, demonstrating the inhibitory effect of
enhanced NEFA oxidation on glucose metabolism. This particular metabolic effect takes
place in states with lipid excess, as in obesity and is considered pathogenic in the
development of insulin resistance and eventually T2DM in obese individuals. This theory
was later confirmed by following studies showing that adipocytes decrease glucose
uptake in peripheral tissues by the release of free fatty acids (Boden 1997) as even short
periods of lipid excess decrease PI3K activity and insulin-stimulated glucose uptake in
muscle (Jacobson et al. 2002; Dresner et al. 1999). It is suggested that by mass action, the
increased plasma free fatty acids (FFAs) augment their cellular uptake and induce their
mitochondrial β-oxidation. As a result, the cellular metabolism may be altered at the level 
of substrate competition, intermediates accumulation, enzyme regulation, intracellular
signaling and/or gene transcription, affecting among others, glucose metabolism. Clinical
studies in healthy volunteers, in which acute elevation of plasma NEFAs resulted in
whole body insulin resistance, confirmed the proposed metabolic model (Dresner et al.
1999). Obese individuals have two main sources of plasma NEFA excess, the meal-
derived fatty acids (high-calorie diets) and the adipose tissue lipolysis especially the
visceral adipose tissue one.
In this direction is the theory regarding pathogenic role of oxidative stress in
insulin resistance and β-cell dysfunction in obese individuals. It refers to a state in which 
imbalance between oxidant generation and antioxidant protection or repair of oxidative
damage exists. Mitochondrial respiratory chains represent a major source of ATP but also
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of cellular ROS production (Newsholme et al. 2007; Turrens 2003; Lenaz 2001), while
plasma or subcellular membrane-associated NADPH oxidases are secondary sources of
intracellular ROS (Newsholme et al. 2009 and 2007). Normally, during the aerobic
cellular metabolic processes, several reactive oxygen species (ROS) are produced. In
normal concentrations, these elements act as necessary messengers in biological systems
(Redox signaling) (Rhee 2006; Dröge 2002). In beta-cells in particular, the
mitochondrial-produced ATP and ROS seem to be involved in maintaining normal
glucose responsiveness (Leloup et al. 2009; Pi et al. 2007; Bindokas et al 2003). In states
of prolonged excessive fuel load such as fats, the excessive mitochondrial fat oxidation
results in excessive production of ROS (Li et al. 2008; Aikawa et al. 2002; Djuric et al
2001; Inoguchi et al. 2000). When abnormally high, they become cytotoxic and damage
cellular structures and organelles (including mitochondria) resulting in defective cellular
metabolism and enhanced cellular apoptosis. This cytotoxic condition, triggers cellular
inflammatory response; it has been demonstrated that the latter stimulates the inhibitory
serine phosphorylation of IRS-1, thus disrupting insulin signal transduction causing
insulin resistance (Wellen and Hotamisligil 2005). B-cells are considered very sensitive
to oxidative stress as they are low in antioxidant enzymes (Robertson and Harmon 2007;
Tonooka et al. 2007). It has been shown that oxidative stress in β-cells disrupts 
mitochondrial function and ATP production which is necessary for the KATP channels
closure. As a result, β-cell secretory capacity is impaired (Zorov et al. 2006; Brady et al.
2004) which in accordance with the oxidative-stress induced β-cell apoptosis, contributes 
to beta-cell failure and diabetes.
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1.2.4 Ectopic Fat Storage Hypothesis
Normally, the adipocytes take up lipids from fat-rich plasma lipoproteins, through
the effect of fat cell-derived lipoprotein lipase and store almost pure triglycerides in
quantities of up to 95% of their volume. This process called lipogenesis is enhanced by
insulin (Vague 1956). In contrast, when energy is needed elsewhere in the body, the
stored fat is mobilized (lipolysis) in the form of NEFAs by the hormone sensitive
lipoprotein lipase, against the effect of insulin. However, when the diet-derived fat intake
is increased as in obesity, fat storage within and around other tissues and organs which
under normal conditions do not store lipids has been demonstrated, including liver,
skeletal muscle and pancreatic β-cells (Ectopic Fat Storage Hypothesis) (Goodpaster and
Kelley 1998; Shulman 2000). There is probably a critical visceral adipose tissue
threshold (CVATT), after which fat deposition is diverted to extra-adipose tissues. It has
been demonstrated that although initially the peripheral organs facilitate the storage-
esterification of the surplus in the form of triglycerides, their limited triglyceride buffer
capacity becomes saturated soon and the excess of lipids enter catabolic pathways. As a
result, excessive mitochondrial production of toxic reactive lipid species ensues
(oxidative stress), which mediate organ-specific oxidative damage and cellular
dysfunction, leading progressively to the development of insulin resistance, impaired
glucose metabolism and finally T2DM (Jacob et al. 1999).
1.2.5 Obesity as a state of chronic low-grade inflammation
In recent years, obesity has been considered as a state of chronic low-grade
systemic inflammation, as it is suggested by the elevated levels of circulatory
inflammatory agents including C-reactive protein (CRP) (Visser et al;1999), tumor
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necrosis factor- (TNF-) (Dandona et al. 1998), interleukin-1 (IL-1) and -6 (IL-6) (Van
Dielen et al. 2001; Yudkin et al. 2000; Visser et al, 1999) plus the increased plasma
circulating mononuclear cells and lymphocytes (Perfetto et al. 2002) in otherwise healthy
overweight and obese individuals. The low-grade inflammation has been implicated in
the development of IR, β-cell dysfunction and T2DM (Laaksonen et al. 2004; Pradhan et
al. 2002); IL-1ß for example induces nitric oxide (NO) production in pancreatic ß-cells,
and may impair of insulin secretion (Wogensen et al. 1990). It was shown that adipose
tissue produces certain bioactive substances that promote inflammation (e.g. interleukin -
6) (Cachofeiro et al. 2006) but also fat tissue per se is infiltrated by inflammatory cells
including lymphocytes and macrophages which also secrete cytokines (e.g. IL-6 and
TNF-) contributing to the whole body inflammatory process (Lumeng et al. 2007); the
degree of the participation is not clear. The pro-inflammatory cytokines increase the
production of serine kinases such as MAPK (mitogen-activated protein kinase), TOR
(target of rapamycin), PI3K and Jnk (Jun N-terminal kinase) (Prada et al. 2005; Ozcan et
al. 2004; Hirosumi et al. 2002; Ozes et al.2001; Rui et al. 2001; De Fea et al. 1997)
which in turn cause serine phosphorylation of IRS-1 thus IR (Rui et al. 2001). In
addition, insulin as well as increased levels of pro-inflammatory cytokines enhance
SOCS (suppressor of cytokine signaling) proteins production which blocks the insulin
signaling circuitry (Emanuelli et al. 2000; Krebs et al. 2000; Endo et al. 1997;
Matsumoto et al. 1997). TNF-α may also impair insulin secretion in pancreatic islet cells 
(Kwon et al. 1999) and may stimulate IL-6 production, which leads to ß-cell destruction
(Pakala SV et al. 1999). Furthermore, high-fat diets in humans and animals (Shi et al.
2005; Turk et al. 2003), even the low-calorie ones (Rankin et al. 2007), as well as acute
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high-fat meal challenges in both T2DM and healthy subjects have been shown to increase
inflammation (Cani et al. 2008; Cani et al. 2007; Nappo et al. 2002), implying a direct
effect of FFAs on inflammatory pathways stimulation. In addition, the stimulatory effects
of monounsaturated fatty acids on TLR-4/NFκB pathway with respect to the secretion of 
adipokines and chemokines (including inflammatory molecules) from adipocytes, has
been demonstrated (Schäffler et al. 2008), while both pharmacological and genetic
intervention in pathways such as JNK and IKK improve glucose metabolism under
conditions of obesity (Uysal et al. 1997; Hotamisligil et al. 1993). Putting together, a
critical role of fats on inflammatory state generation and IR ensues. It has been shown
that, similarly to inflammatory factors (e.g. TNF-), elevated levels of free fatty acids
(FFAs) stimulate the inhibitory serine phosphorylation of IRS-1, thus disrupting insulin
signal transduction and inducing insulin resistance (Wellen and Hotamisligil 2005). The
FFA-stimulated inflammatory serine/threonine kinases JNK, inhibitor of nuclear factor
(NF)-κB kinase (IKK) and protein kinase C (PKC) (Schmitz-Peiffer and Biden 2008;
Arkan et al. 2005; Hirosumi et al. 2002) seems to represent key intermediaries of the
inflammatory pathways that mediate serine phosphorylation of IRS-1 thus block insulin
action. These kinases also stimulate activator protein (AP)-1 complexes and NF-
κB (Hotamisligil GS et al. 2006) thus enhancing the production of inflammatory
mediators including TNF-α and IL-6 (Shoelson et al. 2003; Gao et al. 2002) providing
link between FFA excess and whole body inflammation.
Recent studies explore the connection between gut microbiota, energy
homeostasis and inflammation and its role in the pathogenesis of obesity-related
disorders (Al-Attas et al. 2009; Baker et al. 2009; Miller et al. 2009; Shoelson and
- 46 -
Goldfine 2009; Creely et al. 2007). The concept of ‘metabolic endotoxinaemia’ suggests
that toxins produced in the gut may play a key role in the pathogenesis of obesity-
associated inflammatory state and that food ingestion affects plasma endotoxin levels.
Several current studies provide potential pathogenic mechanisms by which gut
microbiota may disrupt the energy balance equation (Bäckhed et al.2009; Turnbaugh et
al. 2009; Martin et al. 2008; Turnbaugh et al. 2008; Dumas et al. 2006), alter fatty acid
metabolism and composition in adipose tissue and liver (Cani et al. 2007 and 2008),
modulate gut-derived peptides (PYY and GLP-1) (Cani et al. 2009; Samuel et al. 2008;
Zhou et al. 2008; Bäckhed et al. 2007; Cani et al. 2006) and activate the
lipopolysaccharide toll-like receptor-4 axis (Ghanim et al. 2009; Cani et al. 2008;
Anderson et al. 2007; Cani et al. 2007), leading to obesity, insulin resistance, and
diabetes in the host. Previous studies show that gut bacteria can initiate the inflammatory
state of obesity and IR through the activity of lipopolysaccharide (LPS). LPS is a
relatively large molecule consisting of a lipid and a polysaccharide joined by a covalent
bond and is found in the outer membrane of gut derived Gram-negative bacteria. LPS has
strong affinity for chylomicrons by which it crosses the GI mucosa, enters the circulation
and exacerbates postprandial inflammatory reaction (Ghoshal et al. 2009) acting as toxin
that binds to the CD14 toll-like receptor-4 (TLR-4) complex at the surface of innate
immune cells, triggering inflammatory reaction (Shi et al. 2006). Remarkably,
circulating LPS modulates adipose tissue metabolism provoking increased production of
adipokines including TNF-, IL-6 and resistin (Anderson et al. 2007) that exert
detrimental effects on whole body metabolism.
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1.2.6 Endoplasmic Reticulum Stress, Hyperglycemia, and Insulin Resistance
As indicated previously, chronic low-grade inflammation may cause IR by
increasing the production of serine kinases such as MAPK, TOR, and Jnk which in turn
cause serine phosphorylation of IRS-1 inhibiting insulin signal transition (Prada et al.
2005; Ozcan et al. 2004; Hirosumi et al. 2002; Ozes et al. 2001; Rui et al. 2001; De
Fea, Roth 1997; Tanti et al. 1994) thus IR (Rui et al., 2001). In addition, the
proinflammatory cytokines enhance the production of SOCS proteins that block the
insulin signaling circuitry (Emanuelli et al. 2000; Krebs et al. 2000; Endo et al. 1997;
Matsumoto et al. 1997). An alternative theory has been proposed implicating
endoplasmic reticulum (ER) stress as a key factor in obesity-associated chronic
inflammation and IR (Hotamisligil 2006; Nakatani et al. 2005; Ozcan et al. 2004).
Although ER stress response has naturally a protective role in cellular survival and is
activated in states of glucose or nutrition deprivation (Scheuner et al. 2001) to protect
against hypoglycemia and death (Tamatani et al. 2001) in fuel-excess states as in obesity
it deranges glucose metabolism. It has been suggested that NF-κB and JNK pathways 
mediates ER-stress inhibitory effects on insulin signal transduction (Ozcan et al. 2006;
Zhang et al. 2001).
1.3 Influence of glucose on insulin resistance.
1.3.1 Plasma glucose regulation in fasting and postprandial state
Normally, in fasting state, plasma glucose levels are maintained within the normal
range by endogenous glucose release (glycogenolysis and gluconeogenesis); liver
contributes by 80% to the endogenous glucose production and kidneys by 20% (Meyer et
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al. 2002; Stumvoll et al. 1999). In contrast, postprandially, the glycogen breakdown and
glucose release into the circulation are substantially reduced (Woerle et al. 2004; Meyer
et al. 2002) while the hepatic glycogen synthesis increases, so that hyperglycemia to be
avoided and replenishment of glycogen stores to be facilitated. These metabolic
modulations follow changes in plasma insulin (increased) and glucagon (decreased)
concentrations (Woerle et al. 2004; Woerle et al. 2003; Mitrakou et al. 1992) due to
which hepatic glucose-6-phosphatase and phosphorylase are reduced, while glycogen
synthase is activated. The postprandial glucose disposal involves taken up by tissues for
energy production (glycolysis; about 2/3 of taken up glucose) or storage (about 1/3, either
as glycogen or as triglycerides in the adipose tissue) (Woerle et al. 2003). The major
tissues responsible for postprandial glucose disposal are liver (splanchnic), muscle, brain,
and kidney (Meyer et al. 2002). Brain plays a substantial role in glucose disposal which
is in brain’s case insulin independent. Thus, only about 70% of postprandial glucose
uptake is insulin dependent. About 2/3 of the glucose that undergoes glycolysis is
oxidized, while the remainder is converted to gluconeogenic intermediates (i.e., lactate,
pyruvate, and alanine) which are then released back to circulation, enter the hepatic
gluconeogenic pathway and after conversion into glucose-6-phosphate are by released
50% as free glucose back to the circulation and by 50% is incorporated in hepatic
glycogen for future use.
1.3.2 Defects in Skeletal Muscle Control of Glucose Homeostasis in obesity
Skeletal muscle is the primary site of glucose disposition in the body (DeFronzo
1997) and resistance to the actions of insulin in skeletal muscle is a major pathogenic
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factor T2DM. Lipid accumulation within skeletal muscle correlates quite well with
insulin resistance in humans and is one of the suggested mechanisms implicated in the
induction of IR in obesity (Phillips et al. 1996). It has been shown that excessive
accumulation of lipids within the skeletal cells, activate at least in part via increased
ceramide formation the protein kinase C and the JNK/SAPK pathway, which in turn
block insulin signal transduction in muscle (Prada et al. 2005; Kim et al. 2004; Hirosumi
et al. 2002).
1.3.3 Defects in Hepatic Control of Glucose Homeostasis in obesity
The liver plays a key role in obesity-induced hyperglycemia (Kahn, Hull 2006;
Pilkis, Granner 1992). As mentioned above, the glucose production (glycogenolysis) by
the liver is suppressed postprandially so that hyperglycemia to be avoided and
replenishment of glycogen stores to be facilitated. Insulin plays principal role in
modulation of hepatic glucose production as it promotes the synthesis of glycogen and
represses hepatic glucose release. These effects are mediated by insulin-induced
suppressed transcription of the phosphoenolpyruvate carboxykinase enzyme that controls
gluconeogenesis and by the insulin-induced increased transcription of glucokinase and
pyruvate kinase that promote glycolysis (Sutherland et al. 1996). Several hepatocellular
transcription factors and cofactors such as peroxisome proliferators seem to mediate these
effects (Li et al. 2007; Puigserver et al. 2003), modulated by the insulin-activated
Akt/PKB pathway (Cantley 2006; Shaw, Taniguchi et al. 2006; Saltiel, Kahn 2001). In
insulin resistant states, hepatic glucose production is not inhibited postprandially, so that
hyperglycemic excursions to follow meal intake. Hepatic steatosis is a common finding
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in obese individuals (Dixon et al. 2001; Matteoni et al. 1999; Ludwig et al.1980), while
on the other hand recent findings relate liver fat accumulation with reduced hepatic
insulin sensitivity (Seppälä-Lindroos et al. 2002; Schmitz-Peiffer 2000). Putting together,
liver steatosis is a manifestation of IR in obesity (Ferre, Foufelle 2007; Patti et al. 2003).
This association seems to be explained by the role of the transcription factor sterol
regulatory-element-binding protein-1c (SREBP-1c) in the liver that induces the
expression of a family of genes involved in glucose utilization (gluconeogenic genes) and
fatty acid synthesis (lipogenic genes) and can be considered as a thrifty gene (Ide et al.
2004; Azzout-Marniche et al. 2000; Foretz et al. 1999). It has been shown that insulin at
least in part via through the phosphatidylinositol 3-kinase pathway, increases the
hepatocellular concentration of the transcription factor sterol regulatory-element-binding
protein-1c (SREBP-1c). The subsequent SREBP-1c induced lipogenesis contributes to
abnormally high hepatic content of fats (liver steatosis) which in turn reduce hepatic
insulin sensitivity by mechanisms involving substrate competition, antagonism of insulin
signaling or lipotoxicity (Seppälä-Lindroos et al. 2002; Schmitz-Peiffer 2000).
1.3.4 Central Nervous System Control of Glucose Homeostasis
Close hormonal and biochemical cross-talk between central nervous system
(CNS) and peripheral tissues for glucose homeostasis is now well established (Gribble
2005). Leptin that is produced by the adipocytes in increased levels with increasing
adiposity acts on the arcuate nucleus of the hypothalamus which contains high
concentrations of leptin receptor and controls food intake (Morton et al. 2006). Rodents
and humans with reduced levels of leptin (due to leptin gene mutation) or leptin receptor
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demonstrate loss of satiety, increased appetite and severe obesity (Morton et al. 2006;
Elmquist, Marcus 2003). In obesity, despite hyperleptinemia, appetite remains increased,
implying attenuated response to leptin in obesity. This finding, along with the insulin
sensitizing effects of leptin in peripheral tissues (Morton et al. 2006; Elmquist, Marcus
2003) may suggest a contributory effect of dysregulated leptin sensing pathway to obesity
and diabetes development. Remarkably, it seems that neuronal connection between CNS
and fat tissue exists which may actually play important role in appetite regulation. It has
been shown that afferent-nerve signals from intra-abdominal adipose tissue modulate
hunger and sense of satiety by enhancing the hypothalamic sensitivity to leptin (Yamada
et al. 2006). Further to adipose tissue-derived hormonal (leptin) and neural factors that
modulate hypothalamic control of appetite and peripheral insulin effectiveness, recent
data suggest that metabolic agents (long-chain fatty acids) produced by the adipocytes
may also regulate energy balance and metabolic homeostasis by altering the rate of lipid
oxidation in selective hypothalamic neurons (Morton et al. 2006; Elmquist, Marcus
2003). This in turn alters the hypothalamic perception of metabolic balance and changes
respectively the CNS-regulated efferent pathways responsible for fuel intake and
utilization (Cota et al. 2007).
Within the last few years the role of gut-derived hormones on glucose metabolism
and appetite gained a lot of attention and incretin based therapeutic approaches for the
management of T2DM became popular. The glucagon-like peptide (GLP)-1 that comes
from the L-cells of the distal small bowel and the GIP that is produced in the K-cells of
proximal small intestine are low in patients with obesity and T2DM, while administration
of therapeutic doses of GLP-1 analogues contributes not only to improved glucose
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metabolism but also to decreased appetite and weight loss. Whether reduction of these
agents represents a primary or secondary defect in obesity and T2DM is still unknown.
What is known though is that these humoral circuits from gut do not function properly in
obesity and diabetes implying the complexity of the multi-systemic modulation of energy
and modulation via CNS and hypothalamus. Another gut hormone involved in energy
homeostasis is ghrelin which levels increase with fasting and augments feeding (Cota et
al. 2007; Morton et al. 2006; Yamada et al. 2006; Elmquist, Marcus 2003).
The sympathetic and parasympathetic innervation of adipose tissue has been well
documented (Kahn et al. 2006; Boden, Hoeldtke 2003; Ikezu et al. 1999). By acting on
the adiposal β3-adrenergic receptors, the sympathetic nervous system enhances lipolysis 
while the parasympathetic nervous system has been involved in lipogenesis. Both these
function suggest the close cross-talk between CNS and adipose tissue. On the other hand,
it is known the interrelationship between autonomous nervous system and immune
system (e.g., macrophages) (Flierl et al. 2007; Sternberg 2006). Putting together, adipose
tissue cross-talks with immune system however how this is modified in obesity is still
unknown.
Whilst previous discussion has noted the direct effect of insulin on hepatic
glucose production, by promoting gluconeogenesis and repressesing glucogenolysis
(Sutherland et al. 1996) studies also show that the CNS and the arcuate nucleus of the
hypothalamus in particular are involved in the modulation of the hepatic glucose
production (Pocai et al. 2005). Hypothalamus senses with specific proopiomelanocortin
neurons-located ion channels called potassium adenosine triphosphate (K+ATP) channels
the postprandial increase of insulin and glucose levels and via vagus nerve that represents
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the efferent part of the circuit it decreases the hepatic glucose output. It has been shown
that this loop is defective in obesity, contributing to enhance hepatic glucose production
even in postprandial states (Parton et al. 2007).
1.4 The Role of Adipose Tissue in the Pathogenesis of T2DM
Obese individuals tend to be insulin resistant (Rexrode et al. 1996; Bonadonna et
al. 1990). As previously detailed the insulin signaling pathway, as well as the physiologic
role of CNS and organs, are disrupted in subjects with T2DM where normal glucose
metabolism is altered in the liver and skeletal muscle. Previous studies have also referred
to the obesity-related modulations of insulin action and signaling in these organs and
provided current views for the etiologic factors and molecular mechanisms involved in
insulin resistance generation and subsequent impaired glucose homeostasis and T2DM
development in states with excessive fuel load as in obesity. Here we present the critical
role of expanding adipose tissue in insulin signaling defects generation in obesity.
1.4.1 The Role of Adipose Tissue as Source of Free Fatty Acids in the Pathogenesis of
Type 2 Diabetes
Findings from several studies have demonstrated that excessive release of free
fatty acids decreases PI3K activity and insulin-stimulated glucose uptake in peripheral
tissues (Dresner et al. 1999; Boden 1997). Obese individuals have two main sources of
plasma FFA excess, the fat-rich diet and the adipose tissue (lipolysis). Insulin promotes
triglyceride storage in the adipose tissue and inhibits lipolysis. However in obesity, fat
depots become resistant to insulin (Foley et al. 1986; Stern et al. 1972;
- 54 -
Hirsch, Knittle 1970; Salans et al. 1968) so that the hormone sensitive lipase remains
active, driving hydrolysis of the stored triglycerides with subsequent excessive FFAs
release in the circulation. As a result, the circulating FFAs further to generating an
atherogenic lipid profile, they are also taken up by peripheral tissues where they are
either re-esterified and stored as triglycerides or used for energy production (oxidation).
In the long term, the excessive ‘ectopic’ fat storage and oxidation generates oxidative
stress that causes cellular damage and defects in cellular metabolism including IR (Li et
al. 2008; Hotamisligil 2006; Aikawa et al. 2002; Djuric et al. 2001; Inoguchi et al. 2000).
In addition, it also triggers cellular inflammation, resulting in serine phosphorylation of
IRS-1, thus further blocking the insulin signal transduction (Wellen and Hotamisligil
2005).
1.4.2 The Role of Adipose Tissue as an ‘‘Endocrine Organ’’ in the Pathogenesis of Type
2 Diabetes
The traditional view of adipose tissue as a passive reservoir for energy storage is
no longer valid. Studies highlight that human adipose tissue is a complex and highly
active organ controlling energy balance, metabolism and the immune system via the
expression and secretion of a variety of bioactive peptides, known as adipokines that act
locally but also systemically as endocrine hormones (Fruhbeck et al. 2001; Ahima, Flier
2000 ). It has been demonstrated that adipose tissue actively communicates with liver,
skeletal muscle, and the brain via secreted adipokines. The latter have diverse roles and
adipose fat depot mass-modulated expression levels, indicating changes in adipose tissue
mass and energy status and signal this information to organs that control fuel expenditure,
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contributing to energy homeostasis regulation or peripheral insulin action. Current
research has identified over 50 adipocyte-secreted bioactive factors (Table 1.4.2) with
local (autocrine/paracrine) and systemic (endocrine) effects that are produced by the fat
cells, and more are yet to be discovered. As individuals become obese and their
adipocytes enlarge, adipose tissue undergoes molecular and cellular alterations and
produces certain bioactive substances that promote inflammation including tumor
necrosis factor-α (TNF-α), interleukin 6 (IL-6), IL-8 (Cachofeiro et al. 2006).
Initially, the adipocytes have been exclusively blamed for the adipose tissue-
derived pro-inflammatory molecules. Recent studies however, suggest that obesity is
associated with increased infiltration of macrophage (adipose tissue macrophages-ATMs)
within the adipose tissue (Mozaffarian 2006; Sjöström et al. 1999; Stalmer et al. 1993;
Hubert et al. 1983), which in turn secrete high concentrations of inflammatory
compounds such as TNF-α and IL-6, that fuel further systemic inflammation (Lumeng et
al. 2007) and induce the development of insulin resistance. Kintscher et al (2008)
extended the original observations from ATMs to cells of adaptative immunity. They
demonstrated increased T-lymphocytes accumulation within the adipose tissue of obese
rodents mainly by using gene expression analyses and immunohistochemistry; more
interestingly, the T-lymphocytes infiltration preceded that of the macrophages. Similar
are the findings in human adipose tissue of morbidly obese patients as T-cell infiltration
was demonstrated by Wu et al (2003) who also suggested that these T-lymphocytes may
play a role in the development of IR during obesity. The accumulated T-lymphocytes
could in turn produce interferon gamma (IFNγ) that stimulate monocyte chemoattractant 
protein-1 (MCP1) release from the adipocytes(Brake et al. 2006) (Weisberg et al. 2006).
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Several hypotheses have been suggested to explain the accumulation of macrophages in
fat tissue. The most widely accepted suggests that the enlarged adipocytes become
‘fragile’, leaking chemoattractants such as M-CSF and MCP-1 that activate and recruit
macrophages in adipose tissue, even at the early stages of obesity (Takahashi et al. 2008).
1.4.3 Adipokines
 TNF-α for example, is highly expressed in adipose tissues of obese subjects 
(Hotamisligil et al. 1995) and has been proposed as a link between insulin resistance,
obesity, and diabetes (Sánchez et al. 2005). Supporting to this, is the finding that obese
mice lacking either TNF-α or its receptors are protected against developing insulin 
resistance (Uysal et al. 1997), while direct exposure of isolated cells to TNF-α blocks 
insulin signaling transduction and induces a state of insulin resistance in several systems,
including human primary adipocytes (Hotamisligil et al. 1996). TNF-α activates ERK 
and c-Jun N-terminal kinase (JNK) which in turn enhance serine phosphorylation of IRS-
1 in adipocytes (Rui et al. 2001). It has been estimated that JNK activity is increased in
obesity in several metabolically active sites including adipose tissue (Prada et al. 2005;
Ozcan et al. 2004; Hirosumi et al. 2002), in response to various stress signals, including
proinflammatory cytokines, FFAs, ER stress and reactive oxygen species (ROS). JNK in
turn, not only increases the production of inflammatory molecules thus exaggerates
inflammation (Shoelson et al. 2003) but also contributes to insulin resistance through
direct serine phosphorylation of IRS-1. The abnormally Ser-phosphorylated IRS-1
inhibits insulin’s intracellular signal progression causing IR (Pirola et al 2004; White
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2003); this explains why inhibition of JNK decreases the development of obesity-
associated IR (Hirosumi et al. 2002; Uysal et al. 1997; Hotamisligil et al. 1993).
Furthermore, data from studies in animal models have clearly linked resistin to IR
(Satoh et al. 2004; Rangwala et al. 2004; Rajala et al. 2004; Banerjee, Lazar 2003; Rajala
et al. 2003; Steppan et al. 2001). In addition, direct pro-inflammatory effects of resistin in
animal adipose tissue have been shown (Senolt et al. 2007). In contrast to what happens
in animal models though, the role of resistin in humans is less certain. Previous
researchers have documented resistin’s expression (mRNA and protein level) within both
human pre-adipocytes and adipocytes and its expression in higher levels in abdominal fat
(Sc and Om fat depots) compared to thigh and breast adipose tissue depots (McTernan et
al. 2002). Other researchers demonstrated the synthesis and secretion of resistin by the
adiposal macrophages (Curat et al. 2006); the extent of contribution of macrophages to
the overall concentration of resistin in adipose tissue though, remains uncertain. Studies
in humans have identified a strong link between resistin levels and obesity/IR/T2DM
(McTernan et al. 2002; McTernan et al. 2002; Vidal-Puig, O’Rahilly 2001) while others
failed to do so (Kielstein et al. 2003; Patel et al. 2003; Janke et al. 2002). This implies
that resistin might not be a principal mediator of insulin resistance in humans. On the
other hand, recent data from human studies suggest a very strong and consistent
association between resistin and inflammatory molecules in morbidly obese individuals
(De Luis et al. 2010; Kunnari et al. 2006; Iqbal et al. 2005) as well as in patients with
inflammatory diseases (Senolt et al. 2007; Pang, Le 2006; Reilly et al. 2005; Lehrke et al.
2004); plasma resistin levels were positively correlated with inflammatory markers
including TNF-, IL-6 and CRP. In another study, (Lehrke et al. 2004) researchers
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demonstrated TNF--induced resistin elevation, as a result of endotoxinemia.
Furthermore, studies with thiazolidinediones (TZDs) that are insulin sensitizers show that
TZDs reduce resistin levels and CRP values (Chu et al. 2002). Putting together, the lack
of association between resistin and insulin resistance, with the documented presence of
strong relationship between resistin and inflammatory markers may be explained by a
direct stimulatory effect of resistin on inflammatory processes.
Leptin is another adipokine that is secreted by the adipocytes in direct proportion
to adipose tissue mass. It serves as a metabolic signal of energy sufficiency (Friedman,
Halaas 1998) and modulates the function of the hypothalamic-pituitary-adrenal/thyroid
and -gonadal axes (Margetic et al. 2002; Flier et al. 2002; Hileman et al. 2000). Within
the human adipose tissue, increased leptin concentration, as in obesity, exerts pro-
inflammatory effects as it induces the release of TNF-a (Lappas et al. 2005) and the
endothelial-derived MCP-1 production, facilitating the recruitment of macrophages into
the fat tissue (Yamagishi et al. 2001). Furthermore, it has been demonstrated that leptin
levels are rapidly increased by many acute phase cytokines, such as TNF- and IL-6
(Kirchgessner et al. 1997; Sarraf et al. 1997) that are both present in excess in the adipose
tissue of obese individuals (Fried et al. 1998; Hotamisligil et al. 1993). Putting together,
there is an established interlink between leptin and inflammatory mechanism within the
adipose tissue contributing to excessive production and release of inflammatory
mediators.
There are other adipokines in which their role in glucose metabolism in human
subjects is not clear yet or is positive. Chemerin for example is a recently discovered
adipokine (Wittamer, et al. 2007) highly expressed in white adipose tissue (Bozaoglu, et
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al. 2007). Its role in glucose metabolism remains unclear. There are animal data showing
potent anti-inflammatory effects (Cash et al. 2008) and direct stimulatory effect of
chemerin on adipocyte GLUT-4 and adiponectin expression via its own receptor
(Bozaoglu et al. 2007; Goralski et al. 2007; Roh et al. 2007) plus enhancement of IRS-1
tyrosine phosphorylation, suggesting that insulin sensitizing effect of chemerin in adipose
tissue (Takahashia et al. 2008). On the other hand however, the plasma chemerin levels
were associated with BMI, triglycerides, and blood pressure in normal glucose tolerant
subjects (Bozaoglu et al. 2007). Omentin is another protein synthesized and secreted by
the visceral stromal vascular cells of the adipose tissue rather than the adipocytes. It
seems that it improves insulin sensitivity in human subcutaneous and visceral adipose
tissue as it increases Akt phosphorylation and glucose uptake by the adipocytes Kieffer,
Habener 2000) while and its plasma levels have been positively related to adiponectin
and HDL and inversely to obesity and IR in human subjects (de Souza Batista et al.
2007). Whether its role in glucose metabolism is important or not still needs to be
determined.
Adiponectin which is more expressed in subcutaneous than visceral adipose tissue
(Fain et al. 2004), is an adipokine for which a strong and consistent inverse relation to
both inflammation and insulin resistance has been established (Chandran et al. 2003;
Diez, Iglesias 2003); AMPK is suggested as mediator of its insulin-sensitizing effects
(Diez, Iglesias 2003; Yamauchi et al. 2003; Yamauchi et al. 2002). Unlike other
adipokines, serum levels of adiponectin are decreased in obesity and its associated
medical complications (Trujillo 2005). Actually, it has been estimated that plasma levels
of adiponectin decline before the onset of obesity and insulin resistance, therefore a
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potential pathogenetic role of hypoadiponectinemia in the generation of these conditions
(Hotta et al. 2001). Further to its involvement in metabolism, there is also an increasingly
recognized inverse inter-relationship between adiponectin and inflammation. It has been
shown that certain cytokines that increase within the adipose tissue with increasing
adiposity e.g. TNF-α and IL-6, suppress adiponectin expression in adipocytes (Bruun et
al. 2003), while on the other hand adiponectin levels are negatively associated with
inflammatory molecules, including TNF- (Zhou et al.2008; Park et al. 2006; Thakur et
al. 2006; Xu et al. 2003), IL-6 and CRP, but positively related to anti-inflammatory
cytokine IL-10 (Choi et al. 2007; Engeli et al. 2003). The attenuation of
proinflammatory cytokine production by adiponectin is mediated in part by attenuating
the translocation of NFκB to the nucleus (Wulster-Radcliffe et al. 2004; Ouchi et al.
2000), but also by inducing the expression of anti-inflammatory cytokine interleukin-1-
receptor antagonist (Kumada et al. 2004; Wolf et al. 2004) and by suppressing the Toll-
like receptor-4 (TLR-4) signaling pathway (Yamaguchi et al. 2005). Anti-oxidant effects
have been also attributed to adiponectin (via upregulating the uncoupling protein 2 levels)
by which it reduces oxidative stress and inhibits cellular inflammatory pathways
activation (Negre-Salvayre et al. 1997). Finally, it has been recently demonstrated that
adipose tissue may influence insulin sensitivity via non-hormone secretory factors such
as retinol binding protein 4 (RBP4), which is the major transporter of retinoic acid in the
body (Yang et al. 2005; Quadro et al. 1999). It has been shown that increased levels of
RBP4 as in obesity and T2DM decrease the activity of PI3K and the phosphorylation of
IRS-1, aggravating insulin resistance (Graham et al. 2006; Yang et al. 2005).
- 61 -
Table 1.4.2 Differences between adipocytes from subcutaneous (Sc) and visceral
depots (Modified from original Source: Montague & O’Rahilly; 1998)
Factor Regional Difference Reference
Leptin mRNA & protein Visceral  Sc Lebreve AM et al, 1998;
Harmalen VV et al, 1998;
Montague CT et al, 1997
TNF- Visceral  Sc Hube et al, 1999
IL-6 Visceral  Sc Fried SK et al, 1998
PAI-1 Visceral  Sc Shimomura I et al, 1996
Angiotensinogen mRNA Visceral  Sc Van Harmalen V et al, 2000
Resistin Visceral = Sc McTernan PG et al, 2002a
Adiponectin Visceral  Sc Fisher ffM et al, 2002
Androgen receptor mRNA Visceral  Sc Dieudonne M et al, 1998)
PPAR visceral = Sc Montague CT et al, 1998
TZD stimulated pre-
adipocyte differentiation
Visceral  Sc Adams M et al, 1997
Lipolytic response to
catecholamines
Visceral  Sc Rebuffé-Scrive M et al,
1989
Antilipolytic effect of
insulin
Visceral  Sc Zierath J et al, 1998
Lefebvre A-M et al, 1998
1 and 2-Adrenergic
receptor binding and
mRNA
Visceral  Sc Hellmér J et al, 1992;
Arner P et al, 1990
Dexamethasone-induced
increase in LPL
Visceral  Sc Fried SK et al, 1993
2-Adrenergic receptor
agonist inhibition of cAMP
Visceral  Sc Vikman H-L et al, 1996
Insulin receptor affinity Visceral  Sc Zierath J et al, 1998
IRS-1 protein expression Visceral  Sc Zierath J et al, 1998
Insulin receptor Visceral  Sc Lefebvre A-M et al, 1998
Glucocorticoid receptor
mRNA
Visceral  Sc Rebuffé-Scrive M et al,
1990
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1.5 Genetics of Obesity and T2DM
Alhtough there has been a sharp and unexpected upward turn in the prevalence of
T2DM in the last couple of decades cannot be attributed to novel genetic defects, the
genetic component to T2DM cannot be denied, given the high prevalence of the disease
in particular ethnic groups (Knowler et al. 1990; Zimmet et al. 1983), the differences in
incidence rates between monozygotic and dizygotic twins (Newman et al. 1987; Barnett
et al. 1981) and the inheritance seen in families with rare monogenic diabetes (Gottlieb
1980). Several candidate genes have been proposed for human T2DM susceptibility
including PPARγ (Barroso et al. 2006) KCNJ11 (Schwanstecher , Schwanstecher 2002),
CAPN10 (Cox et al. 2004; Altshuler et al. 2000), HNF4A (Hara et al. 2006; Hara et al.
2004; , Silander et al. 2004; Damcott et al. 2004), TCF7L2 (Grant et al. 2006),
IGF2BP2 (Huang et al. 2010), CDKAL1 (Ryoo et al. 2011), SLC30A8 (Kifagi et al.
2011) and HHEX (Ryoo et al. 2011). It is believed that each exerts only a partial
contributing effect to the development of T2DM and that the disease ensues only when
particular combinations of such ‘thrifty’ genes coexist with IR risk factors, such as
obesity. This is exactly what happens with a specific polymorphism of IRS-2 which
seems to increase susceptibility to T2DM, only among obese subjects (Bodhini et al.
2007). Interestingly, population studies and studies in family groups with evidence of
childhood obesity led to the identification of specific genetic variants that predispose to
both insulin resistance and obesity. In particular, further to leptin (Halaas et al. 1996),
gene variants including ENPP1 (Meyre et al. 2005), RBP4 (Yang et al. 2005;
Sivaprasadarao , Findlay 1988; Chambon 1996;), PEPCK (Rodgers et al. 2005;
Moynihan et al. 2005), adiponectin (Vimaleswaran et al. 2008) and UCP2 (Dalgaard
2011) have shown strong link with the development of both obesity and insulin
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resistance/T2DM, while in other cases such as in FTO gene, different polymorphisms
predisposed to T2DM or obesity (Ramya et al. 2011).
Although a clear divide between type 1 diabetes mellitus (T1DM) and T2DM is
suggested, the cross-over in terms of inflammatory pathways may blur those lines. T1DM
is an autoimmune disease in which autoreactive cytotoxic (CD8+) T-cells recognize a
number of antigenic determinants (insulin, IGRIP, GAD65, ICA512/IA-2, and I-A2ß)
(Lieberman et al. 2003; Atkinson, Eisenbarth 2001; Wong et al. 1999) expressed in
pancreatic ß-cells and progressively destroy them. Along with the cytotoxic T-cells, other
components of the inflammatory responses including CD4+ T-cells, macrophages,
natural killer (NK) cells and cytokines take part in insulinitis and ß-cell destruction.
Remarkably, the fact that the CD8+ T-cells are the most abundant cells in T1DM-
associated insulitis (Conrad et al. 1994; Bottazzo et al. 1985) suggests a potential crucial
role of major histocompatibility complex (MHC) in the development of T1DM. In
respect of T2DM studies, recent findings support a critical role of low grade whole body
inflammation and subsequent IR development even in patients with T1DM (Chase et al.
2004); with a reduction in inflammation shown to restore response to insulin.
Furthermore, gathering evidence appears to support that IR, a risk factor for progression
to T1DM may also herald the onset of autoimmune diabetes (Razavi et al. 2006; Sherry
et al. 2005; Betts et al. 2005; Fourlanos et al. 2004). Taken together, chronic
inflammation may accelerate ß-cell death and lead to T1DM. Support for this has been
noted through recent findings showing accelerated β-cell failure and apoptosis by 
inflammatory cytokines including TNF-α (Rui et al. 2001; Kwon et al. 1999), IL-1ß
(Wogensen et al. 1990) and IL-6 (Pakala et al. 1999). Studies have also shown that
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specific polymorphisms in the central human major histocompatibility complex (MHC)
region class III of chromosome 6, where the HLA-B associated transcript 1 (BAT1) lies
(Wong et al. 2003; Spies et al. 1989) predisposes to the development of autoimmune
disorders including T1DM (Allcock et al. 1999). These findings appear related to
previous experiments in monocytes and T-cell lines (Allcock et al. 2001) according to
which BAT1 down-regulates inflammatory cytokines such as TNF-α, IL-1 and IL-6. As 
such this may suggest that BAT1 polymorphisms leads to suppressed BAT1 protein
levels, leading to T1DM, via triggering inflammatory responses rather that autoimmune
processes and if this is accurate, BAT1 inactivating mutations could herald the
development of inflammation and subsequently IR and reduced β-cell secretory capacity 
in T2DM.
1.6 The protein encoded by the HLA-B associated transcript 1 (BAT1)
1.6.1 The major histocompatibility complex (MHC)
The major histocompatibility complex (MHC) is a large genomic region found
on the short arm of chromosome 6 that encodes proteins involved in immune
system processes including immune system response when foreign material presents
inside a cell. This is achieved by displaying pieces of the foreign material
or antigens (MHC:peptide) on the host cell's surface. Recognition of MHC:antigen
complex by immune cells, such as T cells or natural killer (NK) cells activates the
immune response against the presented antigen. Traditionally, MHC is divided into three
classes of clustered genes according to their properties/functions. The class I and II MHC
molecules perform the antigen presentation. In addition, they encode human leukocyte
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antigens (HLAs) that are displayed on the cell surface and define an individual’s tissue
type. Class III MHC genes encode a group of soluble proteins found in the blood
(complement system) that target foreign cells and breaks open their membranes, while
close to them is a cluster of genes that control inflammation. Because of their role to
defend against a great variety of foreign particles such as bacteria, MHC genes must be
able to present a wide range of peptide antigens derived from such digested particles and
are therefore highly polymorphic. It has been shown that specific MHC-related
polymorphisms are associated with either increased or decreased susceptibility to a range
of infectious diseases including tuberculosis, hepatitis and HIV/AIDS, while loss-of-
function MHC gene mutations may lead to autoimmune disorders in which the body fails
to recognize self-antigens for example multiple sclerosis, some forms of arthritis and
diabetes, and inflammatory bowel disease (Cheong et al. 2001; Ota et al. 2001; Price et
al. 1999).
1.6.2 Relation of BAT1 to immunopathologic disorders
The HLA-B associated transcript 1 (BAT1) gene is located in the central part of
class III MHC genomic locus on chromosome 6, between TNF and HLA-B genes (Wong
et al. 2003; Spies et al. 1989). Although it is difficult to study this region because of the
presence of strong linkage disequilibrium within the MHC and the high gene density, it
has been shown that the central part of class III MHC region contains genes that affect
susceptibility to immunopathologic disorders (Cheong et al. 2001; Ota et al. 2001; Price
et al. 1999). Thus, the ancestral haplotype 8.1 (HLA-A1, C7, B8, C4AQ0, C4B1, DR3,
DQ2) for example of this region (HLA-DRB1) was shown to predispose to rapid
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progression of HIV infection and to autoimmune disorders including TIDM, systemic
lupus erythematosus, rheumatoid arthritis, myasthenia gravis, coeliac disease, common
variable immunodeficiency, IgA deficiency and dermatitis herpetiformis (Allcock et al.
1999). These disorders are characterized by dysregulation of inflammatory cytokines
hence they may be influenced by single gene. In addition several genes in the central
MHC locus also have the potential to modulate immune or inflammatory responses in
an antigen-independent manner, as is observed in studies of cultured cells from
healthy carriers of the 8.1 ancestral haplotype however, only six genes
(LTA, LTB, TNF, IKBL, AT6PG and BAT1) are conserved through modern human
evolution (673) which means each constituent gene represents candidate for the observed
genetic associations. Furthermore, antisense studies have shown that BAT1 protein can
down-regulate inflammatory cytokines. Such studies indicate that monocytes and T-cells
(Allcock et al. 2001) BAT1 may encode a negative regulator of the inflammatory
cytokines TNF-α, IL-1 and IL-6 and may therefore influence immunological processes 
including the development of immunopathological diseases (Allcock et al. 2001). Taking
this together studies indicate BAT1 may be directly responsible for the genetic
association. Several other studies have shown an associated reduced BAT1 production
(on a disease-associated haplotype) (Wong et al. 2003) with susceptibility to various
autoimmune disorders. Thus, the restriction fragment length polymorphism (RFLP) of
BAT1 has been associated with myasthenia gravis (Degli-Esposti et al. 1992),
polymorphisms at positions -22 and -348 relative to the BAT1 transcription start site with
T1DM (Price et al. 2004), BAT1 -348T polymorphism with rheumatoid arthritis
(Quiñones-Lombraña et al. 2008), BAT1 polymorphisms in the promoter region at
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positions -22C/G and -348C/T with chronic Chagas cardiomyopathy (Ramasawmy et al.
2006) and the haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, with
susceptibility to hepatitis C virus-associated dilated cardiomyopathy (Shichi et al. 2005).
1.6.3 Structure, biochemical function and cellular localization of BAT1
The first transcript from a protein coding gene that contains both introns and
exons is called pre-mRNA. Current evidence suggests that, after the addition of a poly
(A) tract to its 3' end, the pre-mRNA is modified within the nucleus or during transport to
the cytoplasm to produce a mature mRNA molecule, before it can be used to produce a
correct protein through translation (Tal et al. 1979; Goldenberg & Raskas 1979; Nevins
and Darnell 1978; Lai and Khoury 1978). This RNA modification is called splicing and
refers to removal of the introns to produce the mature mRNA molecule which contains
only exons; the latter is then exported from the nucleus to the cytoplasm and translated.
After splicing, the mature RNA is exported from the nucleus to the cytoplasm. The
splicing and export processes are coupled. For pre-mRNA splicing to occur, a complex of
five specialized small nuclear ribonucleoproteins (U1, U2, U4, U5, and U6; snRNPs)
called spliceosome is necessary (Nilsen 2003; Hastings et al. 2001; Moore et al. 1993).
The spliceosome (U1, U2, U4, U5, and U6) assembles on pre-mRNA in a stepwise
manner, forming the E, A, B, and C complexes. Complex E (early complex) is formed by
the binding of U1 SnRNP to the 5’ splice site while the binding of U2 snRNA to the
branch point leads to the formation of complex A (pre-spliceosome complex). Then, the
snRNPs U4/U5/U6 are bound to complex A, forming complex B which by structural
rearrangement becomes active, able to catalyzes the removal of introns from the pre-
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mRNA segment and the subsequent ligation of the flanking exons. (Shen et al. 2007 and
2006 and 2004). The splicing of the pre-mRNA is a two-step procedure. In the first step,
the 5’ splice site is cleaved to produce linear exon1 and lariat configured intron/exon2
followed by the second step, in which the 3’ splice site is cleaved; then the two exons are
ligated to produce mature RNA (Shin et al. 2004; Cartegni et al. 2002). This RNA
structural rearrangements process requires RNA unwinding (Cordin et al. 2006; Linder
2006; Fairman et al. 2004; Laggerbauer et al. 1998; Raghunathan and Guthrie 1998) that
is performed by a series of splicing factors that are members of the DEXD/H-box protein
family (Sengoku et al. 2006; Rocak and Linder 2004; Silverman et al. 2003; Staley and
Guthrie 1998), but also energy (ATP) with the exception of the formation of the E
complex. Several DExD/H-box splicing factors possess an ATP-dependent RNA
unwinding/helicase activity using the energy of ATP hydrolysis (Staley and Guthrie
1998); BAT1 is such a protein (Shen et al. 2008; Shen et al. 2007; Fleckner et al. 1997).
1.6.4 DEAD-box RNA helicases
The DEAD-box helicases are a family of proteins/enzymes that catalyze the
unwinding of nucleic acids and are involved in various aspects of nucleic acids
metabolism (de la Cruz et al. 1999) The DEAD-box RNA helicases in particular, have
been implicated in every step of RNA metabolism, including RNA synthesis and pre
mRNA splicing, but also ribosome biogenesis, mature mRNA export, translation, decay,
and organellar gene expression (Johnson, McKay 1999; de la Cruz et al. 1999; Aubourg
1999); they contain 9–11 conserved helicase motifs (Cordin et al. 2006; Sengoku et al.
2006). The DEXD/H-box proteins do not have exactly the same properties and do not
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necessarily exert exactly the same function. It has been shown that some attain RNA-
dependent ATPase activity, while others unwind dsRNA in vitro (Yang and Jankowsky
2006; Sengoku et al. 2006; Tanaka and Schwer 2006; Rogers 2002; Wagner et al. 1998;
Wang et al. 1998). In addition, a subset of DEAD-box RNA helicases actively disrupts
misfolded RNA structures thus reverse stable nonfunctional secondary RNA formations
and permit the occurrence of correct folding (Lorsch 2002; Mohr et al. 2002; Tanner NK,
Linder P. 2001).
1.6.5 BAT1 structure/location
The HLA-B associated transcript 1 (BAT1) also called D6S81E or UAP56 is a
human gene encoding a 56-kDa, 428 amino acid protein, member of the DEAD-box
RNA helicases, with important role in the mRNA splicing and the export of the majority
of mature mRNAs from the nucleus to the cytoplasm for translation. Similarly to most
splicing factors, BAT1 is localized in the nuclear speckle (sub-nuclear structures that are
enriched in pre-messenger RNA splicing factors) (Dias et al. 2010). The structure and
crystallographic analysis of UAP56 protein are shown in table 3.1 and figure 3.3,
respectively). The BAT1 protein contains nine conserved motifs that characterize the
DEAD-box family of RNA binding proteins. Some of the motifs are responsible for
binding to mRNA or ATP and others possess ATPase activity (Allcock et al. 2001;
Schmid and Linder 1992). The UAP56’s amino -terminal and carboxy-terminal domains
are connected with a flexible liner (Shi et al. 2004; Zhao et al. 2004). They both have
typical RecA-like fold with seven parallel β-strands surrounded by α-helices on both 
sides. The N-terminal domain contains seven conserved helicase motifs (Q, I, Ia, GG, Ib,
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II, and III) and the C-terminal domain four (IV, QXXR, V, and VI). The crystal structure
of BAT1 indicates that the overall fold of amino-and carboxy-terminal domains is highly
similar (by 35%) to that of the prototypic DExD/H-box protein eIF4A; the latter is
involved in translation initiation (Caruthers 2002; Benz et al. 1999). The overall fold of
each RecA-like domain is similar to that of eIF4A, with differences at the loops and
termini. Taken together, the structural and sequential similarity might also suggest
functional similarity between BAT1 and eIF4A.
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Table 1.6.5 Crystal structure of the human ATP-dependent splicing and export
factor UAP56 - Summary of crystallographic analysis (adopted by Shi et al. 2004)
Data sets UAP56 UAP56-ADP UAP56 (C198A)
Spacegroup P1 P21 P1
Cell dimensions, Å 37.16 × 49.91 ×
62.27
37.00 × 78.09 ×
63.19
37.43 × 49.76 ×
62.81
Cell angles, ° 95.7 × 101.6 ×
111.1
90 × 103.4 × 90 95.6 × 101.9 ×
110.9
No. of proteins per
asu,* V m
1 (2.33 Å3/Da) 1 (1.98 Å3/Da) 1 (2.36 Å3/Da)
Resolution, Å 1.95 2.7 2.4
Measured reflections 107,519 27,997 55,301
Unique reflections 28,304 9,164 14,805
Average I/σ 19.7 15.0 20.9
Completeness, % (I/σ ≥ 
0)
96.1 (87.3) 94.6 (89.1) 92.9 (75.6)
R merge,† % 4.0 (18.0) 8.5 (14.1) 6.0 (10.1)
Refinement
Resolution range, Å 50.0-1.95 50.0-2.8 50.0-2.4
R factor/R free,‡ % 21.8/25.8 21/30 24.3/29.8
No. of protein atoms 3,089 3,017 (1
MgADP)
3,095
No. of solvent
molecules
4 isopropanol, 245
water
1 acetate, 85
water
1 BME, 59 water
rms deviations
Bond lengths, Å 0.008 0.007 0.008
Bond angles, ° 1.22 1.35 1.31
 ↵ * asu, asymmetric unit; V m, Matthews coefficient.
 ↵ † R merge = Σ|I -〈I〉|/Σ〈I〉, where I and〈I〉 are the measured and
averaged intensities of multiple measurements of the same reflection. The sum is
over all the observed reflections.
 ↵ ‡ R factor = Σ||F o| - |F o||Σ|F o|, where F o denotes the observed structure factor
amplitude and F C denotes the structure factor calculated from the model.
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Fig 1.6.5 BAT1 Structure. The structure of UAP56 is shown as a ribbon model (A) and
in a surface representation (B), viewed from a similar direction. (A) Cyan, N-terminal
domain; brown, C-terminal domain; green, interdomain linker. Locations of conserved
helicase sequence motifs are labeled. (B) Blue, positively charged electrostatic potential;
white, neutral electrostatic potential; red, negatively charged electrostatic potential. A
large ATP-binding cleft is formed between the N- and C-terminal helicase domains
(adopted by Shi et al, 2004)
1.6.6 BAT1 and pre-mRNA splicing
As a member of the DEAD-box RNA helicase family, purified human BAT1 is an
active RNA-stimulated ATPase that can hydrolyze ATP (Shen et al. 2007; Zhao et al.
2004; Benz et al. 1999) but also an ATP-dependent RNA helicase that gives BAT1 the
ability to unwind 5’ or 3’ overhangs or blunt end RNA duplexes in vitro. It was shown
that BAT1 attains an important role in pre mRNA splicing process and it is essential for
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the first ATP-dependent spliceosome assembly step (the binding of U2 snRNP to the
branch point sequence) (Fleckner et al. 1997); in this process, the human UAP56
(hUAP56) hydrolyzes ATP to facilitate the U2 snRNP-branch point interaction (Fleckner
et al. 1997). More details regarding role of hUAP56 in pre-mRNA splicing were recently
highlighted (Shen et al. 2008). It was shown that human BAT1 is actively involved in
several pre-mRNA splicing steps. Thus, the ATP-binding and ATPase properties of
BAT1 are required for the interaction of complex E with U2 snRNA for the formation of
pre-spliceosome (complex A). For the following steps of mature spliceosome formation
process and pre-mRNA remodeling, the ATP-binding, ATPase activity and dsRNA
unwindase/helicase properties of BAT1 are required; it has been shown that human
BAT1contacts U4 and U6 small nuclear ribonucleoproteins to promote the unwinding of
the U4/U6 duplex and facilitate stepwise assembly of mature spliceosome (Shen et al.
2008). Remarkably, mutations in the N-terminal domain conserved helicase motifs I, II,
and III result in loss of the ATPase or helicase activity of BAT1 (Zhao et al. 2004).
Fig 1.6.6 Function of UAP56 in pre-mRNA splicing (adopted by Shen et al. 2009)
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1.6.7 BAT1 and nuclear export
The splicing and export processes are coupled. After pre-mRNA splicing and
mature mRNA formation, it is exported through nuclear pore complexes to the cytoplasm
for translation (figure 1.5) (Mandel et al. 2008; Cheng et al. 2006; Chan et al. 2004;
Maniatis and Tasic 2002; Blencowe et al. 1998). Experiments in different organisms
support an essential role of BAT1 for the mature mRNA nucleocytoplasmic export
(Macmorris et al. 2003; Herold et al. 2003; Jensen et al. 2001). In Drosophila for
example, the mature mRNA export is mediated by a heterodimeric transport receptor
(NXF1-p15). The latter, binds the RNA directly or indirectly and transports it from the
nucleus to the cytoplasm. Studies in NXF1-p15 and BAT1 knockdowns revealed striking
similarities of the mRNA expression profiles (significant reduction of the exported
mRNAs, not as a consequence of higher mRNA turnover rates) indicating that these
proteins act in the same pathway plus that BAT1 is critical for the export of the majority
of mRNAs (Herold et al. 2003); remarkable is the existence of a feedback loop by which
blocking to mRNA export triggers the upregulation of BAT1. Similar were the findings
in BAT1 knockdown studies in Caenorhabditis elegans which demonstrated
accumulation of mRNA in the nucleus in the absence of BAT1; these findings support a
key role of UAP56 in mRNA export (MacMorris et al. 2003). The latter was also
supported by studies in higher eukaryotes in which BAT1 associates with spliced mRNAs
with exon junction complex thus might provide a functional link between splicing and
nuclear export (Reichert et al. 2002). It was shown in higher eukaryotes that BAT1
recruits an adaptor protein (REF1) to nascent mRNA which is in turn associated with
NXF1-p15 that eventually translocates the mRNA across the nuclear pore complex. It
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should be noted though that although essential, mRNA exporting properties have been
attributed to BAT1 in mammalian cells, although it is still not clear whether BAT1's
ATPase or helicase activity is required for its function to export mRNA (Gatfield
and Izaurralde 2002; Strässer et al. 2002). It has been shown that, in contrast to REF1,
which is recruited co-transcriptionally only to regions of the transcript in which introns
have been removed, BAT1 is bound along the mRNA independently of the presence of
introns (Kiesler et al. 2002). This means that BAT1 binding to nascent transcripts does
not necessarily lead to the recruitment of REF1. In addition, it was also shown that BAT1
is essential for the export of bulk mRNA, while REF1 is not (Gatfield D et al. 2002 and
2003). Putting together, in higher eukaryotes, BAT1 may act as a critical recruitment
factor that recruits not only REF1but also other/others unidentified protein, which in turn
promotes binding of NXF1:p15 heterodimers or its role in mRNA export may be that of
an helicase which means triggering ATP-dependent mRNA rearrangements that may
facilitate binding of proteins that act as adaptors for NXF1.
Finally, in addition to the role of UAP56 as component of splicing and nuclear
export complexes, it is also supported its role participation in transcription complexes.
The latter comes from findings in yeast where Sub2p (essential messenger RNA export
factor in yeast – its conserved counterpart in metazoans is BAT1) is associated with the
heterotetrameric THO complex that functions in transcription in yeast (Strässer et al.
2002). Putting together, BAT1 provides a bridge between transcription, processing, and
export (Reichert et al. 2002).
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Fig 1.6.7 Nucleocytoplasmic mRNA Export Through the Nuclear Pore Complex
(adopted by Daniel Stoffler web page, Scripps Research Institute)
1.6.8 Clinical significance of BAT1
UAP56 gene is located in the central part of class III MHC genomic locus which
affects susceptibility to immunopathologic disorders (Cheong et al. 2001; Ota et al. 2001;
Price et al. 1999). It is ubiquitously present in organisms from yeasts to humans and
widely expressed in multiple cell types (for example macrophages and hepatocytes)
which implies important role for survival (Allcock et al. 1999). Findings from several
studies have linked reduced BAT1 production with susceptibility to various autoimmune
disorders including myasthenia gravis (Degli-Esposti et al. 1992), T1DM (Price et al.
2004), rheumatoid arthritis (Quiñones-Lombraña et al. 2008) amongst other diseases.
These disorders are characterized by dysregulation of inflammatory cytokines; hence they
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may be influenced by single gene. However, antisense studies have also shown that
BAT1 protein can down-regulate inflammatory cytokines such as TNF-α, IL-1 and IL-6 
and may therefore influence immunological processes including the development of
immunopathological diseases (Allcock et al. 2001). Taken together, BAT1 may be
directly responsible for the genetic association with the above mentioned pathologies.
1.7 Aim of thesis
Obesity and obesity associated disorders such as insulin resistance, T2DM and
cardiovascular disease (CVD) is a pandemic problem. Currently, experimental,
epidemiological and clinical studies casually link inflammation to obesity and T2DM,
characterized by abnormal cytokine production and activation of inflammatory signaling
pathways (Wellen and Hotamisligil 2005). The inflammatory response that emerges in
obesity appears triggered by and resides predominantly in adipose tissue, although other
metabolically active sites, particularly liver, may also be involved during the course of
the disease (Shoelson et al. 2006; Fantuzzi 2005).
The function of BAT1 in human adipose tissue has never been investigated. We
hypothesize that BAT 1 plays an important role in the regulation of the obesity-associated
pro-inflammatory state within the adipose tissue which is considered fundamental in the
development of whole body inflammatory state and subsequent metabolic disorders such
as insulin resistance, T2DM, endothelial dysfunction and CVD. Initially studies will
investigate whether BAT1 is expressed in human adipocytes as well as pre-adipocytes. If
BAT1 expression is detected in human adipose tissue studies will investigate its
expression in the adipose tissue of lean and obese subjects with or without T2DM, as well
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as in different adipose tissue depots (abdominal subcutaneous and visceral depots).
Furthermore studies will address whether different adipose tissue depots alters
distribution of BAT1 examining the effect of body fat distribution on BAT1 expression
(‘Effect of Body Fat Distribution’ hypothesis). If according to our hypothesis, BAT1 is
suppressed in the obese individuals (‘Effect of Obesity’ hypothesis) and in those with
T2DM, as well as in the central (visceral) fat tissue compared to peripheral
(subcutaneous) adipose tissue further analysis will examine whether BAT1 repression
directly contributes to an increase in inflammation by increasing the production of
inflammatory cytokines TNF-α and IL-6, manipulating BAT1 expression in human 
adipocytes (cell line; repression as well as over-expression). In addition, in vitro studies
will examine regulation of BAT1 in human adipose tissue investigating the effect of
hormonal (leptin, adiponectin, resistin), inflammatory (LPS, TNF-) and nutritional
factors (high glucose concentration, high saturated fatty acid concentration) factors
known to pathogenesis of the obesity-associated metabolic defects. As such these
combined studies will elucidate the molecular link between BAT1, obesity and
inflammation which may lead to a new potential pathway to manipulate in the
development of new treatments for insulin resistance, T2DM and CVD.
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Chapter 2
General Methods and Materials
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2.1 General Methods and Materials
This chapter provides a detailed description of the experimental methods and
materials used in this thesis. Furthermore, details of the concentrations and composition
of reagents are provided in the appendices.
2.2. Human Subcutaneous and Omental Adipose Tissue Collection and Processing
Human subcutaneous (Sc) and omental (Om) adipose tissue samples were isolated
from patients undergoing biopsies or elective surgery/liposuction for cosmetic reasons.
The approval of the local ethics committee was issued for all the studies and informed
consent was obtained from all the patients prior to enrolment. Subjects with a history of
malignancy were excluded from the study, while patients with type 2 diabetes on
treatment with anti-diabetic medications or insulin were included and randomized
according to their body mass index (BMI) to the appropriate study subgroup. The fat
samples were utilized in a category II laboratory.
2.2.1 Extracted Adipose Tissue Freezing
Immediately after the collection, 40mL of adipose tissue was aliquoted into a
sterile 50mL falcon (centrifuge tube). The tube was then immediately frozen in liquid
nitrogen (N2) and subsequently transferred into a -80oC freezer, so that any level of
protein degradation or damage to be minimized. The samples were stored in -80oC for
future use.
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2.2.2 Isolation of Mature Adipocytes from the Extracted Subcutaneous and Omental
Adipose Tissue - Collagenase Digestion process
For the isolation of the mature adipocytes from the whole adipose tissue, 25-
30mL of whole fat tissue from patients undergoing biopsies or elective
surgery/liposuction was transferred to a sterile 50 mL falcon. 10 mL of pre-warmed
collagenase (2 mg/mL in HBSS, Worthington Biochemical Corporation, Lakewood, New
Jersey, USA) was added to this and the tissue/collagenase sample was vigorously shaken
by hand so that the collagenase to be well distributed through the whole sample. The
mixture was then incubated in a continuously shaking water bath of 37oC (100
cycles/minute) for 40 minutes, with four vigorous shaking at 10 minute intervals. This
step was considered completed when a smooth homogenous consistency of the sample
was reached meaning complete collagenase digestion. The falcons were then removed
from the water bath, wiped down with 70oC ethanol and put in a sterile primary cell
culture hood, where their contents were filtered through a layer of sterile autoclaved
cotton mesh (Medistore, UK) into a fresh sterile 50 mL falcon. To separate the mature
adipocytes, the mixture was centrifuged at 360 x g for 5 minutes and the falcon content
was separated into three layers-phases; the upper phase containing the adipocytes; the
middle phase containing the collagenase and the lower phase at the bottom, containing
the stromal-vascular fraction (formed by various cell types, including pre-adipocytes,
leukocytes and macrophages).
Any lipid sample was carefully removed from the upper phase of the densely
packed adipocytes; the latter was gently slided into a fresh, sterile 50 mL falcon by tilting
the centrifuge tube. Any contamination of the adipocyte layer from blood or collagenase
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was removed by washing the layer with 30 mL of warmed culture medium (37oC,
DMEM/F-12 Ham’s phenol red free medium, containing penicillin (100 units(U)/mL)
and streptomycin (100 µg/mL); Sigma, UK) and then by gently inverting the tube to
suspend the adipocytes and centrifuging at 190 x g for 30 seconds; this process was
repeated and each wash was followed by removal and discard of the liquid beneath the
adipocyte layer with a sterile 10 mL pipette till the adipocytes appeared free from blood.
When the presence of any macrophage-monocyte/blood contamination in the so isolated
mature adipocyte sample was excluded using immunohistochemistry (McTernan et al.
2002), 1 mL aliquots of adipocytes (approximately 500,000 cells as determined by
haemocytometer analysis) were transferred into 1.5 mL microcentrifuge tubes containing
1 ml 10% Dimethyl sulfoxide (DMSO) in 15% Foetal Calf serum and then immediately
frozen in liquid nitrogen (N2) and subsequently transferred into a -80oC freezer, so that
any level of protein degradation or damage to be minimized; the samples were stored for
future use.
2.2.3 Assessment of Adipocyte Cell Viability by Trypan Blue Staining
A dye-exclusion method was used to assess the viability of mature adipocytes. An
aliquot of compact adipocytes was re-suspended in trypan blue dye (Sigma, UK;
Appendix I) containing phosphate buffer saline (PBS, 120 mM, pH 7.6) and distilled
water (dH2O), followed by vortexing and incubation of the sample mixture for 5 minutes
at room temperature (RT). A homogenous aliquot of the mixture was measured with a
haemocytometer and both viable and non-viable adipocytes were analyzed under a light
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microscope and counted using a cell counter; the non-viable cells stain blue as they take
up the dye.
2.3 Protein Isolation and Quantification
2.3.1 Protein Isolation from human Abdominal Subcutaneous and Omental Adipose
Tissue using Radio-Immunoprecipitation Assay (RIPA) Buffer
For extraction of protein from whole abdominal subcutaneous or omental adipose
tissue, the 50 ml falcons with the tissue sample were transferred from -80oC freezer to a
2 liter Dewar flask containing liquid nitrogen so that the sample did not defrost.
Approximately 100 mg of frozen tissue was excised with a sterile scalpel and the excised
sample was placed in a 5 mL bijou tube with 600 µL Radio-Immunoprecipitation Assay
(RIPA) buffer. A Rotor-Stator Homogenizer (PowerGen 125, Fisher Scientific, UK) was
used at 1100-4200 x g for 30-40 seconds to homogenize the sample, which was then flash
frozen in liquid nitrogen and then removed and allowed to thaw. After thawing, the
mixture was spun at 18,000 x g at 4oC for 30 minutes. Using a 5ml sterile syringe and
hypodermic needle, the infranatant was carefully removed from beneath the lipid layer,
transferred to a fresh, labeled 1.5 mL microcentrifuge tube, and stored in a -80oC for
future use.
2.3.2 Quantification of Protein Concentration
The BioRad DC (detergent compatible) protein assay kit (BioRad, Hercules,
California, USA) (Peterson 1979; Lowry et al. 1951) containing reagent A (alkaline
Copper Tartrate solution), Reagent B (dilute Folin Reagent) and Reagent S (Surfactant
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solution) was used to quantify protein concentration of RIPA extracted samples. The used
protein assay allows the concentration of protein extracted from adipocytes and adipose
tissue to be quantified, thus enabling equal loading of protein samples when carrying out
western blot analysis.
To quantify the protein concentration, 1.5 mL labeled microcentrifuge tubes
containing RIPA extracted protein samples were removed from -80oC storage and
allowed to thaw; then the samples was vortexed to ensure a homogenous sample. 980 µL
of reagent A and 20 µL of reagent S of the BioRad DC (detergent compatible) protein
assay kit were mixed in a glass test-tube, creating a working reagent, A’. 3 µL of protein
extracted from adipose tissue was added to each polypropylene cuvette (Starstedt,
Germany), in which 125 µL of the previously described reagent A’ and then 1 mL of
reagent B were added. Finally, parafilm was placed over each cuvette which was then
mixed by inversion and incubated for 15 minutes at RT.
2.3.3 Standard Curve for BioRad DC Protein Assay
A standard curve of absorbance against protein concentration was concurrently
created using a series of known dilutions of bovine serum albumin (BSA, fraction V,
Sigma, UK) (2 µg/µL) in the range 0-100 µg/µL, using the method outlined above. The
absorbance of both samples and standards was measured at a wavelength of 655 nm,
using a 6505 UV/VIS spectrophotometer (Jenway, UK), allowing the protein
concentration of samples (µg/µL) to be determined.
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2.4 Western Blot Analysis of Protein Isolated from Adipocytes and Whole Adipose
Tissue
2.4.1. Western Blot Analysis of Protein
The western blot (alternatively, protein immunoblot) is an analytical technique
used in the sizing, detection and quantification of specific proteins from a given sample
of tissue homogenate or extract. In short, it uses agarose gel electrophoresis, pre-loaded
with the protein samples, to separate proteins by their size. A molecular weight marker is
loaded with the sample for size comparison. The proteins are then electrophoretically
transferred from the gel to a membrane (typically nitrocellulose or PVDF), where they
are probed (detected) with an antibody raised against the targeted protein. The latter is
then detected using a chemiluminescence detection method as shown in Table 2.1
Table 2.4.1: Composition of Sample Loading Buffer for Western Blot Analysis.
Sample Loading Buffer
Reagent Used Volume Added Final Concentration
Tris HCl (pH 6.8) (BioRad,
Hercules, CA, USA)
625 µL 125 mM
SDS (10%) (Sigma, UK) 500 µL 4%
Glycerol (Sigma, UK) 1000 µL 20% (w/v)
β 2-Mercaptoethanol 
(BioRad, Hercules, CA,
USA)
200 µL 6.5 x 10-3%M (w/v)
Bromophenol Blue 125 µL 2.5 x 10-3%M (w/v)
dH2O 250 µL N/A
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2.4.2 Preparation of Protein Samples Isolated from Adipocytes and Whole Adipose
Tissue for Western Blot Analysis
Quantified proteins were removed from -80oC, defrosted on ice and vortexed to
ensure a homogenous sample. 12-25 µg from each protein sample was pipetted into a pre-
labeled 1.5 mL centrifuge tube containing 10µl loading buffer (Table 2.4.2). Sample
volumes were equalized with varying quantities of distilled water and the mixture (50 µl)
was heated to 95oC for 5 minutes to denature and linearise the protein. After heating, the
microcentrifuge tubes containing the protein samples, loading buffer and distilled water
at a total volume of 50 µl were centrifuged briefly, kept in 4-5oC for 10 minutes so that
any evaporated water to be re-precipitated and then loaded onto the gel .
A rainbow molecular weight marker / ladder (Amersham Biosciences, product code
2892534 – RPN800E, batch 9; UK) with a range of 12 – 225 kDa (Fig 2.1) was diluted
1:5 with loading buffer, also heated to 95oC for 5 minutes and then loaded onto the gel
with each set of samples (one lane per gel). The ladder provides a method of identifying
a protein of a specific molecular weight- size by measuring it against a selection of
proteins of a known size (detailed in appendix III).
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Fig 2.4.2 Rainbow molecular weight marker (Amersham Biosciences, product code
2892534 – RPN800E, batch 9; UK)
2.4.3 Protein Separation using Gel Electrophoresis
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out as a
method of separating out the proteins by the molecular weight-length of the polypeptide
(4% stacking gel, pH 6.8; 10% resolving gel, pH 8.8); the percentage of resolving gel was
chosen according to the size of the protein of interest. The gels casings were prepared
following manufacturer’s instructions; 1.5 millimeter (mm) glass plates were arranged
and clamped in place; distilled water was poured between the plates to ensure they were
watertight and free from any leaks.
The resolving gel was prepared in a 50 mL falcon; the mixture was vortexed for
30 seconds and gently poured into the gel casings, leaving a gap of approximately 15 mm
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from the top of the glass plates for the stacking buffer to be added. A small volume of
methanol was poured onto the top of the resolving gel to initiate polymerization. The gel
was left for about 30 minutes at room temperature to set. Once completely set, methanol
was removed and the gel surface washed gently with distilled water.
The stacking gel was then prepared in a 50 ml falcon; the mixture was vortexed
for 30 seconds and gently poured onto the pre-set resolving gel. Taking care not to
introduce bubbles wells were created into the stacking buffer by inserting 1.5 mm thick, 5
mm wide, 10 well-combs. The stacking buffer was then left to set for 45-60 minutes at
room temperature.
Once completely set, the combs were carefully removed vertically and the wells
rinsed twice with distilled water, using a syringe and hypodermic needle to remove any
traces of excess acrylamide. The glass encased set gels were then securely fixed to
electrophoretic apparatus, placed inside an electrophoresis tank and subsequently filled
with 1 L of 1 x electrode buffer.
The 1.5ml microcentrifuge tubes containing the protein samples, loading buffer
and distilled water that were kept in 5oC for about 10 minutes so that any evaporated
water to be re-precipitated, were removed from the fridge, vortexed well, centrifuged
briefly and loaded onto the gels, using duck-billed tips (Fisher, UK). Using a voltage of
approximately 120 volts (V), proteins were resolved by electrophoresis until the loading
buffer had completely run through the gel and the proteins had separated sufficiently, as
determined by the position of bands visible on the molecular weight marker. Details of
the gels composition are given in appendix III.
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2.4.4 Transfer of Proteins – Electroblotting
After the completion of electrophoresis determined by complete run of the loading
buffer through the gel, the glass plates containing the gels were removed from the
electrophoretic apparatus, and carefully prised open, exposing the gel. The stacking gel
was removed and discarded, and the gels submerged in cold transfer buffer (appendix I)
for approximately 10 minutes at room temperature. Immobilon-PTM PVDF membranes
(0.45 µm) (Millipore, Bedford, Massachusetts, USA) of the size of the gel were
immersed in methanol (100%) for 3 seconds and subsequently washed for 60 seconds
with distilled water. The permeated membranes were then left in transfer buffer for
approximately 10 minutes at RT. Fibre pads and filter paper (2 sets for each gel) at least
of the size of the Immobilon-PTM PVDF membranes were also soaked in transfer buffer
and left for 10 minutes to equilibrate. For the transfer process, a section of filter paper
was firstly laid over a fibre pad and a gel laid onto the filter paper (orientated to be
identical to the loading sequence). The permeabilized Immobilon-PTM membrane was
then carefully placed on top of the gel, taking care throughout to remove any air bubbles.
This arrangement was further sandwiched with a top layer of filter paper and a fibre pad.
The stacks were then placed in transfer casings, in an orientation that would allow
migration of proteins from the gel onto the Immobilon-PTM membrane and submerged
into a tank, containing 1 L transfer buffer (appendix I). A magnetic ‘flea’ was deposited
in the bottom of the tank and an ice pack inserted into the tank to keep the transfer buffer
cool. The transfer apparatus was then placed onto a magnetic stirrer to enhance ion
circulation in the buffer for the generation of a current. Proteins were electrophoretically
transferred at a constant voltage of 100 V for 1 hour in 5oC.
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2.4.5 Primary Antibody Application
After the completion of electrophoresis and the protein transfer, the membranes were
gently removed from the transfer casings and the top right corner was marked, so that the
orientation of the proteins to be distinguished. They were then incubated in 10% non-fat
milk solution (Marvel Milk Powder, Premier Brands, Merseyside, UK), dissolved and
diluted in 0.5% PBS-polyoxyethylene sorbitan monolaurate (tween 20 (0.1% (v/v));
Sigma, UK) on an orbital shaker for 1 hour at room temperature. To block and minimize
any non-specific binding of primary antibodies to the Immobilon-PTM membrane, the
membranes were incubated with milk. After this step, the membranes were removed from
the blocking agent and rinsed three times with PBS, followed by three 10 minute washes
in 0.1% PBS-tween 20 (PBS-T).
The primary antibody was prepared at a concentration of 0.05% PBS-T, to a total
volume of 5 ml so that the membrane to be completely covered and incubated in a 50 mL
centrifuge tube, on an orbital shaker, for either 2 hours at room temperature. The exact
antibody dilutions can be found in chapter 3 where details of the experiments are sited.
Following this, the membranes were transferred to individual trays and rinsed three times
in PBS (120 mM, pH 7.6). Trays were then placed on an orbital shaker and membranes
washed 4 x 10-15 minutes in excess of 0.1% PBS-T to remove any excess primary
antibody.
2.4.6 Secondary Antibody Application
After the completion of the previous step, the membranes were incubated in the
secondary antibody that was previously prepared in 0.05% PBS-T; this process took
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place at room temperature for 1 hour on an orbital shaker (80-100 cycles/min). The
membranes were then rinsed thrice consecutively with PBS, and then underwent a further
4 x 10-15 minute washes in excess of 0.1% PBS-T to remove any excess secondary
antibody.
2.5 Immunodetection of Antibody-Labeled Proteins
2.5.1 Principles of ECL/ECL+ Detection
The horseradish peroxidase (HRP) is an enzyme extensively used in molecular
biology applications primarily for its ability to conjugate to a labeled molecule and
produce a color, fluorimetric or luminescent derivative of the molecule of interest; thus
HRP amplifies a weak signal and allows the targeted molecule to be detected and
quantified. However, the HRP enzyme alone is of little value and its presence must be
made visible. Therefore, the use of a substrate which when oxidized by HRP using
hydrogen peroxide as the oxidizing agent, yields a characteristic change that is detectable
by spectrophotometric methods is necessary.
There are several substrates for the HRP including the light transmitting chemical
luminol. The HRP catalyses the oxidation of luminol; the reaction is accompanied by
emission of low intensity light. However, in the presence of certain chemicals, the light
emitted may be enhanced up to l000-fold making the light easier to detect, increasing
thus the sensitivity of the reaction. Such a light transmitting enhancer is phenol and the
method that makes use of the enhancement of light emission is called enhanced
chemiluminescence (ECL; GE Healthcare, Little Chalfont, Buckinghamshire, UK).
- 92 -
The HRP enzyme is bound to the molecule of interest and acts as the catalyst for
the luminol. Thousands of acridinium ester intermediates per minute are generated by the
oxidation of the lumigen PS-3 acridan substrate, which is catalyzed by the combined
HRP and peroxide. The so produced intermediate products react with peroxide in PH
slightly above 7, producing a sustained, high intensity chemiluminescence. The
application of photographic X-ray film or real-time digital photography can exactly
visualize the light exuding from this reaction.
After the completion of secondary antibody incubation, the three times rinse with
PBS and the further 4 x 10-15 minute washes in excess of 0.1% PBS-T to remove any
excess secondary antibody the membranes were ready for chemiluminescent detection.
For protein immunodetection, the membranes were placed protein side up on an even
sheet of Saran Wrap (Appleton Woods, Birmingham, UK), making sure that any air
bubbles were removed. Depending on the protein being studied, either ECL or ECL+
was utilized and reagents were mixed accordingly in the ratios given in Table 2.2.
In order to allow even and total coverage of the membranes, the reagents were
mixed in sufficient quantities (approximately 1 mL/membrane). The membranes were
then incubated with the reagent mixture at room temperature for 1 minute (ECL) or 5
minutes (ECL+). To remove any excess ECL/ECL+ the corner of the membrane was
blotted onto tissue paper following the 1 minute (ECL) or 5 minutes (ECL+) incubation.
The membranes were then immediately transferred to a clear plastic wallet, not allowed
to dry. Using tissue paper and by gentle wiping over the surface of the plastic any air
bubbles were removed. The wallet was then placed inside a film cassette and the
membranes exposed to photographic X-ray film (Kodak, UK) for varying time points
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(from 1minute to 24 hours) depending on the antibody used, until the targeted protein
became suitably visible for detection and quantification.
Table 2.5.1 Quantities, ratios, and incubation times for chemiluminescence detection
systems used for western blot analysis.
2.5.2 Quantification of Western Blot Protein Bands
The quantification of western blot protein bands was done using Chemigenius
(Syngene, UK). For this purpose, 12-24 μg of the extracted protein was loaded onto a 
10% polyacrylamide gel (Geneflow Ltd., Fradley, UK), under reducing conditions. Then
a mouse BAT1 monoclonal antibody (primary antibody) was utilized (product code:
ab50986, UAP56 antibody [2060C10a], 1:1000; abcam Ltd., UK) and the blots were
developed using a secondary anti-mouse antibody (product code: ab6729, mouse IgG
secondary antibody – H&L, abcam Ltd., UK). Equal protein loading and transfer was
confirmed by examining β-actin (Cell Signaling, UK) expression (Primary antibody, 
1:1000; Secondary antibody, 1:10,000). The ratio of BAT1 to β-actin was used to 
minimize the potential effect of any insignificant differences in protein loading in the
results. Visualization of the produced western blot protein blots was developed by the
Chemiluminescence
Detection System Used
Reagent Ratio Used
(1 : 2)
Membrane Incubation
Time
ECL 1 mL : 1 mL 1 min
ECL+ 50 µL : 2 mL 5 mins
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usage of a chemiluminescent detection system ECL/ECL+ (GE Healthcare, Amersham
Biosciences, Little Chalfont, UK) following exposure to X-ray film and then intensity
was determined using densitometry (GeneTool software, Syngene, UK). The autographs’
quantification was followed by appropriate statistical analysis
2.5.3 Statistical Analysis
An unpaired Students’ t-test was used to compare the protein expression data
between control and treatments. Data were presented as mean±SD. Analyses were carried
out using the SPSS (SPSS Inc. 14.0, Woking, UK) software package. The threshold for
significance was p0.05. Further details of the statistical tests used are given in each
chapter.
2.6 Isolation and Purification of RNA from adipose tissue
Total RNA was extracted from whole AT, using a column-based isolation method
(RNeasy Lipid Mini Tissue Kit; Qiagen, UK), according to manufacturer’s instructions.
After the completion of this process, a DNase digestion step followed so that any
possible genomic DNA (gDNA) contamination, to be removed (appendix II). For the
DNase digestion step, 7 µL (1000 U/mL) of DNase I digestion enzyme (DNase I Kit,
Sigma, UK) was added to the eluted RNA, along with 7 µL reaction buffer (DNase I Kit,
Sigma, UK); the reaction was incubated at room temperature for 15 minutes. After the
completion of 15 minutes the reaction was stopped with the addition of 7 µL stop
solution (50 mM EDTA) (DNase I Kit, Sigma, UK). Following this, the samples were
vortexed, centrifuged briefly and heated to 70oC for 10 minutes for DNase (the process id
described below).
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2.6.1 RNA Quantification
As nucleic acids only absorb light at 260 nm, RNA was quantified using a
spectrophotometer (Nanodrop ND-1000, Labtech, UK) measuring at this wavelength.
The ratios between absorbances 260/280 nm and 260/230 nm were measured to give an
estimate of RNA purity, with respect to contaminants (e.g. proteins, solvents and salts),
which can alter the absorbance ratios as they absorb ultraviolet (UV) light at or around
280 nm (e.g. proteins) or 230 nm (e.g. phenols). Values of ~1.8 for both ratios between
absorbances represent an accepted RNA purity for use.
2.6.2 Reverse Transcription of RNA
1 µL of random hexamers (Invitrogen, UK) and 1 µL 10 mM dNTP mix (dATP,
dGTP, dCTP, dTTP at neutral pH, Invitrogen, UK) was mixed with an aliquot containing
200 ng RNA (diluted with distilled water to reach the desired RNA concentration) into a
1.5ml sterile microcentrifuge tube to a total volume of 13 µL. The mixture was then
vortexed, spun for 15 seconds and heated for 5 minutes to 65oC. After the completion of
this process, the samples were vortexed thoroughly and spun for 15 seconds and reverse
transcription mastermix was prepared to a sufficient volume as to allow for all reactions
(Table 2.6.2). 7 µL of the mastermix were added to each reaction, to a final volume of 20
µL. Each sample was subsequently vortexed thoroughly, spun briefly, incubated at room
temperature for15 minutes and then transferred to a thermocycler (Biorad, UK); there, the
samples were initially heated to 50oC for an hour, and subsequently heated to 70oC for 15
minutes, so that the reaction to be inactivated. The product of this reaction which is
complimentary DNA (cDNA) was then removed from the thermocycler, mixed, spun and
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stored at -20oC for use in the future (further information regarding reverse transcription,
in appendix II).
Table 2.6.2 Contents of Reverse Transcription master mix. *Invitrogen, UK;
**Promega, UK.
Reverse Transcription
Master Mix Components
Volume
Added
Concentration in Final 20 µL
Reaction Volume
5 x Reaction Buffer* 4 µL 1 x (v/v)
SuperScript III Reverse
Transcriptase* (200 U/µL)
1 µL 10 U/µL (v/v)
RNasin (40 U/µL)** 1 µL 2 U/µL (v/v)
0.1M DTT* 1 µL 5 mM
2.6.3 Quantitative Real-Time Polymerase Chain Reaction (QRT-PCR/qRT-PCR)
The quantitative real time polymerase chain reaction is a laboratory technique
used in molecular biology that enables both detection and quantification, as absolute
number of copies of a targeted DNA sequence. It is based on the polymerase chain
reaction, which amplifies and simultaneously quantifies a specific DNA sample. The
reactions were prepared to 25 µL volumes in a 96 well plate, in a reaction buffer
containing Taqman universal PCR mastermix (Applera, UK), 1 μL cDNA and a specific 
commercially available TaqManTM Gene Expression Assay (Applera, UK); the qRT-PCR
reaction was carried out using an ABI 7500 Sequence Detection System (Applera, UK).
All reactions were multiplexed with the housekeeping gene 18S (ribosomal RNA),
provided as a pre-optimized endogenous control assay (Applera, UK). The usage of an
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endogenous control enabled data to be expressed in relation to an internal reference,
allowing for differences in PCR efficiency.
Data were obtained as the cycle number at which logarithmic PCR plots cross a
calculated threshold line or the Ct value. In accordance with the manufacturer’s
guidelines, ΔCt values were determined (ΔCt is equal to the Ct of the target gene minus 
the Ct of the housekeeping gene), and the ΔΔCt method used for comparison of gene 
expression between groups (Applera, UK). To exclude any potential bias due to
averaging data which had been transformed through the equation 2-ΔΔCt, all statistics 
were performed at the ΔCt stage; each measurements was carried out in triplicate. The 
fluorescent label FAM was used to label all target gene probes while the housekeeping
gene was labeled with the fluorescent label VIC. Reactions were as follows: 50oC for 2
minutes, 95oC for 10 minutes, 44 cycles of 95oC for 15 seconds, and finally 60oC for
60seconds. Statistical analysis was performed using student’s t-test. Measurements were
carried out on at least three occasions for each sample.
2.7 Culture and Differentiation of Primary Human Pre-adipocytes
Primary human pre-adipocytes were isolated from human abdominal
subcutaneous and omental adipose tissue as described in 2.2b. The adipocytes were
maintained into 1.5 mL microcentrifuge tubes containing 1 ml 10% Dimethyl Sulfoxide
(DMSO) in 15% Foetal Calf serum in a -80oC freezer, so that any cellular nuclear
function to be ceased. For primary cell culture to be done, the pre-adipocytes were
removed from -80oC and quickly thawed in water bath (temperature 37oC). When the
content of the microcentrifuge tubes was thaw, they were removed from the water bath
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and put in a sterile primary cell culture hood, where their contents (human abdominal
subcutaneous or omental pre-adipocyte cells (n = 5-10) were cultured in an incubator
(37oC, 95% O2, 5% CO2 mix) and grown in 6-well plates to confluence in
DMEM/Ham’s F-12 medium containing 15% foetal calf serum (FCS), penicillin (100
U/ml), streptomycin (100 µg/ml), and transferrin (5 µg/ml). At confluence, pre-
adipocytes were differentiated in differentiation media containing DMEM/Ham’s F-12
phenol red free medium containing glucose (1000 mg/liter), insulin (500 ng/ml),
transferrin (5 µg/ml), biotin (8 μg/ml), Dexamethasone (400 ng/ml), IBMX (44 μg/ml), 
Ciglitazone (3μg/ml) and L-Thyroxine (9ng/ml) for 96 hours. The differentiation media 
were refreshed every 48 hours. After 96 hours the differentiated cells were grown in
nutrition media containing DMEM/Ham’s F-12 phenol red free medium with d-biotin (8
μg/ml), 3% FCS, Dexamethasone (400 ng/ml) and insulin (500 ng/ml) until the cells were 
fully differentiated, as indicated by the accumulation of lipid droplets shown under
x12,000 microscopic observation of the adipocytes (14-20 days). The nutrition media
were also refreshed every 48 hours.
Before any treatments, the growth media were removed and the fully
differentiated adipocytes were grown in normal DMEM/Ham’s F-12 phenol red free
medium containing only 2% serum for 24 hours, so that any effects of growth factors and
other components used in nutrition media to be removed. After 24 hours, the
detoxification media were refreshed and any treatments were then placed in the refreshed
detoxification media for the required time points, depending upon the type of treatment.
The isolation, purification and estimation of RNA and protein extracted from
cultured primary cells are the same with those used in primary cells.
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2.8 Enzyme Linked Immunosorbent Assay (ELISA) / Principles of ELISA Analysis
The ELISA is an immunological technique used to detect the presence and
quantify specific proteins in a sample (in our case cell culture media). An antibody,
specific to the protein of interest, is coated onto individual wells of a microtiter plate
where the samples with the protein of interest (antigen) are pipetted. With this process, an
unknown amount of the antigen is captured by the immobilized antibody on the base of
the well. Then a specific detection antibody is washed over the surface, forming a
complex with the antigen or the antigen antibody. It is important between each step the
plate to be washed with a mild detergent solution so that any proteins or antibodies that
are not specifically bound to be removed. After removal of excess antibody, a HRP-
labeled antibody is added, which binds to the detection antibody to complete the four-
member sandwich. Following a third incubation and subsequent washing, a substrate
solution is added, which is activated by the bound enzyme to produce a detectable signal
for e.g. color. The color intensity is directly proportional to the concentration of the
protein of interest in the original sample. The intensity of the color is then read on a plate
reader (Tecan, UK), alongside a standard curve that is set up concurrently with the
samples of interest.
In this thesis, ready prepared, commercially available assay kits were used for all
ELISA assays performed and the analysis was carried out in accordance with the
manufacturer’s instructions contained within the individual kits. The particular kit
sources and all the corresponding CVs, intra- and inter-assay values for each individual
assay are outlined in the relevant chapters. Appropriate statistical analysis for ELISA
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was carried out using a statistical software package (SPSS for Windows, Version 16.0,
Woking, UK).
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Chapter 3
Characterisation of BAT1 Expression
in
Human Adipose Tissue
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3.1 Introduction
More than 45 morbidities from all body systems have been linked to obesity.
Among them, the increasing prevalence of T2DM has been strongly linked to increasing
adiposity; the term “diabesity” has been suggested as providing the point that T2DM and
obesity often go hand in hand. Data from large epidemiologic studies reveal the parallel
escalation of obesity and diabetes epidemics. It is estimated that 50-60% of patients with
T2DM are obese (NHANES and SHIELD, respectively). Several theories linking
different pathogenic mechanisms that make obese individuals prone to develop diabetes
have been suggested, including the Randle’s cycle’, the ‘Ectopic Fat Storage Hypothesis’
and the role of adipose tissue as endocrine organ. Only in the last few years scientists
have come to consider obesity as a low-grade inflammatory state in the view of increased
plasma circulating mononuclear cells and lymphocytes (Perfetto et al. 2002) in obese
individuals, as well as in the view of increased plasma concentration of pro-inflammatory
cytokines (TNF-, IL-1, IL-6) and acute phase proteins (CRP) in this group of the
population (Yudkin et al. 2002; Van Dielen et al. 2001; Visser et al. 1999; Dandona et al.
1998). It has been proposed that source of the pro-inflammatory molecules is the adipose
tissue (Xu et al. 2003) and in particular the enlarged/hypertrophic adipocytes and the
locally accumulated/chemo-attracted macrophages (Curat et al. 2004; Weisberg et al.
2003; Xu et al. 2003). The close relationship between metabolic and inflammatory
signaling pathways in insulin-sensitive peripheral tissues has been demonstrated,
providing the pathway for the inflammatory-induced insulin resistance and T2DM.
Although significant progress has been made regarding the understanding of the
changes in the adipose tissue hormonal, metabolic and biochemical milieu with
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increasing adiposity, the crucial fundamental factor that drives the inflammatory state
development in the adipose tissue of obese individuals still remains unknown. The HLA-
B associated transcript 1 (BAT1), is an RNA helicase, member of the DEAD-box protein
family that participates in RNA metabolism in particular pre-mRNA splicing and mRNA
nuclear export (Luo et al. 2001) and down-regulates inflammatory cytokines (Allcock et
al. 2001). This anti-inflammatory protein could be of great importance in the
inflammatory state generation within the adipose tissue as its suppression could influence
the local immunological processes and precipitate the inflammatory state generation.
BAT1 also called D6S81E or UAP56 is a human gene encoding a DEAD-box
family RNA helicase. It lies in the central human major histocompatibility complex class
(MHC) III region on chromosome 6, a region of great importance for the immune
function. The HLA-B associated transcript 1 encodes a protein with important role in the
mRNA splicing and mature mRNA transport from the nucleus to the cytoplasm for
translation. Mutations of BAT1 have been linked to several autoimmune disorders
including insulin-dependent diabetes mellitus, rheumatoid arthritis, systemic lupus
erythematous, myasthenia gravis, coeliac disease, dermatitis herpetiformis (Allcock et al.
1999). Little is known about the role and function of the protein encoded by BAT1 gene.
Its ubiquitous presence however, in organisms from yeasts to humans implies a potential
crucial role of this protein in organisms’ survival and immune response. Furthermore,
screening of human cells and tissues for BAT1 revealed its expression in multiple cell
types, notably in macrophages and hepatocytes (Quinones-Lombrana et al. 2008; Price et
al. 2004; Allcock et al. 2001 and 1999).
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The aim of this study was to investigate the expression of BAT1 in human
adipose tissue, the effect of adiposity as well as diabetic status. Further the influence
of obesity with and without diabetes on BAT1 expression to elucidate the importance
of the metabolic state in expression of BAT1.
3.2 Methods & Materials
3.2.1 Subjects
Human AT was collected from patients (age: 44.7 (mean ± SD) ±9.3yrs; BMI:
27.9 (mean ± SD) ±7.3kg/m2; male: female ratio 1:4, fasted for 8hr) undergoing elective
surgery with informed consent, obtained in accordance with LREC guidelines and
approval. All tissue samples were flash frozen and/or utilized for in vitro studies as
detailed below. In total, 43 human non-diabetic AT samples were analyzed, which were
sub-divided into: AbdSc (n=25), and Om (n=18). Subjects providing fat samples were not
on endocrine therapy, (e.g. steroids, HRT, thyroxine) or receiving any anti-hypertensive
therapy. Abdominal subcutaneous adipose tissue was also utilized from T2DM patients
(age: 59.1±8.2 yr; BMI: 35.2±9.2kg/m2, n=8 male: female ratio 2:1).
3.2.2 Extraction of AT RNA for Quantitative PCR
RNA was extracted from AT from AbdSc (n=23), Om (n=18), using RNeasy
Lipid Tissue Mini Kit (Quiagen, Crawley, UK), which included a DNase digestion step to
remove any contaminating genomic DNA. 1g of RNA from each sample was reverse
transcribed (RT) using AMV reverse transcriptase (Promega, Southampton, UK)
according to manufacturers’ instructions (McTernan et al. 2002, Diabetes).
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3.2.3 Microarray
Paired abdominal sc and abdominal omental (n = 10) adipose tissue biopsies were
divided into two cohorts according to BMI (lean, n = 5; BMI, 23.0 ± 1.2 kg/m2; obese, n =
5; BMI, 33.2 ± 3.1 kg/m2). Gene expression in paired abdominal sc and omental adipose
tissue samples were analyzed using the Human Genome U133 plus 2.0 DNA microarrays
(Affymetrix). Preparation of cDNA and hybridization to DNA microarray was performed
according to standard Affymetrix protocols. The hybridization and analysis were performed
according to the Minimum Information about a Microarray Experiment guideline and as
previously assessed for other genes (Saiki et al. 2009; Brazma et al. 2001). Gene
expression profiles from the adipose tissue samples were analyzed using the RMA software
(Affymetrix).
3.2.4 Protein determination & Western blot analysis
Protein concentrations were determined using the Bio-Rad Detergent Compatible
(DC) protein assay kit (Biorad UK). Homogenized human AT were extracted using a 10%
RIPA buffer method (McTernan et al. 2002). Western blot analysis was performed using a
method previously described (McTernan PG et al. 2002) and relative expression was
standardized by using a densitometry quantification software (GeneTools, Geneflow,
Fradley, UK). In brief, 5-20g of protein was loaded onto an 8% polyacrylamide gel
(Geneflow, Fradley, UK), a mouse BAT1 monoclonal antibody (primary antibody; product
code: ab50986, UAP56 antibody [2060C10a], 1:1000; Abcam Ltd., UK) was used to assess
BAT1 expression (Biosource UK, Nivelles, Belgium). Equal protein loading was
confirmed by densitometry using the actin antibody (2.04g/mL, Abcam, Cambridge,
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UK). A chemiluminescent detection system ECL/ECL+ (GE Healthcare, Little Chalfont,
UK) enabled visualization after exposure to X-ray film.
3.2.5 Statistical Analyses
Descriptive statistics for numeric variables (mean, standard deviation, median) along
with 95% confidence limits for mean. In order to explore correlations between numeric
variables Pearson coefficient and additionally non parametric Spearman coefficient were
used. Shapiro-Francia Normality test was used to test the normality of the data. To
compare mean values of BAT1 2 independent samples t-test (the threshold for
significance was p0.05), or one-way ANOVA (in case of 3 or more categories) were
used. In addition the non parametric tests Mann-Whitney and Kruskal-Wallis were used.
For the multiple comparisons after ANOVA, the Scheffe’s multiple test was used. Finally
the linear multiple regression model was used to assess the overall effect of the predictors
to our primary end-point variable (value BAT1). For the graphical presentation bar charts
and box-plots were used.
3.3 Results
3.3.1 BAT-1 microarray expressed in human Sc and Om abdominal adipose tissue
The micro-array analysis met all quality standard criteria with 5’/3’ ratios of 78%
for GAPDH and 60% for β-actin, where it should be noted that values greater than 33% 
are considered acceptable. Furthermore transcript integrity had been maintained at all
stages of RNA extraction and target preparation. Across the arrays there was an average
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present call, as determined by GCOS software, of 38% of total probe sets indicating that
target integrity was with normal boundaries and that low abundance signals were
detectable (expected range of 31.9% for liver to 40.5% for brain; Affymetrix technical
notes). Overall 10,895 probe sets were called as present on all 20 of the arrays with a
further 22,965 being called as present on at least one array.
Initial microarray expression data examined whether BAT1 expression mRNA
expression levels were detectable in human adipose tissue (AT) depots. This data
identified BAT1 mRNA expression in all adipose tissue depots. There was also a noted
change in expression between AT from lean and obese subjects [AbdSc AT lean: 1567
(±SEM) 73 optical density units (ODU), AbdSc AT obese: 1211±53 ODU; Om AT Lean:
1598±34 ODU, OM AT obese: 1387±68 ODU].
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Figure legend 3.3.1. Microarray mRNA expression of BAT1 in Abdominal
Subcutaneous (Sc) and Omental (Om) adipose tissue from lean and obese subjects.
Actual optical intensities are plotted (P-values: *p<0.05).
3.3.2 mRNA expression of BAT1 in human adipose tissue using real-time data analysis
Real time PCR analysis data confirmed the initial microarray BAT1 mRNA
expression levels in human AT depots however the RT-PCR identified more pronounced
changes with adiposity and depot specific expression [AbdSc AT lean: 8.86 (±SEM) 0.19
*↓ Vs  
Sc lean
*↓ Vs 
Om lean
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ΔCT, AbdSc AT obese: 12.37±0.28ΔCT; Om AT Lean: 9.76±0.16ΔCT, OM AT obese: 
11.64±0.17ΔCT; Figure 3.3.2; Figure 3.3.2.1].
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Figure 3.3.2: Relative mRNA expression levels of BAT1 quantified by Real-Time RT-
PCR (n=20) (A) abdominal Subcutaneous (AbdSc) Adipose Tissue (AT): Lean vs Obese
(B) abdominal Omental (Om) AT: Lean vs Obese, and (C) AbdSc Vs Om AT (P-Value:
***p<0.001).
The final figure below also details the relative fold changes in expression
compared between the AT depots as well as examining the effect of how AT taken form
T2DM subjects changes BAT1 mRNA expression [T2DM AbdSc AT: 12.5±0.40ΔCT Vs 
T2DM Om AT 10.81±0.24ΔCT; Figure 3.3.2.1]. 
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Figure legend 3.3.2.1. Relative fold mRNA expression of BAT1 in Abdominal
Subcutaneous (AbdSc) and Omental (Om) adipose tissue from lean and obese subjects, as
well as subjects with type 2 diabetes mellitus (DM). AbdSc lean adipose tissue has been
given an arbitrary figure of 1 to compare with other tissues (P-values: *p<0.05, **p<0.01,
***p<0.001).
3.3.3 The effect of adiposity and gender on mRNA BAT1 expression
Although the data highlighted a change with adiposity further analysis addressed
whether there was a statistically significant correlation between BAT1 expression and
BMI using Pearson and Spearman coefficient. The results showed that using the Pearson
***
***
***
***
***
**
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Coefficient -0.609 with a p-value of p<0.001, which was also affirmed using the
Spearman coefficient -0.603 and a p-value of p<0.001, highlighting that as BMI
increased BAT1 mRNA expression reduced. With analysis of the mRNA data women
tended to have a higher BAT1 mRNA level compared with men (R-value 0.266;
p<0.001).
Figure 3.3.3: Scatter plot of BAT1 mRNA expression versus BMI (Kg/m2, R
value*****; P value, p <0.001)
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3.3.4 Protein expression of BAT1 in human adipose tissue
The effect of AT depot and adiposity for BAT1 protein expression was also
analyzed in both depots (Lean: BMI: AbdSc and Om (mean±SD) 22.26±2.62kg/m2 and
Obese: BMI: AbdSc and Om 31.2±6.2kg/m2). BAT1 expression was significantly
increased in the AbdSc depot compared with Om AT group (Figure: 3.3.4; AbdSc:
6.46±(SEM)1.10 ODU Vs Om AT: 2.97±1.34 ODU; P < 0.05). Furthermore BAT 1
expression altered significantly with adiposity in AbdSc AT (6.46±1.10 ODU Vs Om
AT: 2.97±1.34 ODU; P<0.05; Figure 3.3.4.1).
Figure 3.3.4: Protein expression of BAT1 (38 KDa) between AbdSc and Om AT. A
representative Western blot is shown for BAT1 and equal protein loading was confirmed
by using -actin (P-Value: *P<0.05).
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Figure 3.3.4.1: Protein expression of BAT1 (38 KDa) between AbdSc lean and obese
subjects is shown. A representative Western blot is shown for BAT1 and equal protein
loading was confirmed by using -actin (P-Value: *P<0.05).
Finally, utilizing the human pre-adipocyte cells line Chub-S7 protein expression
of BAT1 was assessed across differentiation, to determine the level of expression in a
pure fat cell population. The figure below highlights clear expression of BAT1 in
isolated human adipocyte cell line (Figure 3.3.4.2).
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Figure 3.3.4.2: BAT1 Protein expression (38KDa) across differentiation in human
Chub-7 cells (n=3).
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3.4 Discussion
The premise of this chapter was to understand the relevance of BAT1 in human
adipose tissue and understand whether its perceived roles in other tissues and cell line
studies may be influential in human adipocytes. To examine this, a series of molecular
techniques were utilized. Initially studies investigated the presence of BAT1 in lean and
obese Abdominal Sc and Om AT through microarray analysis. These studies revealed
that BAT1 was expressed in human Abd Sc and Om AT altered by adiposity and T2DM
status.
Although no functional studies explored the role of BAT1 in this chapter
following microarray analysis further studies addressed whether increasing adiposity
and/or diabetic status may reduce the expression of BAT1 within the AT. Interestingly
initial microarray studies identified that BAT1 expression was reduced with obesity in
either Abd Sc or Abd Om AT. Subsequent analysis by RT-PCR confirmed this
observation with BAT1 mRNA expression reduced with increasing adiposity in both fat
depots and a further reduction in subjects with T2DM. However it should be noted that
microarray data has to be interpreted cautiously as although an extremely sensitive
technique, it can lead to false positives and therefore as in this case the data should
always been supported with specifically designed probe sequences that can ensure the
data is accurate. To affirm the findings from the real time data subsequent studies
examined protein expression of BAT1 and confirmed the real time PCR data.
Additionally, whilst it was established that BAT1 was expressed at the gene and protein
level in human adipose tissue further studies determine the expression of BAT1 in
isolated human adipocytes, as assessed by undifferentiated and differentiating human pre-
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adipocyte Chub 7 cells. These findings established that pure cultured human adipocytes
express BAT1.
Although obesity reduced expression of BAT1 in either Abd Sc or Abd Om AT it
was interesting to note that BAT1 expression was observed to be much higher in lean
AbdSc AT than in either omental AT groups (lean or obese) or in either Abd Sc or Om
depot once subjects became diabetic. Such an observation may be due to the knowledge
that Abd Sc appears to represent the least insulin resistant tissue compared with Abd Om
AT or an epicardial AT. However Abd Sc AT importance should not be underestimated
in the pathogenesis of T2DM and may represent the last adipose tissue which tries to
buffer ectopic fat from other tissues reducing inflammatory responses (Carobbio et al.
2011). With BAT1 mRNA expression reduced in obese and T2DM states this may
incapacitate BAT1 functionality to reprise the production of inflammatory cytokines and
co-current insulin resistance. The BAT 1 expression would also tend to fit with the
subjects at most risk of insulin resistance, with men tending to show a lower BAT 1
expression compared with women.
Taken these finding together, indicate that if BAT1 expression is suppressed with
increasing adiposity and remain suppressed, through to the development of T2DM and
thereafter this may reduce the capacity to response to the inflammatory insults. Such
BAT 1 suppression in the adipose tissue of obese subjects could be associated with
unhindered local release of inflammatory cytokines e.g. IL-6, TNF- that generate a local
pro-inflammatory state initially with later systemic effects. Interestingly, within the
subgroup of the obese subjects (with or without diabetes) BAT1 was significantly more
suppressed in the Abd Sc adipose tissue compared with Om AT. This may not be what
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many studies would anticipate as omental AT is often viewed as the critical site in the
generation of the metabolic disturbances (e.g. Isomaa et al. 2001; Kahn, Flier 2000;
Kissebah & Krakower 1994; Larsson et al. 1984). This finding however, could imply a
more important role of peripheral Abd Sc AT in the generation of inflammation in
obesity than other studies might consider currently (Carobbio et al. 2011). Although often
noted in Abd Sc AT is to have comparable or significant adipokine protein expression
and release compared with Om AT (McGee et al. 2011; Harte et al. 2005; Fisher et al.
2005; McTernan et al. 2003; McTernan et al. 2002). Besides AT depot being important
for BAT 1 expression these current studies also examined predictors of BAT1 expression
such as BMI, age, gender and T2DM status. The statistic analysis revealed that increased
BMI, male gender and presence of diabetes were all associated with suppressed BAT1
expression.
In conclusion this chapter has identified that BAT1 is clearly expressed in human
adipose tissue and isolated human adipocytes, further that fat depot, adiposity, diabetic
status and gender can impact on the expression of BAT 1. However, as the human
adipose tissue contains several cell types except of adipocytes, including fibroblasts,
macrophages, lymphocytes and endothelial cells, and some particular cell types increase
with increasing adiposity for e.g. macrophages (Weisberg et al. 2003) and lymphocytes
(Kintscher et al. 2008; Wu et al. 2007) it will be important to establish if BAT1
expression is regulated in human adipocytes. Further to understand whether local release
of inflammatory cytokines influence BAT 1 expression and as such suggest how obesity
and diabetic status may affect BAT1 activity.
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Chapter 4
BAT1 Expression in the Immortalized Human Subcutaneous
Pre-adipocyte Cell Line Chub-S7
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4.1 Introduction
In the previous chapter BAT1 expression at mRNA and protein level was
established in human adipose tissue. However, since adipose tissue is composed of
several cell types including macrophages, lymphocytes, endothelial cells, amongst other
cell type, the identification of BAT1 expression in the whole adipose tissue is obviously
not synonymous with BAT1 expression in the isolated adipocytes. Therefore, this chapter
will focus on the expression of BAT1 in isolated human adipocyte cell line and how
expression changes through differentiation using the human subcutaneous pre-adipocyte
cell line Chub-S7, also called CNCM I-2663. The human pre-adipocyte Chub-S7 (CNCM
I-2663) cell line is a well-characterized human preadipose cell line (Jha, Banga et al.
1998). Chub-S7 represents a transformed human pre-adipocytes immortalized by co-
expression of human telomerase reverse transcriptase (hTERT) and papillomavirus E7
oncoprotein (HPV-E7) genes. The pre-adipocytes are derived from the subcutaneous
abdominal white adipose tissue of a 33-year-old severely obese female subject.
Cell lines are widely used in molecular and cellular biology, for the study of
intracellular activities, but also for the elucidation of the effects of extracellular
molecules and cell-cell interactions. They are produced by extraction from tissue
containing a heterogeneous cell population including the cell type of interest, which is
separated from several other cell types allowing for subsequent isolation of the cell clone
of interest. As soon as the cell clone is isolated, it is then cultured so that the total cell
number increases over several generations and the population is uniform in its lineage.
However, the isolated and grown homogenous cellular population will survive
only a limited number of passages in an in vitro culture and then they will start to
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senesce. Therefore, the cells need to be immortalized. This is usually achieved by
infecting the cells with a recombinant vector, which could be a recombinant plasmid, a
recombinant virus or a retrovirus that harbors in its genome an oncoprotein gene and the
telomerase reverse transcriptase gene (hTERT). It was demonstrated (Kiyono, Foster et
al. 1998) that if the hTERT genes are derived from the same species as the cells being
immortalized, this could prevent senesce of cells caused by the shortening of the
chromosome's telomeres as it happens with allogenic TERTs. The immortalized cell line
derived still attains the karyotype and exhibit metabolic patterns that are essentially
identical to those of the non-immortalized original cells that are not tumorigenic. These
special properties make cell lines useful human cellular models for research studies.
The immortalized Chub-S7 pre-adipocytes can be maintained in a serum-free
chemically defined medium to achieve differentiation into mature white adipose cells.
These Chub-S7 cells have been used in a limited fashion in comparison with either
human pre-adipocytes or 3T3-LI studies; as such these present studies will also examine
how the Chub-S7 cells differentiate over time (Marshak, Greenwalt et al. 2002). The aim
of the current chapter therefore was to use the immortalized Chub-S7 pre-adipocytes and
examine the cells through differentiation, as a model cell line for subsequent experiments.
For these studies it was important to investigate lipid metabolism as noted by a glycerol
release assay, lipid accumulation by an oil red O staining. Measuring lipid accumulation
is important as adipocytes can rapidly grow in size and number during differentiation
with these processes being regulated genetically and hormonally, involving multiple
genes, through lipogenesis (triglyceride formation), and lipolysis (triglyceride
breakdown (Gregoire and Smas 1998; Dicker et al. 2007). Gene expression levels are
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also an important genetic marker of differentiation to be analysed during Chub-S7
differentiation assessing adiponectin, PPAR, CCAAT enhancer-binding protein alpha
(CEBP) and perilipin. The ability of Chub-S7 cells to either proliferate or differentiate
is under close regulation from various adipogenic factors, such as peroxisome proliferator
activated receptor (PPAR)-γ (MacDougald and Mandrup 2002) and free fatty acids 
(FFAs) as well as adipogenic inhibitory factors, that inhibit hyperplastic growth, such as
inflammatory cytokines, that include interleukin-6 (IL-6) (Skurker et al. 2005; Maury and
Brichard 2010) growth factors (MacDougald and Mandrup 2002), and certain androgens
(Dieudonne et al. 2000, Allan and McLachlan 2010). Finally, analysis of differentiation
will examine protein release of adiponectin and leptin into the media from differentiating
adipocytes, as established protein markers combined with the other data to determine that
the Chub-S7 have reached full differentiation.
4.2 Methods
4.2.1 Differentiation of Chub-S7 Cells
Chub-S7 were cultured into tissue culture flasks until confluent and then
trypsinized to obtain sufficient number of cells to carry out the study. The preadipocytes
from the same passage were grown in 6-well plates (104 cells/well in 2 ml media) to
confluence in DMEM/Ham’s F-12 phenol-free medium (Invitrogen, UK) containing 10%
FCS, penicillin (100 U/ml), streptomycin (100 μg/ml), and transferrin (5 μg/ ml). At 
confluence, preadipocytes were differentiated in differentiation media (Promocell,
Germany) containing biotin (8 μg/ml), insulin (500 ng/ml), Dexamethasone (400 ng/ml), 
IBMX (44 μg/ml), L-Thyroxin (9 ng/ml) and Ciglitazone (3 μg/ml) for 72 h. After this 
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period, the differentiating cells were grown in nutrition media containing (NM)
DMEM/Ham’s F-12, 3% FCS, D-biotin (8 μg/ml), insulin (500 ng/ml) and 
Dexamethasone (400 ng/ml) until fully differentiated (14–25 days). The viability of
adipocytes was assessed using the trypan blue dye exclusion method. Total RNA and
protein were isolated from these cells during differentiation.
4.2.2 Real time PCR adipogenic gene methodology
To determine the metabolic pattern of the novel human adipocytes cell line Chub-
S7, the expression of adipocytes-specific markers was assessed using qRT-PCR, at
different time points during cellular maturation. qRT-PCR was used to assess the
expression of adipocytes-specific markers in Chub-S7 at different time points during
cellular maturation including adipogenic transcriptional factors like PPARγ and C/EBPα,  
mRNA Expression for adiponectin, PPAR, perilipin and CEBP, genes were analyzed
using commercially available gene expression assays (PE Applied Biosystems,
Warrington, UK). BAT1 mRNA expression through differentiation was also examined
using commercially available gene expression assays. All reactions were multiplexed
with the housekeeping gene 18S, provided as a preoptimized control probe (PE Applied
Biosystems, Warrington, UK), enabling data to be expressed in relation to an internal
reference to allow for differences in RT efficiency. Data were obtained as Ct values
according to the manufacturer’s guidelines and were used to determine ΔCt values (ΔCt 
= Ct of the target gene - Ct of the housekeeping gene). Measurements were carried out
on at least three occasions for each sample. To exclude potential bias due to averaging
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data that had been transformed through the equation 2-∆∆Ct, all statistics were performed
at the ΔCt stage as part of the standard operating procedures.  
4.2.3 Measurement of adipokine release in differentiating Chub-S7 cells.
During differentiation conditioned media was collected and assayed for both
leptin and adiponectin secretion, using commercially available solid phase enzyme-
linked immunosorbent assay (ELISA) kits (leptin, Millipore; adiponectin Millipore, UK).
Conditioned media were analyzed using a ELISA, the leptin ELISA had an assay limit of
0.5 ng/ml, CV intra-assay 2.5-4.7% and inter-assay variability was 1.2-4.6%;
adiponectin’s assay limit was 0.75ng/ml, CV intra-assay 7.2% and inter-assay variability
was 2.2-8.2%.
4.2.4 Lipolysis studies in differentiating Chub-S7 cells.
To undertake the lipolysis analysis conditioned media was collected during
differentiation of the Chub-S7 cells and examined for glycerol release as a measure of
lipolysis (µM/mL) using a commercial colorimetric kit (Randox Laboratories, Co.
Antrim, UK). Conditioned media was analyzed for free glycerol content using the
glycerol free assay reagent and glycerol standards according to manufacturer’s protocol.
25l of conditioned media was taken and added to 200l of free glycerol reagent this
was incubated for 15mins at RT and absorbance read at 540nm. Glycerol release in the
samples was calculated from the standard curve using known standards of glycerol.
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4.2.5 Lipid staining of differentiating Chub-S7 cells
Oil red O is a fat soluble dye and stains lipids within the adipose cell, therefore it
represents a well established reagent to use to assess lipid accumulation in adipocytes.
Removal of oil red O following staining of the adipocytes acts as an indirect measure of
lipid accumulation. Lipid staining using Oil Red O was undertaken through a modified
method by Mcvean et al, (Mcvean et al, 1965). To assess lipid accumulation at set time
points during differentiation cells were washed with hanks’ balanced salt solution
(HBSS) and stained with 2.5% Oil Red O (wt./vol in isopropanol) (Gurr Ltd., London,
UK) for 15 min at room temperature (RT). Cells were quickly washed with distilled
water and viewed with a light microscope. Subsequently 100% isopropanol (Fisher
Scientific Ltd., Loughborough, UK) was added to elute Oil red O staining and amount of
lipid determined by measuring absorbance 520nM. Photographs were also taken to
examine lipid accumulation during differentiation.
4.2.6 Protein Expression of BAT1 in Chub-S7 cells
As described in chapter 3 western blot analysis was performed using a method
previously described ( McTernan PG, McTernan CL, et al. 2002) and relative expression
was standardized by using a densitometry quantification software (GeneTools, Geneflow,
Fradley, UK). In brief, 5-20g of protein was loaded onto an 8% polyacrylamide gel
(Geneflow, Fradley, UK), a mouse anti-human BAT1 monoclonal antibody (primary
antibody; product code: ab50986, UAP56 antibody [2060C10a], 1:1000; Abcam Ltd., UK)
was used to assess BAT1 expression (Biosource UK, Nivelles, Belgium). Equal protein
loading was confirmed by densitometry using the actin antibody (2.04g/mL, Abcam,
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Cambridge, UK) for loading control. A chemiluminescent detection system ECL/ECL+
(GE Healthcare, Little Chalfont, UK) enabled visualization after exposure to X-ray film.
4.2.7 Statistical analysis
For analysis of protein expression and gene expression data, statistical analysis was
undertaken using unpaired t tests unless otherwise stated, where data were analyzed
using nonparametric tests as previously stated in Chapter 3 with full details given in
Chapter 2 and appendices. The threshold for significance was P < 0.05. The data in the
text and figures are presented as the mean ± SEM unless otherwise stated.
4.3 Results
4.3.1 Analysis of adipogenic gene in CHUB-S7 cells during differentiation
For the preadipocyte differentiation, the induction of PPARγ and C/EBPα is very 
critical. The analysis of the RT-PCR data showed that during the process of
differentiation the Chub-S7 PPARγ  expression increased about 4.2-fold at day 3 
compared to day 0; the level of PPARγ expression peaked at day 6 to 7.5 fold and then 
gradually decreased but always above the control levels (Figure: 4.3.1.1). Upon
differentiation induction expression of C/EBPα increased by almost 20 fold after day 03 
in DM and then gradually decreased after day 06 but was always significantly elevated at
all time points. Even after day 25, the expression was still 6 fold high. After day 03
IBMX and PPAR-agonist, Ciglitazone were removed from the treatments. Even in the
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absence of ciglitazone and IBMX the PPAR-γ and C/EBPα induction was maintained. 
[276].
The mRNA expression was examined across differentiation also for perilipin,
Hexose-6-Phosphate Dehydrogenase (H6PD) and adiponectin. Table 4.3.1 shows all the
actual ΔCt values for the genes examined during Chub-S7 cell differentiation (n=4). This 
data is then presented in a graphic form showing the mRNA expression for each
individual gene as a relative fold expression with day 0 given an arbitrary value of 1.
Expression of all these genes significantly increased during adipogenesis (Figures:
4.3.1.1; 4.3.1.2; 4.3.1.3; 4.3.1.4 & 4.3.1.5).
Table 4.3.1 The gene expression profile for PPAR, Perilipin, CEBP Hexose-6-
Phosphate Dehydrogenase (H6PD) andadiponectin across differentiation. The gene
expression data show the ΔCt±(SEM) changes at several interval points duriong 
diffferentation (Day 0-25).
Day PPAR
SEM ΔCt
Perilipin
SEM ΔCt 
CERB
SEM ΔCt 
Hexose 6PD
SEM ΔCt 
Adiponectin
SEM ΔCt 
0 18.27±0.19 29.13±0.12 27.19±0.54 22.31±0.53 25.56±0.05
3 17.12±0.38 17.08±0.34 21.94±0.61 18.76±0.12 22.06±0.54
6 15.63±0.31 16.74±0.27 22.17±0.32 17.77±0.09 22.75±0.66
9 16.08±0.51 19.63±0.41 26.16±0.27 21.29±0.23 23.59±0.17
12 17.78±0.09 17.68±0.16 25.05±0.38 20.15±0.28 24.11±0.25
15 17.69±0.13 20.92±0.47 24.9±0.19 20.56±0.47 23.13±0.21
18 18.17±0.18 20.02±0.4 24.48±0.46 18.57±0.32 23.22±0.82
25 18.11±0.32 24.24±0.43 25.73±0.34 26.89±0.08 24.15±0.16
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Figure 4.3.1.1 PPAR mRNA expression in Chub-S7 cells. This figure shows the
relative fold difference in PPARγ mRNA expression, with Day 0 taken as 1. All 
ΔCt±(SEM) data are shown in Table 4.3.1; P-value: *p<0.05).  
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Figure 4.3.1.2 CERB mRNA expression in Chub-S7 cells. This figure shows the
relative fold difference in CERB mRNA expression, with Day 0 taken as 1.
All ΔCt±(SEM) data are shown in Table 4.3.1; P-value: *p<0.05).   
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Figure 4.3.1.3 Perilipin mRNA expression in Chub-S7 cells. This figure shows the
relative fold difference in Perilipin mRNA expression, with Day 0 taken as 1.
All ΔCt±(SEM) data are shown in Table 4.3.1; P-value: *p<0.05).   
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Figure 4.3.1.4 Hexose 6PD mRNA expression in Chub-S7 cells. This figure shows the
relative fold difference in Hexose 6PD mRNA expression, with Day 0 taken as 1.
All ΔCt±(SEM) data are shown in Table 4.3.1; P-value: *p<0.05).   
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Figure 4.3.1.5 Adiponectin mRNA expression in Chub-S7 cells. This figure shows the
relative fold difference in Adiponectin mRNA expression, with Day 0 taken as 1. All
ΔCt±(SEM) data are shown in Table 4.3.1; P-value: *p<0.05).   
4.3.2 BAT1 mRNA expression in Chub-S7 during differentiation
BAT 1 mRNA expression was measured during the process of differentiation.
There was a significant increase in BAT mRNA expression over time up until day 12
(Day 0: 11.41±0.10 ΔCt; Day 3: 10.65±0.03ΔCt*; Day 6: 10.31±0.03ΔCt**; Day 9: 
10.07±0.03 ΔCt**; Day 12:  9.37±0.06 ΔCT***; *p<0.05, **p<0.01; ***p<0.001). After 
day 12 BAT1 mRNA expression appeared to reduce, however after day 12 the BAT1
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expression significantly decreased below control levels (Day 15: 11.65±0.04 ΔCt; Day 
18: 12.87±0.01 ΔCt**; p-values: **p<0.01, n=4; Figure 4.3.2.1).
Figure 4.3.2.1 BAT 1 mRNA expression in Chub-S7 cells. This figure shows the
relative fold difference in BAT 1 mRNA expression, with Day 0 taken as 1. All
ΔCt±(SEM) data are shown in text above; P-value: *p<0.05; **p<0.01).   
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4.3.3 Measurement of adipokine release from differentiating Chub-S7 cells.
Secreted leptin and adiponectin were measured in conditioned media from
differentiating Chub-S7 by ELISA. Secretion of leptin increased over differentiation from
day 0 to a maximum level at Day 18 and Day 21 (Day 0: 1.02±0.039ng/ml; Day 3:
1.12±0.33ng/ml; Day 6: 4±0.40ng/ml*; Day 9: 4.7±0.35ng/ml*; Day 12: 5.6±0.64ng/ml*;
Day 15: 7.75±0.7ng/ml**; Day 21: 9.7±1.1ng/ml**; Day 25: 8.8±0.34ng/ml** p-values:
p<0.05; **p<0.01, n=4; Figure 4.3.3.1).
Figure 4.3.3.1: Leptin release from differentiating Chub-S7 cells over time. This
figure shows leptin secretion over time, with significant changes noted comparing day 0
versus days 3-25 (p-values: *p<0.05; **p<0.01).
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Additionally adiponectin release was also measured. Adiponectin release data
showed that secretion increased over time with a maximal increase measured at Day 9
with a subsequent reduction. It should be stressed that adiponectin secretion was very low
from these human adipocytes in comparison to other adipokines. (Day 0: 0.3±0.01ng/ml;
Day 3: 0.42±0.03ng/ml; Day 6: 0.5±0.01ng/ml; Day 9: 0.7±0.05ng/ml*; Day 12:
0.4±0.02ng/ml; Day 15: 0.45±0.06ng/ml; Day 21: 0.45±0.07ng/ml; Day 25: 5±0.04ng/ml;
p-value: *p<0.05; n=4; Figure 4.3.3.2).
Figure 4.3.3.2: Adiponectin release from differentiating Chub-S7 cells over time.
This figure shows adioponectin secretion over time, with significant changes noted
comparing day 0 versus days 3-25 (p-values: *p<0.05; **p<0.01).
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4.3.4 Lipid accumulation in differentiating Chub-S7 cells.
To undertake the lipolysis analysis these studies examined glycerol release as a
measure of lipolysis. Glycerol release data showed that lipolysis increased over time as
lipid content within the differentiating Chub-S7 cells increased, showing a clear turnover
of glycerol. (Day 0: 4.9±0.61g/ml; Day 3: 5.3±0.75g/ml; Day 6: 8.5±0.91g/ml; Day
9: 13.4±0.56g/ml*; Day 12: 14.64±1.62g/ml*; Day 15: 15.5±1.56g/ml**; Day 21:
16.7±1.97g/ml**; Day 25: 16.75±2.04g/ml**; p-value: *p<0.05; **p<0.01; n=4;
Figure 4.3.4.1).
Figure 4.3.4.1: Glycerol release from differentiating Chub-S7 cells over time This
figure highlights the change in glycerol release over time, Day 0-25 with significant
changes noted comparing day 0 versus days 3-25 (p-values: *p<0.05; **p<0.01).
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4.3.5 Measurement of lipid accumulation using Oil Red O in differentiating Chub-S7
cells.
Oil red O release from lipid stained Chub-S7 cell was measured across
differentiation with lipid accumulation quantified with spectrophotometric analysis noted
at a wavelength 520nM with absorbance defined as optical density units ODU. There was
a significant increase in lipid accumulation over time compared with baseline ((Day 0:
0.1±0.01 ODU; Day 3: 0.12±0.01 ODU; Day 6: 0.14±0.01 ODU Day 9: 0.16±0.01 ODU;
Day 12: 0.22±0.01 ODU; Day 15: 0.24±0.01 ODU; Day 18: 0.26±0.02 ODU**; Day
25:0.26±0.02 ODU**; p-values: **p<0.01, n=4; Figure 4.3.5.1.).
Figure 4.3.5.1: Oil Red O staining from differentiating Chub-S7 cells over time. This
figure highlights the change in Oil Red O staining over time, Day 0-25 with significant
changes noted comparing day 0 versus days 3-25 (p-value: *p<0.05).
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Furthermore, oil red O stained pictures of Chub-S7 at different stages of
differentiation clearly highlighted lipid droplets accumulation in the cytoplasm which is
compatible with maturation of the primary human abdominal subcutaneous adipocytes
and full expression of adipocyte-specific metabolic profile (Figure 4.3.5.2). It should be
noticed that there was no significant changes in lipid droplet accumulation after day 12.
As such this data taken together suggest that Chub-S7 are differentiated to adipocytes
(expression of specific adipogenic markers) soon after adding differentiation media (day
3) and become fully maturated (lipid droplet accumulation) by day 12.
Fig 4.3.5.2 Cytoplasmic lipid accumulation in Chub-S7 during differentiation. This
figure shows Oil Red O staining in differentiating Chub-S7 cells over time, Day 0-25.
The photographs show the oil red O staining at A) day 3; B) Day 6; C Day 9; Day 12
(magnification x40).
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4.3.6 BAT1 protein expression in differentiating Chub-S7 cells.
BAT 1 protein expression was measured during differentiation. There was a
significant increase in BAT protein expression over time which was comparable to
mRNA data up until day 12 (Day 0: 0.808 ± 0.0157 ODU Day 6: 1.0963 ±0.0883
ODU; Day 12: 1.4037±0.0699 ODU; Day 18: 1.655 ±0.0569 ODU; *p<0.05,
**p<0.01, Figure 4.3.6.1). BAT1 protein was expressed in the pre-adipocyte and
increased significantly with progressing maturation.
Figure 4.3.6.1 BAT 1 protein expression in Chub-S7 cells. This figure shows the
changes in BAT 1 protein expression, over, day 0-18, with significant changes noted
comparing day 0 versus days 3-25
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4.4 Discussion
Whilst we understand the role of the human pre-adipocyte differentiation and
factors that can affect lipid metabolism, mRNA and protein expression and secretion of
adipokines in human subcutaneous pre-adipocytes (Tian et al. 2010; Dicker. et al, 2007;
Payne et al. 2007; Marshak et al. 2007; Deng et al. 2006; Kappes et al. 2000), it is less
documented in the human preadipocyte cell line Chub-S7. Previous studies have utilised
Chub-S7 cells as a useful model to characterise human metabolism but less have focussed
on factors which change as a result of differentiation (Leyvraz et al. 2009; Bujalska et al.
2008; Garruti et al. 2007; Gathercole et al. 2007; Darimont et al. 2005; Qiao et al. 2005).
Interestingly there are many parallels to be drawn between the previous papers
examining differentiation in human pre-adipocytes to the data presented here on the
Chub-S7 cells. Many examining differentiation investigated lipolytic action and the role
of lipolysis as a predictor in the state of preadipocyte differentiation. Dicker et al. (2007)
noted that mRNA expression of lipolysis related metabolism reached maximal effect
much earlier during differentiation than measuring glycerol release which mirrors the
findings for the glycerol and oil-red O data noted form the Chub-S7 cells. Many mRNA
gene patterns examined over differentiation appeared to reach their maximum by day 8
(Dicker et al. 2007). The data presented in this chapter examining perilipin and PPAR
mRNA expression, identified a similar pattern with a significant increase in mRNA
expression from day 0 up until day 6 and a clear reduction after that day. During the
process of differentiation the cells were given rosiglitazone to drive differentiation
substantially. The mRNA PPAR data showed the Chub-S7 cells clearly responded to
this stimulus – thus affirming PPAR‘s role in lipid metabolism, during differentiation of
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pre-adipocytes (Deng et al. 2006). All mRNA data confirmed that the Chub-S7 behave in
a similar fashion to abdominal subcutaneous differentiating pre-adipocytes (Dicker et al.
2007).
These current studies also examined mRNA expression of CAAT/enhancer-
binding protein alpha (C/EBP alpha) which, along with C/EBP beta, is documented to
regulate diacylglycerol acyltransferase 2 (DGAT2) expression during adipogenesis.
DGAT2 is an important enzyme to catalyze the final step of triglyceride (TG) synthesis
for lipid accumulation. Previous studies have shown that in primary murine pre-
adipocytes and 3T3-L1 cells DGAT2 expression closely mimics expression of C/EBP
genes: C/EBP and β expression known to change during differentiation. These current 
studies showed that Chub-S7 cells increased prior to day 6 and then led to a significant
reduction in CEBP mRNA expression which mirrors previous analysis in other murine
cells (Payne et al. 2007; Dicker et al. 2007). Hexose-6-phosphate dehydrogenase (H6PD)
catalyzes the first two principal steps in the reactions of the pentose phosphate pathway in
the endoplasmic reticulum (ER), thereby generating reduced NAD (NADPH) within the
luminal compartment. It has an important role in adipogenesis which has been
documented to be attributed to H6PD (Atanasov et al. 2004; Hewitt et al. 2004; Odermatt
et al. 2006). The current data on H6PD in this chapter again affirms previous studies
from other human cultured pre-adipocytes undergoing differentiation (Senesi et al. 2008).
Secretion of adipokines was also examined as a marker of differentiation. These
current finding of leptin release from Chub-S7 cells align with previous studies
examining changes in leptin secretion during differentiation (Mutch et al. 2009;
McTernan et al. 2003). Additionally the measurement of adiponectin release was also in
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agreement with previous studies noting a significant up regulation of adiponectin mRNA
and protein secretion post 3 days (Kappes et al. 2000; Tian et al. 2010 Mutch et al.
2009).
As the current findings of the Chub-S7 cells were similar to those noted in
primary human adipocytes, the expression of BAT1 mRNA and protein during
differentiation in this cell system was investigated. BAT1 expression increased with
progressing maturation up to a stage of lipid accumulation after which BAT1 remains
unchanged; further (extreme) increase in adiposity and abnormally high fat storage may
result in suppressed BAT1 expression as described in chapter 3. This will be further
investigated in the later chapters. BAT1 is a cellular DExD/H-box RNA-helicases which
performs an essential role for cellular mRNA export by recruiting the adaptor proteins to
spliced and unspliced mRNAs (Thomas et al. 2011). BAT1 therefore may have a role in
the translational control of some of the genes required for differentiation or adipogenesis
and inflammation which needs to be further investigated.
In summary, this chapter has examined differentiation markers including
lipolysis, adipogenesis, gene and protein expression data, to highlight that Chub-S7 cells
are comparable with primary human pre-adipocytes and that BAT1 is expressed at
mRNA and protein levels in adipocytes at concentrations that increase with increasing
differentiation. In the following chapters we utilise primary human adipocytes to test how
hormonal, nutritional and inflammatory molecules influence BAT1 expression and
modulation of gene and protein levels.
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Chapter 5
The influence of nutritional and inflammatory factors on BAT1
expression in primary adipocytes
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5.1 Introduction
Obesity has been considered a state of chronic low-grade systemic inflammation,
as it is suggested by the increased levels of C-reactive protein (CRP) (Visser et al; 1999),
tumor necrosis factor-(TNF-) (Dandona et al. 1998), interleukin-1 (IL-1), IL-6 (Van
Dielen et al. 2001; Yudkin et al. 2000; Visser et al. 1999), mononuclear cells and
lymphocytes (Perfetto et al. 2002) in the blood of otherwise healthy obese individuals.
The low-grade inflammation has been implicated in the development of insulin resistance
(IR), (Laaksonen et al. 2004; Pradhan, Ridker 2002) and β-cell failure (Wogensen et al.
1990). The adipose tissue participates actively in this pro-inflammatory state through
generation of bioactive molecules (Cachofeiro et al. 2006) that promote inflammation but
also by recruiting inflammatory cells (lymphocytes and macrophages) (Brake et al. 2006;
Weisberg et al. 2006) which in turn secrete inflammatory cytokines (e.g. IL-6 and TNF-
) fueling whole body inflammation (Lumeng et al. 2007). Whilst inflammation is
known to occur the insults that mediate these chronic low-grade effects are less clear,
although nutritional status appears important.
Most population-based studies evaluating the relationship between diet and risk of
T2DM demonstrate that high fat intake, especially the saturated fat, has adverse effect on
insulin effectiveness, increase risk of diabetes (Hunnicutt et al. 1994; Marshall et al.
1994) plus enhance systemic inflammation in the whole body (Cani et al. 2008 and 2007;
Nappo et al. 2002) but also in adipocytes (Schäffler et al. 2008). Similarly to
inflammatory factors (e.g. TNF-), elevated levels of free fatty acids (FFAs) stimulate
the inflammatory serine/threonine kinases JNK, IKK and PKC (Schmitz-Peiffer and
Biden 2008; Arkan et al 2005; Hirosumi et al. 2002) causing serine phosphorylation of
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IRS-1 thus blockage of insulin action. These kinases also stimulate the AP-1 complexes
and the NF-κB (Hotamisligil 2006) thus enhance the production of inflammatory
mediators including TNF-α and IL-6 (Shoelson et al. 2003; Gao et al. 2002) (Figure 5.1).
Other epidemiologic studies have also revealed that diets with high glycemic index
increase the risk of T2DM (Ludwig 2007; Lindstrom et al. 2006) while postprandial
hyperglycemia per se has been directly linked to inflammation, IR and β cell dysfunction 
(Dandona et al. 2005; Ludwig 2002). The enhanced fuel oxidation and excessive
mitochondrial ROS production provide the pathogenic mechanisms by which increased
carbohydrate intake exerts pro-inflammatory effect (Ceriello, Motz 2004).
Furthermore, potential insults may also arise directly from the gut besides glucose
and lipids. In recent years the connection between gut microbiota and obesity-related
disorders have been increasingly recognized and explored (Cani, et al, 2007, 2008; Brun
et al, 2007; Al-Attas et al. 2009; Baker et al. 2009; Miller et al. 2009; Shoelson and
Goldfine 2009; Creely et al. 2007). The hypothesis of ‘metabolic endotoxinaemia’
suggests that toxins produced in the gut may disrupt the energy balance equation
(Turnbaugh et al. 2009; Martin et al. 2008; Turnbaugh et al. 2008; Bäckhed et al. 2007;
Dumas et al. 2006), alter fatty acid metabolism and composition in adipose tissue and
liver (Cani et al. 2007, 2008), modulate gut-derived peptides (PYY and GLP-1)
(Samuel et al. 2008; Cani et al. 2009; Zhou et al. 2008; Cani et al. 2006) and activate
the TLR-4 axis (Ghanim et al. 2009; Cani et al. 2008; Anderson et al. 2007; Cani et al.
2007), leading to obesity, IR and diabetes in the host. Lipopolysaccharide (LPS) is such
a gut bacteria-derived toxin implicated in inflammation and IR seen in obesity; it
suggests the outer cell wall membrane of gram-negative bacteria transverses the gut
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mucosa attached to damaging lipoproteins to lead to systemic inflammation (Creely et al,
2007; Baker et al, 2009; Al-Attas et al, 2009; Brun et al, 2007; Miller et al, 2009; Harte
et al, 2010; Dixon et al, 2008). More specifically previous work has shown that LPS has
an immediate impact on the innate immune pathway in human AT, acting via TLRs
which recognize antigens, such as LPS, to initiate an acute phase response to infection
(Kaisho & Akira 2002). Stimulation of the TLRs leads to intracellular activation of
NFB, a key transcription factor in the inflammatory cascade that regulates the
transcription of numerous pro-inflammatory adipokines (including IL-6, IL-11, PAI-1,
ANG II, resistin and TNF-). As such, LPS may act as a mediator of inflammation
through activation of NFB leading to a rapid response within AT, primarily increasing
inflammation and subsequent metabolic risk (Muzio, et al, 2000; Lin et al, 2000; Kopp et
al, 2009; Song et al, 2006; Shoelso & Goldfine 2009; Alhusani et al, 2010; Gregor &
Hotamisligil 2007; Wellen & Hostamisligil, 2005; Hotamisligil 2005; Xu et al, 2009;
Doroudgar et al, 2009; Nishimura et al, 2009).
The aim of these studies were therefore to look both at the direct effects of
nutritional factors (saturated fats and glucose) and inflammatory insults (LPS) on changes
in BAT1 expression in human differentiated Abd Sc adipocytes, as well as to examine the
role of particular inflammatory cellular pathways such as TLR-4/NFκB and JNK in 
BAT1 modulation.
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5.2 Research Design and Methods
5.2.1 Subjects
Human AbSc AT was collected from overweight non smoking female patients
(age: 54.0 (mean±SD)±2.65yr; BMI: 28.43(mean±SD)±1.0 kg/m2, undergoing elective or
liposuction surgery with informed consent obtained in accordance with LREC guidelines
and with ethics committee approval. The selected samples were from subjects of the same
gender (females), postmenopausal so that any effect of sex hormones to be elucidated. In
addition, the subjects were not smoking, had no other medical issues and were not on any
medication. In total, 9 human non-diabetic primary AT samples were analyzed.
5.2.2 Cell Culture
In brief, human abdominal subcutaneous (Abd Sc) pre-adipocytes were
differentiated as previously described in chapter 4. On day 12, the fully differentiated
adipocytes were grown in normal DMEM/Ham’s F-12 phenol-free medium containing
only 2% serum (detoxification media) for 24 hr to remove effects of growth factors and
other components in nutrition media. The selected treatments (NEFA, glucose, LPS) were
then placed in the fresh detoxification media for several different time points. LPS and
glucose were purchased from Sigma-Aldrich Corp. (Poole, UK), NEFA (Stearic-Palmitic
acid Mixture) from Fluka Chemicals Ltd. (Gillingham, UK).
5.2.3 Protein determination & Western blot analysis
Protein concentrations were determined using the Bio-Rad Detergent Compatible
(DC) protein assay kit (Biorad UK). Homogenized human AT were extracted using a 10%
RIPA buffer method (McTernan PG et al. 2002). Western blot analysis was performed
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using a method previously described (McTernan CL et al. 2002) and relative expression
was standardized by using a densitometry quantification software (GeneTools, Geneflow,
Fradley, UK). In brief, 5-20g of protein was loaded onto an 8% polyacrylamide gel
(Geneflow, Fradley, UK), a mouse BAT1 monoclonal antibody (primary antibody; product
code: ab50986, UAP56 antibody [2060C10a], 1:1000; Abcam Ltd., UK) was used to assess
BAT1 expression (Biosource UK, Nivelles, Belgium). For inhibition studies, Abd Sc
adipocytes were incubated with NFκB inhibitor (NF-κB: SN50, 50 µg/mL; Calbiochem, 
UK) or c-Jun N-terminal Kinase (JNK) inhibitor (SP600125, 10 µM; A.G. Scientific,
Inc., San Diego, CA). Equal protein loading was confirmed by densitometry using the
actin antibody (2.04g/mL, Abcam, Cambridge, UK). A chemiluminescent detection
system ECL/ECL+ (GE Healthcare, Little Chalfont, UK) enabled visualization after
exposure to X-ray film.
5.2.4 Statistical methods
For analysis of protein expression and gene expression data, statistical analysis
was undertaken using unpaired t tests unless otherwise stated, where data were analyzed
using nonparametric tests as previously stated in Chapter 3 with full details given in
Chapter 2 and appendices. Treatment effect was defined relatively to control value as
 %
Control
ControlTRT 
. In every case, at least three independent experiments performed in
triplicates to ensure reproducibility. The threshold for significance was P < 0.05. The data
in the text and figures are presented as the mean ± SEM unless otherwise stated.
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5.3 Results
5.3.1 Effect of NEFAs on BAT1 expression in human primary AbdSc adipocytes; the role
of NFκB and JNK pathways   
Previous studies have shown the effectiveness of the selected NEFA
concentrations and the particular time points in human differentiated adipocytes (Gao et
al. 2010; Richard et al. 2008; Wen et al. 2006; Bueno et al. 2008). Dose and time course
studies were performed to assess BAT1 protein at 24, 48 and 72 h with control and
NEFA-treated adipocytes (0.5 and 2mM). BAT1 was significantly suppressed by the
effect of NEFA on all selected different times and treatment concentrations in
comparison with control, baseline time zero [NEFA 72hr, 0.5 mM -11.4% (mean±SEM)
± 11.7%***; 24hr 2 mM -43.3% ± 11.0%***; 48hr 2 mM -8.9% ± 9.8%**; 72hr 2 mM -
87.8% ± 3.2%***; Total 0.5 mM -11.4% ± 11.7%***; Total 2 mM -52.7% ± 7.1%***,
p-value: **p<0.01, ***p<0.001, Figure 5.3.1]
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Control NEFA NEFA NEFA NEFA
2 mM 2 mM 2 mM 0.5 mM
24 hr 48 hr 72hr 72 hr
Figure 5.3.1 BAT1 protein expression in NEFA-treated AbdSc adipocytes (n=3-7),
on different times and treatment concentrations. In the figure, values were measured
by normalizing against the endogenous control â-actin (protein of interest/â-actin) and
compared with control [(TRT-Control)%/Control], (p-values: **p<0.01, ***p<0.001).
In order to investigate whether NEFA modulate BAT1 expression via TLR-
4/NFκB and JNK inflammatory pathway, these pathways were blocked by treating the 
adipocytes with NFκB inhibitor (50 μg/ml) (SN50, CalBiochem, Nottingham, UK) or 
JNK inhibitor (10 μM/ml) (SP600125, A.G. Scientific, Inc., San Diego, CA), respectively 
for 24 hours; the adipocytes were then treated with NEFA 2mM for 72 hours. At the end
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of the study, BAT1 protein was examined and compared with control (baseline time zero)
and NEFA-only treated adipocytes (2mM for 72 hr, without previous treatment with
NFκB inhibitor or JNK inhibitor); dose and time course studies were performed to assess 
BAT1 protein at 14, 24, and 48 hr. The used treatment doses and conditions were based
on previous studies in adipocytes (Takahashi et al. 2008; Kusminski et al. 2007; Baan et
al. 2006). BAT1 expression in NEFA-treated adipocytes in which JNK pathway was
previously blocked didn’t differ compared with control, baseline time zero (p>0.05).
NFkB inhibitor, failed to prevent the inhibitory effect of NEFA on BAT1 [NEFA 72h 2
mM -87.8% (mean±SEM) ± 3.2%***;  NFkB inh 24h 50μg/ml + NEFA 72h 2 mM  -
45.2% ± 5.2%***; JNK 24h 50 μg/ml +NEFA 72h 2mM -5.3% ± 0%, p-value: 
***p<0.001, Figure 5.3.1.1]. The ANOVA F-test (for means comparison) and Kruskal-
Wallis rank test confirmed the previous findings (Figure 5.3.1.2 and 5.3.1.3).
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                            NEFA 2mM        NFkBinh 50 μg/ml 24H      JNKinh 10 μM 24H  
72 hr + NEFA 2mM 72 H + NEFA 2mM 72 H
Figure 5.3.1.1 BAT1 protein expression in AbdSc adipocytes (n=3-7) treated only
with NEFA 2mM for 72 hr or with NFkB inhibitor 50μg/ml for 24 hr and then with 
NEFA 2mM for 72 hr or with JNK inhibitor 10 μM/ml for 24 hr and then with 
NEFA 2mM for 72 hr. In the figure, values were measured by normalizing against the
endogenous control â-actin (protein of interest/â-actin) and compared with control [(TRT-
Control)%/Control], (p-values: ***p<0.001).
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NEFA 2mM         JNKinh 10 μM 24H  
72H + NEFA 2mM 72 H
Figure 5.3.1.2 BAT1 protein expression in AbdSc adipocytes (n=3-7) treated with
NEFA 2mM for 72 hours or with JNK inhibitor 10 μM/ml for 24 hrs to block JNK 
pathway and then with NEFA 2mM for 72 hr. In the figure, values were measured by
normalizing against the endogenous control â-actin (protein of interest/â-actin) and
compared with control [(TRT-Control)%/Control], (p-values: *p<0.05, ***p<.001).
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NEFA NFkB inhibitor 50μg/ml 24hr                                                                                                  
2mM +
72hr NEFA 2mM 72hr
Figure 5.3.1.3 BAT1 protein expression in AbdSc adipocytes (n=3-9) treated with
NEFA 2mM for 72 hr or with NFkB inhibitor 50μg/ml for 24 hr to block NFkB 
pathway and then with NEFA 2mM for 72 hr. In the figure, values were measured by
normalizing against the endogenous control â-actin (protein of interest/â-actin) and
compared with control [(TRT-Control)%/Control], (p-values: **p<0.01, ***p<.001)
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The following figure (Figure 5.3.1.4), summarizes the mean effect of NEFA,
regardless of treatment duration. As it is shown NEFA at both high (2mM) and low
(0,5mM) concentrations have significant repressive effect on BAT1 protein expression in
human adipocytes, while inhibition of JNK pathway ameliorates this effect.
Figure 5.3.1.4 Summary effects of NEFA on BAT1 protein expression in naive or
previously treated with JNK or NFkB inhibitor human AbSc AT-derived
adipocytes. In the figure, values were measured by normalizing against the endogenous
control â-actin (protein of interest/â-actin) and compared with control [(TRT-
Control)%/Control], (p-values: *p<0.05, **p<0.01, ***p<0.001).
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5.3.2 Effect of high glucose concentration on BAT1 expression in primary adipocytes
Fully differentiated AbdSc adipocytes (n=3-5) were incubated in serum-free
medium and treated with high concentrations of glucose (30mM and 60mM,
respectively). The BAT1 protein was estimated at two different time points (24 and 72
hr) in naive (control) and treated cells. The selected doses and treatment duration were
based on previous studies with glucose treatments in adipocytes (Gao et al, 2010; Zhang
et al, 2009; Zu et al, 2008; Nelson et al, 2000). The analysis using t-test showed that
BAT1 was significantly repressed by glucose in a dose and time dependent manner in
comparison with control, baseline time zero [24h Glucose 30nM -0.1% (mean±SEM) ±
15.7%; 72h 30mM -16.1% ± 17.2%*; 72h 60mM -15.6% ± 4.1%***; total Glucose
30mM -8.1% ± 20.1%**, p-value: *p<0.05, **p<0.01, ***p<0.001, Figure 5.3.2].
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Control Glucose Glucose Glucose
30mM 60mM 30mM
24 hr 72 hr 72 hr
Figure 5.3.2 BAT1 protein expression in AbdSc adipocytes (n=3-5) treated with high
concentrations of glucose (30mM and 60mM, respectively) for 24, 72 hr,
respectively. In the figure, values were measured by normalizing against the endogenous
control â-actin (protein of interest/â-actin) and compared with control [(TRT-
Control)%/Control], (p-values: *p<0.05, **p<0.01, ***p<0.001).
- 158 -
5.3.3 Effect of LPS on BAT1 protein expression in primary adipocytes
For this study, the primary human adipocytes were treated with LPS (5ng/ml and
25ng/ml). Dose and time course studies were performed to assess BAT1 protein at 1, 6,
12, 24 and 72 hr in controls and LPS-treated adipocytes. The used treatment
concentrations were based on previous studies with LPS on adipocytes (Lira et al. 2011;
Penfornis and Marette 2005). Based on the in vitro experiments LPS significantly
represses BAT1 when compared with control [1 hr LPS 5ng/ml -30.5% (mean±SEM) ±
20.9%**; 6 hr 5ng/ml -43.5% ± 19.3%***; 12 hr 5ng/ml -43.7% ± 17.1%***; 24 hr
5ng/ml -33.2% ± 23.6%**; 1 hr LPS 25ng/ml -34.2% ± 10.2%***; 6 hr 25ng/ml -16.3%
± 10.3%***; 12 hr 25ng/ml -49.5% ± 16.0%***; 24 hr 25ng/ml -45.6% ± 11.0%***; 72
hr LPS 25ng/ml -47.1% ± 16.3%***; Total LPS 5ng/ml -38.3% ± 9.5%***; Total LPS
25ng/ml -38.2% ± 6.1%***, p value: **p<0.01, ***p<0.001, Figures: 5.3.3, 5.3.3.1].
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Control LPS LPS LPS LPS
5ng/ml 5ng/ml 5ng/ml 5ng/ml
1 hr 6 hr 12 hr 24 hr
Figure 5.3.3 BAT1 protein expression in AbdSc adipocytes (n=3-5) treated with
5ng/ml LPS over time (1-24 hr). In the figure, values were measured by normalizing
against the endogenous control â-actin (protein of interest/â-actin) and compared with
control [(TRT-Control)%/Control], (p-values: **p<0.01, ***p<0.001).
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Control LPS LPS LPS LPS LPS
25ng/ml 25ng/ml 25ng/ml 25ng/ml 25ng/ml
1 hr 6 hr 12 hr 24 hr 72 hr
Figure 5.3.3.1 .BAT1 protein expression in AbdSc adipocytes (n=3-5) treated with
25ng/ml LPS over time (1-24 hr) and Total, respectively. In the figure, values were
measured by normalizing against the endogenous control â-actin (protein of interest/â-
actin) and compared with control [(TRT-Control)%/Control], (p-values: ***p<0.001).
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In summary the selected nutritional factors (glucose and saturated fats) and
cytokines involved in the pro-inflammatory state generation in obesity on BAT1 protein
expression were compared (analysis with Mann-Whitney test) (Figure 5.3.3.2).
Figure 5.3.3.2 Summary of negative mean effect on BAT1 protein expression in
human AbdSc AT adipocytes. In the figure, values were measured by normalizing
against the endogenous control â-actin (protein of interest/â-actin) and compared to
baseline time zero controls [(TRT-Control)% / Control], (p-values: *p<0.05, **p<0.01,
***p<0.001)
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5.4 Discussion
This study investigated the relationship between nutritional factors and BAT1
specifically those involved in the pre-inflammatory state generation in obesity (glucose
and saturated fats). In addition, the effect of pro-inflammatory agents (LPS) on BAT1
expression in human differentiated AbdSc adipocytes was examined, along with potential
molecular pathways that mediate BAT1 modulation. AbdSc adipocytes of overweight,
non-diabetic, female subjects were used for these studies. The cells were cultured and
differentiated as described in chapter 2 and treated with the addition of the agent of
interest (glucose, saturated fats or LPS) in the fresh detoxification media for pre-
determined time points. At the end of the treatment duration, the cells were collected, and
the BAT1 protein expression was evaluated from the isolated cellular protein content.
This study showed that all the selected factors altered BAT1 protein expression
(Figure 5.3.4.2). Interestingly despite the insult utilized all achieved negative effects on
BAT 1 expression in each case. Thus, it was shown that NEFAs significantly repressed
BAT1 expression in human adipocytes. This is in accordance with previous findings
linking saturated fats with inflammation within the adipocytes (Schäffler et al. 2008).
Although findings from in vitro studies cannot directly translated into the clinical setting,
these findings might suggest a central role of NEFA excess in obesity-associated
inflammatory process via BAT1 suppression. Furthermore, according to this study, JNK
pathway may mediate NEFA-induced BAT1 suppression, highlighting that a main
inflammatory pathway has an important influence of BAT1 expression. Furthermore
recent studies in human adipocytes has shown that JNK activity appears to influence
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NFB expression in certain circumstances which highlights the interconnectivity between
the pathways (McGee, et al, 2011).
Previous studies have clearly show a strong link between hyperglycemia and
inflammation (Dandona et al. 2005; Ludwig 2002), while the primary study in chapter 3
demonstrated BAT1 suppression in the adipose tissue of patients with T2DM compared
with non-T2DM subjects. In this direction, these current studies showed that glucose in
excess directly represses BAT1 in human adipocytes in a dose- and treatment duration-
dependent manner providing another nutritional factor that could exacerbate
inflammation.
The study of the effect of LPS on BAT1 expression revealed potent repressive
effects of this agent on BAT1 after acute (1 hr) or chronic prolonged (72 hr) exposure of
human adipocytes to low (5ng/ml) or high (25ng/ml) dose of LPS. These findings are in
accordance with the metabolic endotoxinaemia theory according to which toxins
produced in the gut may be related to the obesity-associated inflammation and metabolic
disorders (Turnbaugh et al. 2009; Cani et al. 2008; Martin et al. 2008; Turnbaugh et al.
2008; Bäckhed et al. 2007; Cani et al. 2007;Dumas et al. 2006).
In summary, this study highlighted that nutritional (NEFA and glucose) and
inflammatory insults in excess modulate BAT1 expression in adipocytes. All of the
examined agents repressed BAT1. This may suggest a protective mechanism by which
adipocytes recognize the forthcoming inflammatory storm and get prepared to counteract
it. This hypothesis becomes even more interesting considering the downregulating effect
of BAT1 on TNF- in T-cells and monocytes (Allcock et al; 2001). The fact that so
many different molecules, nutritional or inflammatory, effectively repress BAT1 could
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suggest that this protein is sensitive to biochemical/biomolecular changes within the cell
and highly regulated, thus predisposes, at least in the case of human adipocytes, to the
generation of inflammation, when nutritional factors or inflammatory agents in excess
alter the micro-biochemical balance within the adipocyte. As such further studies to
evaluate whether local paracrine adipokine factors may also regulate its expression. This
would be important to determine to identify the influential nature of primary insults and
down-stream pro-inflammatory or anti-inflammatory adipokines.
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Chapter 6
The influence of human recombinant pro- and anti-inflammatory
adipokines on BAT1 expression in human differentiated adipocytes
- 166 -
6.1 Introduction
Adipose tissue is a complex and highly active organ controlling energy balance,
metabolism and the immune system via the expression and secretion of a variety of
bioactive peptides, known as adipokines that act locally but also systemically as
endocrine hormones (Fruhbeck et al. 2001; Ahima, Flier 2000; Figure 1.8). Amongst the
myriad of adipokines, some affect insulin signaling and inflammatory pathways and as
such may contribute to the pathogenesis of obesity linked T2DM; adipokines of note such
as leptin, resistin and adiponectin appear to represent important mediators of metabolism.
The following will briefly highlight these adipokines and the rationale for their use in
examining their influence on BAT 1 expression which would be considered to form part
of an anti-inflammatory intracellular response.
Leptin is secreted by the adipocytes in direct proportion to adipose tissue mass.
Insulin, glucocorticoids, IL-6 and TNF-α enhance leptin secretion (Kirchgessner et al.
1997; Sarraf et al. 1997), while free fatty acids and PPAR-γ agonists have the opposite 
effect (Margetic et al. 2002). Subcutaneous AT accounts for the majority of leptin
secretion compared to omental depot (Fain et al. 2004). The effects of leptin on energy
homeostasis and its diverse endocrine properties in the regulation of neuroendocrine and
endocrine systems functions are diverse. Leptin serves as a metabolic signal of energy
sufficiency (Friedman, Halaas 1998) and modulates the function of the hypothalamic-
pituitary-adrenal/thyroid and -gonadal axes (Margetic et al. 2002; Flier et al. 2000;
Hileman et al. 2000). In addition, it increases glucose transport in muscle (Minokoshi,
Kahn 2003) via AMPK activation, plus attains immunomodulatory properties (alters the
cytokine production by the immune cells) (Lord et al. 1998). Within the human adipose
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tissue in particular, leptin in excess (as in obesity) exerts pro-inflammatory effects as by
inducing the release of TNF- (Lappas et al. 2005) and the endothelial-derived MCP-1
production; the latter facilitates the recruitment of macrophages into the fat tissue
(Yamagishi et al, 2001).
Within this pro-inflammatory milieu resistin, has also been observed to act in an
inflammatory capacity (Mohammed et al, 2009) in addition to leading to dysregulation of
insulin signaling (Satohet et al, 2004; Rajala et al.,2004; Rangwala et al, 2004; Rajala et
al, 2003). These previous findings imply a pathogenic role of resistin in the obesity-
associated insulin resistance in animal models (Banerjee & Lazar 2003; Steppan et al,
2001). However the role of resistin in human has been more controversial. Previous work
with the research team has previously documented its expression within both human pre-
adipocytes and adipocytes and its expression in higher levels in abdominal fat (Sc and
Om fat depots) compared to thigh and breast adipose tissue depots (McTernan et al,
2002; Kusminski et al, 2007). Other studies demonstrated its synthesis and secretion by
the adipose tissue macrophages (ATMs) (Curat et al, 2006); the extent of contribution of
macrophages to the overall concentration of resistin in adipose tissue though, remains
uncertain. Studies in humans have identified a link between resistin concentration and
obesity/IR/T2DM (McTernan et al, 2002; McTernan et al, 2002; Vidal-Puig & O’Rahilly
2001), while others failed to do so (Kielstein et al, 2003; Patel et al, 2003; Janke et al,
2002). Recent data also suggests whoever that there appears to be a positive association
between resistin and inflammation in morbidly obese individuals (De Luis et al, 2010;
Iqbal et al, 2005; Kunnari et al. 2006) as well as in patients with inflammatory diseases
(Qatanani et al, 2009; Senolt et al, 2007; Lehrke et al, 2004); plasma resistin levels in
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particular were positively related to inflammatory molecules including TNF-, IL-6 and
CRP. Taken together, resistin seems to attain pro-inflammatory properties. As such
resistin remains an interesting pro-inflammatory adipokine to study in human adipose
tissue.
Unlike other adipokines, adiponectin an anti-inflammatory adipokine decreases
with increasing adiposity (Trujillo et al, 2005). Adiponectin is higher in abdominal
subcutaneous AT than omental adipose tissue (Fain et al, 2004) and a strong and
consistent inverse relation with both inflammation and IR has been documented for this
adipokine (Chandran et al, 2003; Diez & Iglesias 2003); the latter probably via AMPK
activation (Yamauchi et al, 2003; Diez & Iglesias 2003; Yamauchi et al, 2002).
Interestingly, its plasma levels decline before the onset of obesity and IR suggesting a
potential role of hypoadiponectinemia in the pathogenesis of these disorders (Hotta et al,
2000). It has been shown that certain adipokines that increase within the AT as during
weight gain also can lead to suppression of adiponectin expression in adipocytes; TNF-α 
and IL-6 being two such adipokines (Bruun et al, 2003). Additionally adiponectin may
also decrease inflammation by reducing the inflammatory mediators TNF-, IL-6, CRP
(Zhou et al, 2008; Park et al. 2006; Thakur et al, 2006; Xu et al, 2003), suppressing the
TLR-4 signaling pathway (Yamaguchi et al, 2005) as well as by increasing several anti-
inflammatory cytokines for e.g. IL-10 (Choi et al, 2007; Engeli et al, 2003) and
interleukin-1-receptor antagonist (Kumada et al, 2005; Wolf et al, 2004). The
attenuation of the pro-inflammatory adipokines by adiponectin is thought in part to occur
through NFκB activation (Wulster-Radcliffe et al, 2004; Ouchi et al, 2000). Furthermore,
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adiponectin exerts anti-oxidant effects (it upregulates the uncoupling protein 2
expression) further reducing inflammation (Negre-Salvayre et al, 1997).
The aim of the chapter was therefore to look at the direct effects of individual
human recombinant adipokines to ascertain the individual effect of such adipokines on
BAT 1 expression in human differentiated Abd Sc adipocytes.
6.2 Research Design and Methods
6.2.1 Subjects
Human AbSc AT was collected from overweight non smoking female patients
(age: 54.0 (mean±SD)±2.65yr; BMI: 28.43(mean±SD)±1.0 kg/m2, undergoing elective or
liposuction surgery with informed consent obtained in accordance with LREC guidelines
and with ethics committee approval. The selected samples were from subjects of the same
gender (females), postmenopausal so that any effect of sex hormones to be elucidated. In
addition, the subjects were not smoking, had no other medical issues and were not on any
medication. In total, 9 human non-diabetic primary AT samples were analyzed.
6.2.2 Cell Culture
In brief, human abdominal subcutaneous (Abd Sc) pre-adipocytes were
differentiated as previously described in chapter 4. On day 12, the fully differentiated
adipocytes were grown in normal DMEM/Ham’s F-12 phenol-free medium containing
only 2% serum (detoxification media) for 24 hr to remove effects of growth factors and
other components in nutrition media. The selected treatments (leptin, resistin, and
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adiponectin) were then placed in the fresh detoxification media for several different time
points (0 24, 72 hr). rh Leptin and adiponectin were purchased from Sigma-Aldrich Corp.
(Poole, UK), while rh resistin was purchased from Phoenix Pharmaceuticals, (Belmont,
CA, USA).
6.2.3 Protein determination & Western blot analysis
The process that was described in previous chapters was also followed for these
studies.
6.2.4 Statistical methods
For analysis of protein expression and gene expression data, statistical analysis
was undertaken using unpaired t tests unless otherwise stated, where data were analyzed
using nonparametric tests as previously stated in Chapter 3 with full details given in
Chapter 2 and appendices. The threshold for significance was P < 0.05. The data in the
text and figures are presented as the mean ± SEM unless otherwise stated.
6.3 Results
6.3.1 Effect of leptin on BAT1 protein expression in primary human Abd Sc adipocytes
Two different concentrations of rh Leptin were used for these studies; rh Leptin
0.5 μg/ml and 1.5 μg/ml, respectively. The BAT1 protein was estimated at two different 
time points (24 and 72 hr) in naive and treated cells. Previous studies have shown the
effectiveness of the selected leptin concentrations and the particular time points in human
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adipocytes (Ambatia et al. 2007; Ho et al. 2006; Cohen et al. 2001). Dose and time
course studies were performed to assess BAT1 protein at 24 and 72 hr in controls and
leptin-treated adipocytes. The analysis using t-test showed that BAT1 was significantly
suppressed by the effect of rh leptin in comparison with control, baseline time zero (rh
Leptin 24 hr, 0.5 μg/ml -29.8% (mean±SEM)±18.3%***; 72h 0.5 μg/ml -
14.3%±22.8%***; 72h Leptin 1.5 μg/ml -5.8%±11.2%***; Total 0.5 μg/ml -
21.2%±14.2%***, p-value: ***p<0.001, figure 6.3.1).
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Control rh leptin rh leptin rh leptin
0.5g/ml 0.5g/ml 1.5g/ml
24 hr 72 hr 72 hr
Figure 6.3.1 BAT1 protein expression in leptin-treated Abd Sc adipocytes (n=4-6),
on different times (24 hr, 72 hr) and treatment concentrations (0.5μg/ml and 1.5 
μg/ml). The overall (total) effect of leptin on BAT1 expression is also shown. Equal
protein loading was determined by â-actin. In the figure, values were measured by
normalizing against the endogenous control â-actin (protein of interest/â-actin) and
compared to baseline time zero controls [(TRT-Control)%/Control], (p-value:
***p<.001).
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6.3.2 Effect of resistin on BAT1 protein expression in primary human AbdSc adipocytes
Two different concentrations of rh resistin were used for these studies (50 ng/ml
and 200ng/ml, respectively) at two different time points (24 hr 72 hr) based on previous
studies of the research team (Kusminski et al. 2007). Dose and time course studies were
performed to assess BAT1 protein at 24 and 72 hr in control and rh resistin-treated
adipocytes. The analysis using t-test showed that the overall (total) effect of resistin on
BAT1 protein expression was significantly reduced, although it varied depending on the
selected dose and duration of treatment compared with baseline zero hr (24h rh resistin,
200 ng/ml: -16.4%(mean± SEM)13.0%; 72h rh resistin 200 ng/ml: -5.1% ±20.7%; 24h rh
resistin, 50 ng/ml: -31.9% (mean± SEM)15.9%***; 72h rh resistin, 50 ng/ml: -
11.9%±31.5%*; total resistin: 200 ng/ml -10.8% ±10.5%, total resistin 50 ng/ml: -20.8%
±18.2%***, p-values: *p<0.05, ***p<.001, Figure 6.3.2).
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Control rh resistin rh resistin rh resistin rh resistin
24 hr 200 ng/ml 200 ng/ml 50 ng/ml 50 ng/ml
24 hr 72 hr 24 hr 72 hr
Figure 6.3.2 BAT1 protein expression in resistin (50ng/ml and 200ng/ml,
respectively)-treated AbSc AT adipocytes (n=4-6), at two different time points (24 hr,
72 hr, respectively). The total effect of resistin on BAT1 expression is also shown. Equal
protein loading was determined by â-actin. In the figure, values were measured by
normalizing against the endogenous control â-actin (protein of interest/â-actin) and
compared to baseline time zero controls [(TRT-Control)% / Control], (p-values: *p<0.05,
***p<.001).
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6.3.3 Effect of adiponectin on BAT1 protein expression in primary human Abd Sc
adipocytes
As adiponectin is considered to have anti-inflammatory properties (Zhou et al.
2008; Choi et al. 2007; Park et al. 2006; Thakur et al. 2006; Engeli et al 2003; Xu et al.
2003), it would seem that BAT1 expression should increase with adiponectin treatment.
Τhe abdominal subcutaneous adipocytes were treated with adiponectin (15 μg/ml); BAT1 
protein in naive (control) and treated cells was estimated after 24 hours of treatment.
Previous studies have shown the effectiveness of the selected adiponectin concentration
and the particular time point in human adipocytes (Zoico et al. 2009; Ajuwon et al.
2005). According to this study adiponectin (15 μg/ml for 24h) had a negative effect on 
BAT1 expression when compared with control, baseline time zero: –45.5% (mean ±
SEM)±17.0%, p-value: p>0.05, figure 6.3.3).
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Control rh adiponectin
                                15 μg/ml 
24 h
Figure 6.3.3 BAT1 protein expression in adiponectin (15μg/ml)-treated AbdSc AT 
adipocytes (n=4-6), for 24 hr. Equal protein loading was determined by â-actin. In the
figure, values were measured by normalizing against the endogenous control â-actin
(protein of interest/â-actin) and compared to baseline time zero controls [(TRT-
Control)% / Control], (p-value: p>0.05).
Previous experiments, in chapter 5 showed that LPS was a significant repressor
for BAT1 protein in human Abd Sc adipocytes. In this current chapter it was investigated
whether adiponectin may reverse the negative effect of LPS on BAT1. Therefore, the
cells were pre-treated with rh adiponectin (15μg/ml) for 24 hr and then incubated with 
LPS (25ng/ml) for a further 24 hr. Following this experiment BAT1 expression was
estimated in the treated cells and compared with that of the LPS 25ng/ml (for 24 hours)-
treated cells. This study showed that BAT1 gets suppressed by LPS despite previous
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treatment with adiponectin (24h LPS 25 ng/ml: –45.6% (mean± SEM)±11.0 %***, 24h
rh Adiponectin 15 μg/ml + LPS 25 ng/ml: –55.6%±17.2%***; p-value: ***p<.001,
Figure 6.3.3.1).
Control rh adiponectin LPS
15 ng/ml 24 hrs 25 ng/ml 24 hrs
+
LPS 25 ng/ml 24 hrs
Figure 6.3.3.1 BAT1 protein expression in Abd Sc adipocytes (n=4-6) treated with
LPS 25ng/ml for 24 hours or with adiponectin 15 μg/ml for 24 hours and then with 
LPS 25ng/ml for 24 hours. Equal protein loading was determined by â-actin. In the
figure, values were measured by normalizing against the endogenous control â-actin
(protein of interest/â-actin) and compared to baseline time zero controls [(TRT-
Control)%/control], (p-value: ***p<.001).
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6.4 Discussion
This study investigated the relationship between adipokines and BAT1
specifically pro-inflammatory (leptin, resistin) or anti-inflammatory (adiponectin)
adipokines. Therefore, human adipocytes isolated from AbSc AT of overweight, non-
diabetic, female subjects were used, that were cultured and differentiated as described in
chapter 2; when fully differentiated, the cells were treated with the addition of the agent
of interest (rh leptin, rh resistin or rh adiponectin) in the fresh detoxification media for
pre-determined time points. At the end of the treatment duration, the cells were collected,
the cellular protein content was isolated and the BAT1 protein expression was evaluated.
For this study the influence of rh leptin on BAT1 expression was determined, this
showed leptin led to a direct reduction in BAT1 expression. This direct effect may be
considered in the light of previous studies that indicate leptin can lead to an increase in
the production of TNF- in human AT (Lappas et al. 2005). As such taken these studies
together suggests that despite leptin increasing TNF- production leptin has a more
dominant effect to repress BAT1 protein expression. This is an interesting finding
considering that leptin increases with increasing adiposity, which means it could be
responsible, at least in part, for the obesity-associated BAT1 down-regulation as observed
in data in chapter 3.
These current studies also showed that rh resistin significantly suppressed BAT1
protein expression. In addition, it was noted that the duration of cellular exposure to rh
resistin excess, the more potent the down-regulatory effects were on BAT1 protein
expression. Findings from previous studies highlight the association between resistin and
inflammatory response in morbidly obese individuals as well as positive correlation
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between plasma resistin levels and other pro-inflammatory cytokines TNF-, IL-6 and
CRP (De Luis et al, 2010; Kunnari et al, 2006; Iqbal et al, 2005; McTernan et al, 2002;
McTernan et al, 2002; Vidal-Puig & O’Rahilly, 2001). As noted for leptin, again resistin
appeared to lead to a down-regulation of BAT1 protein expression.
Finally, it was investigated whether the anti-inflammatory adipokine, adiponectin
may enhance BAT1 protein expression. This study highlighted a trend towards rh
adiponectin reducing BAT1 expression although this did not reach statistical significance.
This is however in contrast with the initial assumption according to which rh adiponectin
would enhance BAT expression. However the increase in BAT1 expression may not have
occurred as there was no inflammatory insult to respond to therefore a second set of
experiments was undertaken to consider this point. Previous experiment, in chapter 5,
investigated the effect of LPS on BAT1 protein in human Abd Sc adipocytes and showed
that LPS was a significant repressor for BAT1, therefore in this current chapter cells were
pre-treated with rh adiponectin (15 μg/ml) for 24 hr and then incubated with LPS 
(25ng/ml) for a further 24 hr. Following this experiment BAT1 expression was
examined. This study showed that rh adiponectin failed to reverse the repressing effect of
LPS on BAT1 protein expression. This highlights that the action of LPS with pre-
incubation of rh adiponectin or co-current incubation didn’t affect BAT1 protein
expression. This suggests that LPS has more potent action on BAT1 reduction.
Furthermore that rh adiponectin has little or no influence on regulating BAT1 protein
expression in Abd Sc differentiated adipocytes.
In summary, this study highlighted that BAT1 appears to be regulated by
inflammatory adipokines, whilst the anti-inflammatory influence of adiponectin to raise
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BAT 1 expression was not observed. Taken together along with the observed effects of
LPS following incubation with rh adiponectin it seems that BAT1 expression seems more
profoundly regulated by inflammatory factors. BAT1 may represent a first line, non-
selective, cellular protective signaling factor and is therefore affected by several different
factors through common inflammatory pathways.
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CHAPTER 7
Final Discussion
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7.1 Discussion
We understand that obesity and T2DM are considered inflammatory disorders
with common pathways by which several pathogenic components of obesity affect
glucose metabolism, IR and the development of T2DM. BAT1 is a cellular DExD/H-box
RNA-helicases which performs an essential role for cellular mRNA export by recruiting
the adaptor proteins to spliced and unspliced mRNAs (Thomas et al. 2011). As such, this
thesis has examined the impact that the molecule, BAT1, has during adipogenesis as well
as the influence of nutrients and pro-inflammatory factors on its expression.
Whilst the role of BAT1 in the adipocyte has not been investigated, to date, we
have clear evidence that BAT1 has anti-inflammatory properties which may be altered by
metabolic states such as obesity and T2DM. This data has been derived from studies
investigating monocytes and T-cell lines (Allcock et al; 2001), which suggest BAT1 acts
an anti-inflammatory agent that downregulates several pro-inflammatory cytokines, such
as TNF-α, IL-1 and IL-6. This suggests that BAT1 could play a protective role against the 
obesity-associated low-grade inflammatory state that contributes to diabetes development
and hence has led to investigations into human adipose tissue (AT) and the adipocyte
itself.
The rationale for examining BAT1 in AT has come from several piece of previous
research examining the role of BAT1 in autoimmune disorders. BAT1 is coded by a gene
located in the central part of the class III MHC genomic locus on chromosome 6, between
TNF and HLA-B genes localized in the nuclear speckle (Thomas et al. 2004; Alpert and
Hashini 1993; Dias et al. 2010); this genomic region contains genes that affect
susceptibility to immunopathologic disorders (Cheong et al. 2001; Ota et al. 2001; Price
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et al. 1999). Further studies have shown that polymorphisms in BAT1 can lead to several
auto-immune based disorders (Wong et al. 2003; Quiñones-Lombraña et al. 2008;
Ramasawmy et al. 2006; Shichi et al. 2005; Price et al. 2004; Conrad et al. 1994;
Bottazzo et al. 1985); whilst BAT1 can also be down-regulated by inflammatory
cytokines (Van Harmelen et al. 1997). It is also apparent that an autoimmune condition
can also occur concurrently with an inflammatory disorder, such as Type 1 diabetes
(Chase et al. 2004); whilst a reduction in inflammation, in Type 1 diabetes can restore
response to insulin without necessarily improvement in autoimmune pathology.
Furthermore, emerging evidence supports the concept that IR, a consequence of
inflammation, can precede the herald the onset of autoimmune diabetes (Razavi et al.
2006; Sherry et al. 2005; Betts et al. 2005; Fourlanos et al. 2004). Taken together,
chronic inflammation may, at least, accelerate ß-cell death and lead to T1DM;
concurrently polymorphisms of BAT1 have also been directly associated with T1DM
which indicates BAT1 may be a crucial factor for the development of chronic
inflammation.
AT is a critical tissue in the response to inflammatory insults, which can occur in
many forms, as well as maintaining energy, satiety, blood pressure and homeostatic
control through many cellular processes. AT has also been increasingly viewed as an
important tissue to understand therapeutically, despite its complexity. Within this thesis,
BAT1 was considered within the context that, based on other studies, it might be a
suitable target to influence within adipose tissue. Therefore to understand the role of
BAT1 in adipose tissue this thesis sought to investigate the expression and regulation of
BAT1. Initial studies investigated BAT1 expression in ex vivo human AT which
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highlighted that increasing adiposity and T2DM status reduced BAT 1 expression. In
addition, that BAT 1 expression was altered by AT depot, for instance BAT 1 expression
being increased in AbdSc AT taken from lean subjects compared with either Om lean AT
or obese AT. Furthermore there was a gender influence in BAT 1 expression with, again,
an increased expression noted in women.
As has long been known human AT contains many different types of cells besides
adipocytes, including fibroblasts, macrophages, lymphocytes, pre-adipocytes and
endothelial cells. In addition, some particular cell types increase with increasing adiposity
e.g. macrophages (Weisberg et al 2003) and lymphocytes (Kintscher et al 2008; Wu et al
2007). As such, subsequent studies determined the expression of BAT1 in both human
primary pre-adipocytes cells and the human pre-adipocyte cell line, Chub-S7, as a
considered pure population of adipose cells. In both cell types BAT1 expression (mRNA
and protein) was observed to increase with lipid accumulation, expressing a similar BAT
1 expression level in differentiating pre-adipocytes at day 6 compared with mature
adipocytes. Once it was clear that the Chub-S7 pre-adipocyte cells differentiated well,
and BAT 1 expression was comparable to primary human differentiated pre-adipocyte
cultures, the effect of nutrients and inflammatory factors on BAT1 expression were
examined, as well as the NFB and or JNK pathways which may affect BAT 1
expression directly/indirectly. Both glucose and NEFA were shown to repress BAT 1
expression, which was in keeping with the ex vivo data determined in terms of AT from
obese and T2DM subjects, indicating the impact of both factors on BAT1 expression.
Furthermore that NEFA reduced BAT1 expression which appeared substantially more
influenced by the JNK pathway, using inhibitor studies. However these studies also
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indicated a synergistic action of both JNK and NFB when used in combination to reduce
BAT1 expression, indicating interconnectivity between JNK and NFB pathways, as
noted in other human AT studies examining other molecules (McGee et al, 2011).
Studies also showed LPS, a known systemic gut derived factor, reduced BAT1
expression. Such findings were, again, in keeping with the previous ex vivo AT data since
LPS is raised in conditions of metabolic disease (Creely et al 2007). Further analysis of
the potential paracrine influences of leptin and resistin on differentiated primary
adipocytes highlighted BAT 1 repression whilst adiponectin appeared to have no
significant effect alone to alter BAT 1 expression or reduce LPS induced BAT1
repression. Examining the current thesis data it appears that BAT1 is more influenced by
glucose and NEFA than paracrine inflammatory or anti-inflammatory adipokines. BAT1
therefore represents a first line, non-selective, cellular protective signaling factor which is
influenced by several different factors through common inflammatory pathways. As such,
with BAT1 expression altered so readily by inflammatory factors this may suggest to
potentially exploit BAT1 protective anti-inflammatory mechanism as a drug target,
although further future studies would need to explore this in more depth.
7.2 Future Directions
This thesis has altered our understanding as to the factors that could affect BAT1
expression systemically or in a paracrine fashion within the adipocyte. Our current
findings highlight that BAT1 is down-regulated by increasing adiposity, and
detrimentally influenced by glucose, NEFA, LPS and adipocytokines. These findings
could suggest that BAT1 suppression is an early event in the pathogenesis of a low
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chronic inflammatory state and that early intervention to modulate BAT1 may either
impede the inflammatory response or reduce its progression. Therefore future studies
could examine two distinct areas, firstly, human studies to examine the impact of weight
loss in BAT1 expression from AT as well as mononuclear blood cells to determine local
cellular impact on BAT1 as well as systemic impact. This may highlight the potential for
BAT1 expression to be reversed as the inflammatory insult reduces indicating that the
effects are reversible. Secondly, other human AT depots could be examined with
particular reference to epicardial fat an important reservoir. This depot, situated between
the visceral layer of the pericardium and the anterior face of the myocardium, has been
shown to provide non-esterified fatty acids (NEFA) to the myocardium (Marchington &
Pnd 1990; Marchington et al, 1989). Therefore it would be interesting to examine
whether BAT1 expression behaves differently in this depot due to the constant flux on
fatty acids required by the myocardium. Does BAT 1 activity depend on its AT location,
as noted with the AbdSc and OM data detailed? As epicardial AT from patients with and
without coronary artery disease differs in their inflammatory status and BAT1 activation
and could, this be manipulated to reduce the inflammatory status in this important AT site
(Baker et al, 2009. Kostner et al, 2012).
Future studies could also use transgenic mouse models to overexpress BAT1
preferentially in adipose tissue to construct further data into the functionality of BAT1.
This research may encourage the initiation of further trials to elucidate the beneficial
effects of BAT1 and potentially lead to the development of new anti-inflammatory agents
for the management of immunopathologic disorders as well as IR, T2DM and CVD.
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7.3 Conclusion
BAT1 is expressed in human adipocytes at mRNA and protein level. It is down-
regulated by several nutritional (saturated fats, high glucose concentration) and
inflammatory factors (LPS) as well as by adipokines, including leptin and resistin.
Adiponectin however has little or no influence on regulating BAT1 protein expression in
AbdSc differentiated adipocytes. The BAT 1 protein has anti-inflammatory properties, as
noted in other studies, and is repressed by many different molecules in AT; this could
suggest that BAT1 represents part of a first line cellular protective pathway by which
adipocytes respond to detrimental agents. As a first line cellular response to
‘inflammation’ this protective molecule, BAT1, may be affected by several different
factors via common cellular pathways with the potential to exploit its anti-inflammatory
properties.
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APPENDIX I: Buffers and Solutions
AI. 1 WESTERN BLOTTING SOLUTIONS
1.1 Sodium Dodecyl Sulphate (SDS) (4%)
10 ml 20% SDS solution
50 ml dH2O
Solution stored at room temperature (RT)
1.2 Loading buffer
625 μl Tris-HCl (pH 6.8) 125 mM 
500 μl SDS 4% 
1 ml Glycerol
200 μl Dithiothreitol (DTT) 
125 μl Bromophenol Blue 
250 μl Distilled H2O
Electrode Buffer for SDS-PAGE Electrophoresis
REAGENT FINAL CONCENTRATION
(X5)
QUANTITY
(DILUTED IN 1L)
Tris 1.24 x 10-1M 15 g
Glycine
(Biorad, Hercules,
CA, USA)
9.6 x 10-1M 72 g
SDS 20% (v/v) 25 ml
Transfer Buffer for Electrophoretic Transfer
REAGENT FINAL CONCENTRATION
(1X)
Quantity
(DILUTED IN 4L)
Tris 25 mM 15.15 g
Glycine 192 mM 72.0 g
Methanol 100% 1 L
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1.3 Phosphate Buffered Saline (PBS) (pH 7.6)
PBS 120 mM
NaCl 2.7 mM
KCL, 10 mM
Solution stored at RT.
1.4 PBS-Tween (PBS-T) (1.0%)
1 L PBS (prepared as above)
1 ml Phosphate Buffered Saline (PBS) (‘Tween 20’ (0.1% (v/v), Sigma UK).
Solution stored at RT.
1.5 PBS/PBS-T solution for antibody preparation (0.5%)
X quantity 1.0% PBS-T (prepared as above)
X quantity PBS (prepared as above)
1.6 Tris-buffered Saline-Tween (TBS-T) (10X): 0.5M Tris Base, 9% NaCl, pH
7.6
61 g Trizma base
90 g NaCl
1 L dH2O
Solution mixed to dissolve; pH adjusted using HCl. Solution stored at RT.
1.7 TBS-T (1X)
TBS-T (10X) diluted (1:10) with dH2O
1.8 Blocking Solution for Millipore® filters (20%)
20 g non-fat milk solution (Marvel Milk Powder, UK)
200 ml PBS 0.5% PBS (Tween 20 (0.1% (v/v), Sigma UK)
AI. 2 GENERAL CELL-CULTURE SOLUTIONS
2.1 Lysis buffer
Ammonium Chloride (NH4Cl) 0.154 mol/l
Potassium Bicarbonate (KHCO3) 10 mmol/l
2.2 Collagenase
50mls of Hank’s Buffer Salt Solution
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450mls of dH2O
5mls Pen/Strep
Stored at -20° C
2.3 Transferrin
Transferrin is a serum protein, responsible for the binding and transfer of iron to cells. It
has a molecular weight of around 80 kiloDaltons and contains two high-affinity Fe3+
binding sites. In the cell-culture media, tranferrin binds iron, and prevents its loss from
the medium. It is also capable of binding other metal irons in the medium at
concentrations which are toxic.
2.4 Phenol red-free medium
Dulbecco’s minimal essential medium (DMEM/F-12) Phenol red free 1% transferrin
Penicillin (100 U/ml) and streptomycin (100 mg/ml) added.
Medium was stored at 4° C.
AI. 3 SOLUTIONS AND BUFFERS USED IN RT-PCR
3.1 DNase Treatment
DNase I REACTION BUFFER STOP SOLUTION
1 U/μl in 
50% Glycerol
10 mM Tris-HCl (pH7.5)
10 mM CaCl2
10 mM MgCl2
200 mM Tris-HCl (pH 8.3)
20 mM MgCl2
50 mM EDTA
3.2 Reverse Transcription Buffer
100 mM Tris-HCl (pH 9.0 at 25oC)
500 mM KCl
1% Triton® X-100
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APPENDIX II: Reverse Transcription (RT) and Quantitative Real-
Time Polymerase Chain Reaction
AII. 1 SYNTHESIS AND EXPRESSION OF mRNA
The genes encoding proteins are in nuclear chromosomes and are made of
deoxyribonucleic acid (DNA). They contain coding (exons) and non-coding (introns)
regions the number of which differs according to the gene. The genetic information
contained in the genes, needs to be transferred in the cell cytoplasm to be decoded-
translated into the specific polypeptide chain. This process is mediated by RNA
polymerase that removes from the DNA of the gene all the introns, synthesizing
messenger ribonucleic acid (mRNA) that contains only coding regions (exons). This
process is called transcription. The so produced mRNA will be translated in cytoplasmic
ribosomes to the specific protein. The assessment of mRNA expression, allows for
estimations to be made as to the level of protein expression of a particular gene of
interest.
AII. 2 RT-PCR
As the polymerase chain reaction (PCR) amplifies DNA sequences, DNA needs
to be synthesized from the mRNA template. This process is termed ‘reverse
transcription’, is catalyzed by the enzyme reverse transcriptase and the produced DNA is
called complementary DNA (cDNA). The term complementary comes from the fact that
the new-formed DNA (cDNA) contains the complimentary bases to that on the mRNA
strand.
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AII. 3 QUANTITATIVE REAL-TIME PCR
As mentioned in chapter 2, the quantitative real time polymerase chain reaction is
a laboratory technique used in molecular biology that enables both detection and
quantification, as absolute number of copies of a targeted DNA sequence. It uses
fluorescence technology to monitor amplicon production during each PCR cycle; this
enables the analysis of the amount of template rather than the amount of amplified
product at the endpoint of the reaction. In this study, an ABI 7700 Sequence Detection
system was used to analyze the mRNA levels. This system utilizes TaqMan chemistry for
highly accurate quantification of specific mRNA levels.
TaqMan probes contain a fluorescent reporter dye and a quenching dye. The latter
is usually on the 3' base, while the fluorescent reporter dye is usually on the 5' base; due
to the close proximity of the two, the quenching dye prevents emission of any
fluorescence as long as the probe is intact. During the Quantitative Real-Time PCR
however, the probe anneals between the forward and reverse primer sites within the PCR
product of interest. Thus, when the Taq DNA polymerase replicates a template on which
a TaqMan probe is bound, its 5' exonuclease activity cleaves the probe. This results in
removal of the fluorescent reporter dye from the proximity of the quenching dye allowing
a florescent signal. Each amplification cycle adds more florescent signal of the targeted
cDNA sequence, which becomes intense enough to be detected and quantitatively
measured by a laser and charged coupled device (CCD) camera, used in Quantitative
Real-Time PCR.
The principles of the TaqMan Sequence Detection Chemistry are demonstrated in
figure II.1. The probe, containing both the fluorescent reporter and quencher dyes, is
- 194 -
attached to the targeted cDNA. The reporter dye is cleaved from the probe during the
polymerization, which enhances the fluorescence of the reporter. Each amplification
cycle enhances further the intensity of the fluorescence, allowing the monitoring of the
reaction in real-time
Fig II.1. Principles of the TaqMan Sequence Detection Chemistry. Attachment of the
probe to the targeted cDNA. Cleavage of the dye from the probe during the
polymerization and subsequent enhancement of the reporter’s fluorescence.
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APPENDIX III: Western Blotting (WB)
AIII. 1 CALCULATION OF THE SAMPLES’ PROTEIN CONTENT FOR
WESTERN BLOT ANALYSIS
A spectrophotometer at 655 nm was used to analyze the protein samples. The
calculation of the optical densities converted to protein content (μg) each time samples 
were assayed, was made by the construction of a standard curve using bovine serum
albumin (BSA) diluted in dH2O, (Figure AIII.1.1). To exclude any interference with
calculated protein sample concentrations, a mixture containing only Reagent S, Reagent
A and Solution B, had no optical density (protein signal).
Figure III.1. The calculation of the protein content in proteins samples extracted from
adipose tissue and isolated adipocytes was made used as a reference standard curves at
the one shown in the graph. Bovine serum albumin was diluted in dH2O to known
concentrations and absorbance read at 655 nm on a spectrophotometer.
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